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Summary 
Positron emission tomography in vivo characterisation of the pathology of 
frontotemporal dementia 
William Richard Bevan-Jones 
Frontotemporal dementia (FTD) is clinically and pathologically diverse, encompassing the 
behavioural variant FTD; non-fluent variant primary progressive aphasia; and semantic 
variant primary progressive aphasia. These are usually associated with either tau or TDP-43 
pathology, with highly variable clinicopathological correlations.  Neuroinflammation also 
contributes to the pathogenesis of FTD, but its relevance to the disease spectrum is 
incompletely understood. There is a critical need for better understanding of how drivers of 
pathophysiology, such as neuroinflammation and protein aggregation, relate to the 
heterogeneity of clinical disease in vivo. This knowledge gap currently forms a significant 
barrier to the development of effective treatments in FTD.   
I review the clinical, pathological and genetic features of FTD and the role of PET for 
measuring in vivo components of pathophysiology in this setting. I then describe a series of 
case studies and group analysis of FTD syndromes, using positron emission tomography 
(PET) radioligands to visualise and quantify different aspects of pathophysiology in vivo.     
[18F]AV-1451tau was introduced primarily to study tau pathology in Alzheimer’s disease 
using, which differs from FTD tauopathy in several respects.  I examined the sensitivity and 
specificity of [18F]AV-1451 in FTD, in vivo, through (i)  [18F]AV-1451 imaging of the FTLD-
tau pathology in a case of FTD due to a MAPT 10+16 mutation in the microtubule associated 
protein tau, and a second pre-symptomatic case with the same mutation; (ii) [18F]AV-1451 
imaging of a cohort of seven cases with Semantic Dementia and one case of FTD from a 
C9orf72 expansion, both strongly associated with TDP-43 pathology without tau; and (iii)  the 
increase in [18F]AV-1451 binding, and changes in the distribution of binding, in thirty one 
patients spanning the three major FTD syndromes in comparison to matched controls.  
The literature on the role of neuroinflammation in FTD is more limited.  I used the PET 
ligand [11C]PK-11195, as an established marker of activated microglia. I report the elevation 
in [11C]PK-11195 binding, and the change in its distribution, in a case of a pre-symptomatic 
MAPT 10+16 mutation carrier; and in twenty nine patients spanning the three major FTD 
syndromes in comparison to matched controls.  
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In addition to reporting the correlations between PET ligand binding and disease severity, I 
describe the relationship across regions and across syndromes between [18F]AV-1451 and 
[11C]PK-11195 binding. In view of the marked variations in affinity of [18F]AV-1451 for 
different tau isoforms and TDP43-pathology, my analyses focus on multivariate distributions 
rather than absolute binding potential. The results show high correlations between [18F]AV-
1451 and [11C]PK-11195 binding in each FTD syndrome. However, in the healthy MAPT 
10+16 carrier, the distribution of elevated [11C]PK-11195 binding is much more extensive 
that the elevation of [18F]AV-1451, suggesting that inflammation might precede the 
aggregation of tau.   
I discuss the limitations of the PET ligands, and summarise the insights into FTD 
pathogenesis arising from my series of observational studies.  The role of new PET ligands, 
and the integration of PET in future clinical trials are discussed.   
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Chapter 1: Introduction  
 
Overview  
In this chapter I review the clinical syndromes of Frontotemporal dementia (FTD), along with 
their neuropathology, genetics and imaging features.  I outline the heterogeneity that 
characterises these disorders, and how this impacts on our understanding of the biology of 
disease, complicating the development of both symptomatic and disease modifying therapies.  
Finally, I introduce the concept of using positron emission tomography (PET) as a method of 
investigating pathophysiology in vivo and how this technique may provide valuable insights 
which may help improve our understanding of the mechanisms of disease and potential 
avenues for treatment approaches. 
Introduction   
Frontotemporal dementia (FTD) was described by Arnold Pick in series of cases from 1892, 
although the earliest clinical description in keeping with frontotemporal dementia may have 
been that published by William Bevan Lewis from the West Riding Asylum in 1878 (Bevan-
Lewis, 1878).  The index cases (Pick, 1892, 1901, 1904, 1906) described by Pick illustrated 
the range of symptoms resulting from what we now call FTD.  The pathology associated with 
FTD was first described in 1911 by Alois Alzheimer who coined the term ‘Pick bodies’ for 
the characteristic intracellular inclusions. The last hundred years have allowed greater 
characterisation of the clinical features and neuropathology of these illnesses, in what is now a 
spectrum of frontotemporal lobar degeneration (FTLD), causing FTD, progressive 
supranuclear palsy and corticobasal syndrome. FTD is the second commonest cause of young 
onset dementia after Alzheimer’s disease, and carries a lifetime risk of about 1 in 750 (Coyle-
Gilchrist et al., 2016). In up to 40% of cases there is a family history of dementia and in 20% 
there is a monogenic cause (Bang, Spina, & Miller, 2015; Rohrer, Guerreiro, et al., 2009).  
Treatment options remain limited, with little evidence base from randomised controlled trials, 
no licenced therapies for symptom relief and no disease modifying treatments.  Furthermore, 
the heterogeneity of FTD, in both clinical syndromes and in neuropathological subtypes, has 
posed significant challenges for the understanding of pathophysiology and consequently for 
the development of treatments.  The clinical presentations are diverse and are categorised as 
either the behavioural variant of FTD (bvFTD) (Rascovsky et al., 2011), or as one of two 
language variants or primary progressive aphasias (Gorno-Tempini et al., 2011); non-fluent 
variant primary progressive aphasia (nfvPPA) or semantic variant primary progressive 
aphasia (svPPA).   
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In recent years progress has been made in the clinical phenomenology of FTD, in particular 
refining the diagnostic criteria for the clinical syndromes of FTD and for the underlying 
neuropathological aetiologies.  However, our understanding of the biology of disease and how 
it relates to the clinical illness remains incomplete, and the dire need for effective therapies to 
ameliorate the personal, social and economic impact of these diseases unmet.  There remain 
several challenges which confront the FTD research community and prevent us from 
improving this situation.  These challenges take many forms including public and institutional 
awareness of these relatively rare diseases, a disparity in funding compared with other 
neurodegenerative diseases such as Alzheimer’s disease and motor neurone disease, and the 
clinicopathological complexity of FTD.  In particular this last factor is a prominent barrier to 
the development of both symptomatic and disease modifying treatments targeting specific 
aspects of pathophysiology.  As well as impacting on drug development and clinical trials, the 
complex biology of FTD also complicates the identification of pre-symptomatic and 
diagnostic biomarkers.  In order to move clinical management of FTD beyond 
phenomenology and tertiary specialist clinics and toward the biological diagnosis and 
treatment of disease, there is in particular a desperate need to develop biomarkers which 
identify, segregate, quantify, map and track aspects of pathophysiology over time in vivo.  
The substance of this doctoral thesis will be using positron emission tomography (PET) as an 
approach to address this need. 
The clinical syndromes of FTD 
Although FTD syndromes have been recognised in various forms for over a century, the 
interest in the disease and the criteria to define it have varied.  In the last 25 years there has 
been a resurgence of interest in FTD as a neurodegenerative disease causing circumscribed 
deficits in particular domains whilst sparing others, in other words reflecting the anatomical 
location of the neurodegenerative damage.  In the last 10 years international working parties 
have established consensus criteria for diagnosis of behavioural and language variants of 
FTD.  In the following sections (summarised in table 1.1) I will present a canonical account of 
the current clinical and neuropathological classifications as well as genetic aetiologies, 
highlighting where needed the relevance of older diagnostic approaches particularly when it 
affects the interpretation of older studies.  
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Syndrome Clinical features Neuropathologies Genetic aetiologies 
BvFTD 3 of: 
Behavioural disinhibition 
Apathy or inertia 
Loss of empathy 
Stereotyped/ritualistic 
behaviour 
Hyperorality 
Focal executive deficits 
TDP-43 (50%) 
Type A, B, C or D 
Tau (40%) 
Pick’s, CBD or PSP 
C9orf72 expansions 
GRN mutations 
MAPT mutations 
 
SvPPA Impaired confrontational 
naming 
Impaired single word 
comprehension 
+ 3 of: 
Impaired object knowledge 
Surface dyslexia 
Spared repetition 
Spared speech production 
TDP-43 type C (90%) 
Pick’s tauopathy or 
Alzheimer’s pathology 
(rarely) 
Almost never 
NfvPPA 1 of: 
Agrammatic language 
production 
Speech apraxia 
2 of: 
Impaired syntactic 
comprehension 
Spared single word 
comprehension 
Spared object knowledge 
Tau (60%) 
CBD, PSP or Pick’s 
TDP-43 (30%) 
Alzheimer’s pathology 
(10%) 
GRN (rarely) 
 
 
Table 1.1: summary outline of core clinical features, neuropathology and genetics of each FTD syndrome. 
 
Behavioural variant of FTD 
Behavioural variant FTD is characterised by change in personality with behavioural 
disturbance (Rascovsky et al., 2011).  This may involve apathy and withdrawal, disinhibition, 
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impulsivity, irritability and socially inappropriate behaviour.  There are also deficits in theory 
of mind, social cognition and emotional processing.  These features lead to a breakdown in 
social comportment, interpersonal relationships and self-care.  Although not a classical feature 
of the diagnostic criteria, episodic memory impairment may be seen early on (Hornberger & 
Piguet, 2012; Rascovsky et al., 2011) and other features such as apraxia or eye movement 
disorders may emerge later in the disease.  Features of anterior horn cell dysfunction occur in 
up to two fifths of patients, whilst florid motor neuron disease is seen in about 15% (Burrell, 
Kiernan, Vucic, & Hodges, 2011), with parkinsonism evident in one fifth (Ber et al., 2006). 
A genetic cause for this presentation is relatively common with mutations in the three main 
genes found in FTD known to cause this syndrome: the microtubule associated protein tau 
(MAPT) gene (Hutton et al., 1998); the Progranulin (GRN) gene (Baker et al., 2006) and the 
hexanucleotide repeat expansion C9 open reading frame 72 (C9orf72) (Gijselinck et al., 2012) 
accounting for 60% of genetic cases and around 20% of all cases (Rohrer, Guerreiro, et al., 
2009).   
The pathology in genetic behavioural variant FTD cases is determined by, and typical of, the 
specific mutation, whilst in sporadic cases pathology it is split almost equally between tau 
pathology (40%) and TAR-DNA binding protein 43 (TDP-43) pathology (50%).  In sporadic 
cases neuropathology is not accurately predicted by clinical syndrome, although the 
development of signs consistent with progressive supranuclear palsy increases the likelihood 
of tau pathology whilst the development of coexistent motor neurone disease or psychosis 
increases the likelihood of TDP-43 pathology.  The course is variable with a mean survival of 
4.5 years from diagnosis (Coyle-Gilchrist et al., 2016) and the development of dysphagia and 
anterior horn cell signs carry a poor prognosis.  Treatment is mainly based on anecdotal 
evidence and directed towards alleviation of carer burden and distress, and amelioration of 
affective and motor symptoms.  
Semantic variant of primary progressive aphasia 
The semantic variant of primary progressive aphasia (also called semantic dementia [SD]) 
(Hodges & Patterson, 2007; Hodges, Patterson, Oxbury, & Funnell, 1992; Hodges et al., 
2010; Snowden, Goulding, & Neary, 1989; Warrington, 1975), is characterised by poor 
semantic knowledge, and whilst a bilateral disease, the syndrome may be predominantly left 
or right sided in presentation.  Left dominant disease is most common, presenting with fluent 
but empty speech, impaired single word comprehension, anomia, semantic paraphasias and 
superordinate category errors, as well as surface dyslexia (regularisation of irregular words) 
on reading.  The clinical picture is different in right dominant cases with early prosopagnosia, 
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impaired emotional recognition and behaviour features such as rigidity and obsessiveness 
(Chan et al., 2009).  Although asymmetric at outset, the syndromes of left and right-semantic 
dementia become progressively bilateral, affecting behaviour, personality and facial 
recognition as well as language.  Posterior cortical functions are relatively well preserved and 
motor features are highly unusual (Bang et al., 2015).   
There is a strong clinicopathological correlation between the syndrome of semantic dementia 
and TDP-43 type C pathology (Hodges et al., 2010; Snowden, Neary, & Mann, 2007; Spinelli 
et al., 2017), which is seen in up to 90% of cases.  It is very rare for this type of FTD to have a 
monogenic basis.  The disease has a relatively long course with a mean survival of 9.1 years 
from diagnosis (Coyle-Gilchrist et al., 2016).  Symptomatic pharmacological treatment targets 
amenable symptoms such as mood and the mainstay of management is social support. 
Non-fluent variant of primary progressive aphasia 
The non-fluent variant of primary progressive aphasia (Gorno-Tempini et al., 2011), 
(formerly also called progressive non-fluent aphasia [PNFA]) is characterised by non-fluent, 
effortful speech which may be agrammatic, with or without apraxia of speech (which rarely 
may occur in the absence of aphasia (Josephs et al., 2012)) and oro-buccal apraxia on 
examination.  Phonological paraphasias and binary confusion, for example verbally of ‘yes’ 
and ‘no’, are common features.  Reading aloud is often easier than spontaneous speech but is 
typically aprosodic.  Naming is usually normal, whilst other domains such as memory and 
visuospatial function are well preserved.  Features such as eye movement disorders, limb 
apraxia and extrapyramidal signs may appear during the disease course sometimes to an 
extent that constitutes corticobasal syndrome or progressive supranuclear palsy (Deramecourt, 
Lebert, Buee, Maurage, & Pasquier, 2010; Josephs et al., 2006), whilst dysexecutive features 
and mild behavioural changes may become apparent as the disease progresses.   
Non-fluent variant primary progressive aphasia may rarely result from mutations in the GRN 
gene when the mutation and the disease are associated with TDP-43 type A pathology (Bang 
et al., 2015; Mackenzie et al., 2011).  In sporadic cases the pathology is more commonly tau 
(Spinelli et al., 2017) but cannot be definitively predicted from the syndrome, although it has 
been postulated that apraxia of speech may predict the presence of tauopathies such as 
progressive supranuclear palsy or corticobasal degeneration (Josephs & Duffy, 2008).  Mean 
survival is 8-10 years from symptom onset (Coyle-Gilchrist et al., 2016; Hodges, Davies, 
Xuereb, Kril, & Halliday, 2003; Spinelli et al., 2017) and whilst the neuropathology 
underlying the syndrome is heterogeneous this does not seem to impact on prognosis, 
although there may be differences in behavioural profile and motor features (Spinelli et al., 
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2017). Clinical management focuses on managing the frustration of aphasia and preserving 
other daily functions as far as possible. 
Logopenic aphasia 
A further subtype of PPA is the logopenic variant of primary progressive aphasia (lvPPA).  It 
is typically early onset in age and presents with language deficits dominated by word finding 
difficulties and significant anomia which can lead to slow speech with ‘word finding’ pauses.  
Another marked feature is impaired sentence repetition, thought to result from a deficit in 
phonological short term memory.  Single word repetition and comprehension are typically 
spared.  Later in the disease sentence comprehension may become impaired (Gorno-Tempini 
et al., 2008).  Cognitive decline is faster than other variants of PPA and spreads to involve 
other domains such as visuospatial function and episodic memory (Leyton, Hsieh, Mioshi, & 
Hodges, 2012).  Whilst the combination of non-fluent speech and speech sound errors may 
cause confusion with nfvPPA, the impairment in confrontational naming and lack of 
significant agrammatism or speech apraxia usually differentiates the two (Montembeault, 
Brambati, Gorno-Tempini, & Migliaccio, 2018).  Although lvPPA has historically been 
categorised as a subtype of FTD clinically, it is strongly associated with focal Alzheimer’s 
pathology (Mesulam et al., 2008; Spinelli et al., 2017), typically present posterior to the peri-
sylvian fissure and into the parietal lobe.  Thus it is now generally regarded as a form of focal 
onset Alzheimer’s disease (Mesulam et al., 2008), in the same way as other focal syndromes 
of Alzheimer’s disease such as posterior cortical atrophy (Migliaccio et al., 2009).  As a result 
of this strong association with Alzheimer’s disease, lvPPA is not discussed further in this 
thesis. 
For all FTD syndromes, the diagnosis is clinical, based on diagnostic criteria (Gorno-Tempini 
et al., 2011; Rascovsky et al., 2011) which frame the predominant symptoms and signs at the 
time of presentation, supported by the pattern of atrophy on MRI (Gordon, Rohrer, & Fox, 
2016; Gorno-Tempini et al., 2004; Rohrer et al., 2010), and confirmed by genetic mutation if 
present (Gorno-Tempini et al., 2011; Rascovsky et al., 2011).  Over time symptoms and signs 
may evolve and broaden so that language variants develop behavioural changes and vice 
versa, or motor signs become apparent, perhaps reflecting the early localisation of pathology 
to particular networks with subsequent spread through connected regions (Seeley, 2008).  In a 
similar fashion the labels which best describe an individual’s illness may also change with 
this pattern of evolution such that the patient presenting with change in personality and 
behaviour in keeping with behavioural variant FTD who subsequently develops postural 
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instability and a supranuclear gaze palsy may then be better described as having progressive 
supranuclear palsy. 
Neuropathology in FTD 
The morphology and distribution of protein aggregates define the pathological diagnosis and 
classification of these neurodegenerative diseases.  The pathologies which cause FTD fall 
under the umbrella term of Frontotemporal lobar degeneration.  A feature of these pathologies 
is their heterogeneity, both in the way that more than one pathology can cause the same 
clinicoanatomical syndrome (e.g. bvFTD may be caused by various subtypes of tau or TDP-
43) and in that one specific type of pathology may be the cause of a variety of clinical 
phenotypes (e.g. Pick’s disease pathology may cause bvFTD or nfvPPA) (Seeley, 2017).  
The protein aggregates which cause FTD syndromes are predominantly of either tau or TDP-
43, with neuronal loss affecting the superficial layers of frontal and temporal cortex, with 
particular severity in layer II.  Loss of Von Economo cells occurs in layer Vb and is an early 
and specific feature of FTD (Seeley, 2008; Seeley et al., 2006). There is also heterogeneity of 
biochemistry and morphology within the subtypes of protein aggregates observed.  Although 
the predominant proteinopathies are tau or TDP-43, other protein aggregates are occasionally 
seen.  To complicate matters further, there is a poor correlation between clinical phenotype 
and pathology such that in most cases neuropathology cannot be accurately predicted by 
clinical syndrome.  In the following sections I will briefly describe the characteristics of both 
tau and TDP-43 aggregation and mention some of the rarer aggregated proteins found in FTD. 
Tau 
Tau is an intracellular protein primarily involved in the assembly and stabilisation of 
microtubules and therefore important in axonal transport.  It is produced from the MAPT gene 
found on chromosome 17. Alternative splicing during transcription enables the production of 
six different isoforms from this single gene, which differ in their microtubule binding 
domains and which predominate at different stages of brain development.  Aggregates of tau 
are hyperphosphorylated, sometimes with other post-translational modifications, and may be 
composed predominantly of 3-repeat or 4-repeat isoforms, or a balance of both.  Classification 
of tau pathology is based upon the predominant isoform type, aggregate morphology, cell 
type affected and distribution of pathology (Dickson, Kouri, Murray, & Josephs, 2011).  The 
three main categories are: Pick’s disease pathology characterised by intracellular inclusions of 
3-repeat tau formed of straight filaments and called Pick bodies; progressive supranuclear 
palsy pathology characterised by predominantly subcortical globose tangles, coiled bodies and 
tufted astrocytes formed of straight filaments of 4-repeat tau; and lastly corticobasal 
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degeneration pathology, also a 4-repeat tauopathy forming astrocytic plaques, coiled bodies 
and neuropil threads with a predominantly cortical distribution.     
TDP-43 
TDP-43 is an intracellular protein which is encoded by the TAR-DNA binding gene found on 
chromosome 20 (Borroni et al., 2009).  It is an important regulator of protein and RNA 
homestasis with two main functions: regulation of transcription by its involvement in 
alternative splicing; and stabilization of RNA molecules.  Consequently in health it is 
localised predominantly to the cell nucleus (Buratti & Baralle, 2008).  Aggregates of TDP-43, 
mislocalised to the cytoplasm, are found in several neurodegenerative diseases but are 
particularly associated with FTD and motor neurone disease (Warraich, Yang, Nicholson, & 
Blair, 2010).  Most recently, Limbic-predominant age-related TDP-43 encephalopathy 
(LATE) has been described as another TDP-43 related disease entity typically presenting in 
older people with an Alzheimer’s-like, predominantly amnestic, dementia syndrome, but 
characterised neuropathologically by the presence of TDP-43 proteinopthy in medial temporal 
lobe structures (Nelson et al., 2019).  The TDP-43 pathology of Frontotemporal lobar 
degeneration can be divided into four subtypes, A to D, based on morphology and 
distribution(Mackenzie et al., 2011).  Recently a type E has been proposed (Lee et al., 2017) 
representing a more ‘virulent’ subtype with widespread, immature TDP-43 pathology and a 
more rapid clinical course. 
Less than 10% of cases of FTD examined at post mortem have neuropathology which is not 
tau or TDP-43.  The majority of these cases have aggregates of Fused in sarcoma protein 
(FUS) (Neumann et al., 2009).  Aggregates of charged multivesicular body protein 2B 
(CHMP2B) pathology are the next most recognised finding (Skibinski et al., 2005).  Whilst 
the relationship between pathology and clinical phenotype is weak, there is a far stronger 
association between the monogenic causes of FTD and neuropathology. 
Genetics of FTD 
Approximately 40% of people presenting with FTD have a family history of dementia or 
related neurodegenerative disease and 10% have a strong autosomal dominant family history 
of FTD (Rohrer, Guerreiro, et al., 2009).  Approximately 20% of cases are identifiable as 
genetic at presentation, with 60% of these genetic cases resulting from a mutation in the 
MAPT or GRN genes, or from a hexanucleotide repeat expansion in C9orf72 (Bang et al., 
2015).  With improved understanding of the relationship between genetics and overlapping 
neurodegenerative phenotypes, it is now recognised that family history of any 
neurodegenerative disease, especially motor neurone disease, parkinsonism or psychosis, can 
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be a relevant expression of a mutation in other family members.  Apart from C9orf72 and 
VCP, there are few reliable phenotypic features to indicate genotype or pathology in bvFTD, 
although brain imaging can be helpful given the association of GRN mutations with extreme 
asymmetry and of MAPT mutations with symmetrical temporal lobe atrophy respectively 
(Cash et al., 2018).  In the following sections I briefly summarise the characteristics of the 
main genes, their typical clinical syndromes and pathologies.  
Microtubule associated protein tau 
The MAPT gene, found on chromosome 17 (Neve, Harris, Kosik, Kurnit, & Donlon, 1986), 
plays a key role in microtubule homeostasis and therefore in axonal transport.  Tau is a 
microtubule associated protein which undergoes a wide range of post translational 
modifications controlling its behaviour.  Its primary function in normal neuronal physiology 
is the stabilization of microtubules through which it has effects on key neuronal processes 
such as axonal transport.  More recently a role for tau has been postulated in long term 
synaptic plasticity, specifically in the activity dependent decrease in synaptic activity known 
as long term depression (Medina, Hernández, & Avila, 2016).  The MAPT gene contains 16 
exons.  Alternative splicing of exons 2, 3 and 10 results in the expression of 6 different tau 
isoforms (Goedert, Spillantini, Jakes, Rutherford, & Crowther, 1989).  Inclusion or exclusion 
of exon 10 produces a protein with 4 or 3 repeat binding domains and normal tau function 
requires a balance of 3 and 4 repeat isoforms.  Whilst integral to normal neuronal function, 
aggregates of tau are characteristic of several neurodegenerative diseases.  Mutations in 
MAPT were the first described genetic cause of FTD (Hutton et al., 1998) and post mortem 
examination reveals subtypes of tau pathology which vary by mutation and encompasses the 
biochemical and morphological spectrum of tau aggregation (Cairns, Lee, & Trojanowski, 
2004).  The clinical presentation is generally behavioural, may occur with or without 
parkinsonism, and has been described in association with other presentations of 
frontotemporal lobar degeneration such as progressive supranuclear palsy (Morris et al., 
2003).  Although rarer, semantic (Bessi et al., 2010), non-fluent (Munoz, Ros, Fatas, Bermejo, 
& Yebenes, 2007) and amnestic presentations are described.   
C9orf72 
C9orf72 is found on chromosome 9.  The role of the C9orf72 protein is not fully understood 
but it is found pre-synaptically and seems to play an import role in endosomal trafficking, 
particularly in neurons (Farg et al., 2014).  A hexanucleotide repeat length greater than thirty 
appears to lead to both loss of function, primarily affecting immune cells (Lall & Baloh, 
2017; O’Rouke et al., 2016), and a toxic gain of function related to the generation of sense 
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and anti-sense RNA species, and of toxic dipeptide repeat proteins (Moens, Partridge, & 
Isaacs, 2017).  These repeat expansions are unstable and vary between tissues but are not fully 
penetrant and while the effect of expansion size on onset age and disease severity remains 
unclear, it appears that repeat length is not predictive (Benussi et al., 2014; Blitterswijk et al., 
2013).   
The neuropathology is classically TDP-43 aggregates, predominantly of type B (Mackenzie et 
al., 2011), although very rare cases with additional  tau pathology have been described 
(Snowden et al., 2012).  The pathological hallmark of C9orf72 disease is the presence of 
dipeptide repeat aggregates, formed by unconventional repeat-associated non-ATG translation 
(Ash et al., 2013; Mori et al., 2013; Rohrer et al., 2015).  It is the most recently described 
gene to account for a large number of cases of FTD (Dejesus-Hernandez et al., 2012; Renton 
et al., 2011), for example a recent European study found C9orf72 expansions to account for 
10% of all frontotemporal lobar degeneration cases, almost 20% of familial cases and 6% of 
sporadic cases (van der Zee et al., 2012).   
The cognitive phenotype is most often behavioural, however expansions have also been 
associated with amnestic, non-fluent and semantic presentations.  Psychotic features are more 
common than in sporadic behavioural variant FTD (Devenney et al., 2014) and psychiatric 
symptoms may predominate early in an illness such that psychiatric diagnoses like obsessive 
compulsive disorder, schizophrenia, bipolar disorder and depression often precede the 
diagnosis of FTD (Cooper-Knock, Shaw, & Kirby, 2014; Lindquist et al., 2013). Motor 
features are common, with parkinsonism present in up to one third of cases (Rohrer & 
Warren, 2011).  Although occurring sporadically and with other mutations, the FTD-motor 
neurone disease complex is strongly associated with expansions in C9orf72 (Burrell et al., 
2016; Snowden et al., 2012).  The phenotype can be pure motor neurone disease, of which 
expansions in C9orf72 are the most common genetic cause (Farg et al., 2014).  Expansions in 
C9orf72 have also been found in people with clinical syndromes consistent with Alzheimer’s 
disease, corticobasal syndrome, parkinsonian illnesses including dementia with Lewy bodies, 
Huntington’s disease and progressive ataxias (Cooper-Knock et al., 2014; Lindquist et al., 
2013).  Consequently phenotypic variability may be seen even within the same family. 
Progranulin 
GRN is found on chromosome 17 and consists of 13 exons which produce a precursor protein 
that has diverse immune regulatory functions.  These include potential antagonism of the 
tissue necrosis factor receptor and autocrine functions, as well as playing a role in lysosome 
homeostasis (Tang et al., 2011; Toh, Chitramuthu, Bennett, & Bateman, 2011).  It therefore 
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has a broad range of effects on both neurons and glial cells (Ahmed, Mackenzie, Hutton, & 
Dickson, 2007; Filiano et al., 2013).  Mutations in GRN are associated with 
haploinsufficiency and reduced concentrations in both serum and CSF (Gijselinck, Van 
Broeckhoven, & Cruts, 2008; Shankaran et al., 2008).  The neuropathology of GRN mutations 
is characterised by TDP-43 aggregation of type A (Mackenzie et al., 2011). It was first 
described as a cause of FTD in 2006 (Baker et al., 2006; Cruts et al., 2006) and most 
commonly presents as a predominantly behavioural syndrome or with a non-fluent aphasia 
(Chen-Plotkin et al., 2011; Yu et al., 2010).  Features of motor neurone disease are rare but 
parkinsonism can occur (Rohrer & Warren, 2011).  The phenotype may show variability even 
within the same family (Gabryelewicz et al., 2010). 
Other monogenic causes 
Other genetic causes are rare and the remainder of cases result from less common mutations 
in genes such as CHMP2B, FUS, TBK-1 and VCP, although these make up less than 5% of 
genetic cases.  In addition, mutations in presenilin 1, presenilin 2, Prion, TDP-43 and others 
can rarely present with FTD-like phenotypes (Blauwendraat et al., 2018).  Given the high 
rates of family history of FTD, dementia, or other neurodegenerative disease in individuals 
with FTD it seems likely there are further monogenic causes yet to be discovered, particularly 
in phenotypes such as FTD – motor neurone disease (Burrell et al., 2016). 
Other genetic factors 
The importance of genetics is not only clinical but also provides insights into the mechanisms 
of disease and consequently into potential therapeutic approaches.  The role of genes beyond 
monogenic aetiology is therefore important.  Alongside proposed cognitive factors which may 
impact on the course of dementia (Stern, 2009), other genetic factors seem likely to account 
for the differences in onset, progression and phenotype seen even within families with the 
same FTD-causing mutation.  Polymorphisms in several different genes have been recognised 
to confer risk or protection in frontotemporal lobar degeneration.  For example, progressive 
supranuclear palsy and corticobasal degeneration, the pathologies of which may account for 
behavioural and non-fluent presentations of FTD, are more common in individuals with the 
H1 haplotype of the MAPT gene, a finding reproduced in a clinical cohort with FTD (Baker et 
al., 2018; Verpillat et al., 2002).   
Another important gene which modulates risk is Transmembrane protein 106b (TMEM106b), 
a protein involved in lysosomal function, single nucleotide polymorphisms of which have 
been identified from recent genome-wide association studies as risk alleles in FTLD-TDP43 
(Van Deerlin et al., 2010), particularly in cases due to mutations in C9orf72 or GRN 
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(Cruchaga et al., 2011; Gallagher et al., 2014; Van Blitterswijk et al., 2014; Van Deerlin et al., 
2010).   The risk allele of TMEM106b has also been shown to modulate the effect of 
environmental factors such as education on grey matter volume in carriers of C9orf72 
hexanucleotide repeat expansions (Premi et al., 2017), and to correlate with structural changes 
in healthy carriers (Adams et al., 2014) as well as with grey matter volume in homozygous 
carriers with FTD (Harding et al., 2017).   
Genes related to immune function have also been implicated as risk factors for FTD by 
genome-wide association studies (Ramanan & Saykin, 2013).  Amongst these is a variant of 
triggering receptor expressed on myeloid cells 2 (TREM2), a protein which is important in 
regulation of phagocytosis by activated microglia and which confers significant risk for 
Alzheimer’s disease, whilst a variant in Interleukin 1-β is associated with an earlier age of 
onset of bvFTD.  Apolipoprotein E alleles have also been associated with FTD and have also 
previously been shown to modulate neuroinflammation through effects on inflammatory 
receptor signalling to a pro-inflammatory phenotype (Tai et al., 2015).   Building on the 
potential mechanistic importance of inflammation in FTD, in the next section I will discuss 
neuroinflammation more generally before focusing on the evidence for neuroinflammation in 
FTD. 
Neuroinflammation  
The presence of innate immune functions in the central nervous system, and particularly the 
concept of neuroinflammation, is increasingly recognised as a potentially important and 
modifiable component in the process of neurodegeneration.  However, despite many studies 
of population genetics, post mortem tissue and animal models, the understanding of the 
presence and timing of in vivo neuroinflammation in neurodegenerative disease remains 
incomplete.   
Until recently the brain was often regarded as an ‘immune privileged’ organ, that is one where 
inflammation can only occur in the context of direct infection or after breakdown of the blood 
brain barrier allowing migration of peripheral immune cells.  However, it is now known that 
cell types within the brain express pattern recognition receptors which can activate 
inflammatory signalling pathways in response to particular pathogen associated molecular 
patterns, thus providing a potential basis for intrinsic neuroinflammation.  Linking this 
intrinsic neuroinflammation with neurodegeneration is evidence that misfolded proteins may 
be able to trigger these pathways in a similar manner by acting as danger associated molecular 
patterns, in essence causing ‘sterile’ neuroinflammation (Graeber, Li, & Rodriguez, 2011; 
Heneka, Kummer, & Latz, 2014).  Within this world of central nervous system inflammation, 
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microglia play a key role (Nakajima & Kohsaka, 2001).  Therefore, when referring to 
neuroinflammation in this thesis I will be implying the presence of activated microglia 
unrelated to an extrinsic stimulus.  Microglia are the resident macrophages of the central 
nervous system and are sensitive to brain injury and disease becoming activated by a wide 
range of pathophysiological insults (Nayak, Roth, & McGavern, 2014).  They are found in 
differing densities throughout the brain and their phenotype differs depending on localization.  
Through their surveillant, pruning, phagocytic, proliferating and neuromodulatory 
phenotypes, microglia can effect neurons, astrocytes and blood vessels and play a major role 
in normal brain homeostasis, influencing cerebral tissue maintenance and neuronal plasticity 
(Gomez-Nicola & Perry, 2015).  These effects are important in neurodevelopment, adult brain 
homeostasis, and are likely to be important in neurodegeneration.  In the healthy adult brain 
the microglial phenotype is predominantly surveillant and highly sensitive to almost any 
disturbance of central nervous system homeostasis, being activated through Toll-like receptor 
signalling pathways (Carpentier, Duncan, & Miller, 2008) by a range of pathophysiological 
insults (Nakajima & Kohsaka, 2001; Nayak et al., 2014).  These activated microglia may then 
alter brain homeostasis through several mechanisms including inflammatory pathways, effects 
on plasticity and cytotoxic effects, the purpose of which are to eradicate the stimulus and 
repair damage (Banati, 2002a; Banati, Gehrmann, Schubert, & Kreutzberg, 1991).  In the 
context of neurodegenerative disease, where aggregated protein species may be the triggering 
danger associated molecular patterns, these effects may modulate the subsequent course of the 
neurodegenerative cascade in either a protective or, as this state of activation may become 
chronic, ineffective and potentially toxic, a deleterious manner (Gomez-Nicola, Fransen, 
Suzzi, & Perry, 2013; Pasqualetti, Brooks, & Edison, 2015; Serrano-Pozo, Betensky, Frosch, 
& Hyman, 2016).   
Neuroinflammation in neurodegenerative disease 
Evidence for neuroinflammation in FTD comes from post mortem studies of pathology in 
patients, studies of pathology in animal models, genome-wide association studies, 
epidemiological studies and from studies of biomarkers such as cerebrospinal fluid and PET.  
However, the vast majority of research into neuroinflammation in neurodegenerative disease 
has been outside of FTLD in illnesses such as Alzheimer’s disease, Parkinson’s disease and 
motor neuron disease.  Whilst the exact mechanisms of neuroinflammation may not be the 
same across different neurodegenerative diseases, there are many parallels which may be 
drawn (Guillot-Sestier & Town, 2018).  It has been shown that aggregated protein species can 
activate microglia (Heneka et al., 2014), and that a robust innate immune response 
characterised by activated microglia is part of the neuropathology of several 
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neurodegenerative diseases (Lant et al., 2014; Venneti, Wang, Nguyen, & Wiley, 2008). 
There is also evidence of a pro-inflammatory profile of cytokines in the brains of people with 
neurodegenerative disease (Heneka et al., 2015).  The hypothesis of a role for 
neuroinflammation in neurodegenerative disease was supported by epidemiological studies of 
Alzheimer’s disease which found a risk reduction in those using long term anti-inflammatory 
medication (Mcgeer & Mcgeer, 2007; McGeer & McGeer, 2013).  Genome-wide association 
studies have also implicated genes with immune function in several neurodegenerative 
illnesses including Alzheimer’s disease, Parkinson’s disease and motor neuron disease 
(Ramanan & Saykin, 2013).  Animal models of these diseases have demonstrated that 
inflammatory changes precede and interact with other features of neurodegeneration (Krabbe 
et al., 2013; Streit, Braak, Xue, & Bechmann, 2009), form a major component in the evolution 
of chronic neurodegeneration and if modulated can affect the disease course (Bhaskar et al., 
2010; Martínez-Muriana et al., 2016; Nash et al., 2013; Spangenberg et al., 2018).  They have 
also shown the potential interplay between systemic inflammation and the innate immune 
response in the brain (Cunningham et al., 2009).   
Despite this cumulative evidence, the exact inflammatory phenotype of individual 
neurodegenerative diseases remains elusive and there have been conflicting reports of whether 
a pro- or an anti-inflammatory phenotype predominates in Alzheimer’s disease (Brosseron, 
Krauthausen, Kummer, & Heneka, 2014).   
Neuroinflammation in FTD 
There is also converging evidence to support activation of innate immunity in the central 
nervous system in FTD. First, a robust innate immune response characterised by activated 
microglia is part of the neuropathology of FTD and the pattern of this neuroinflammation, as 
with protein aggregation, differs in FTD from Alzheimer’s disease (Lant et al., 2014).  
Genetic studies have also indicated a link between the immune system and FTD, in particular 
the finding that mutations in the GRN gene, whose product is a protein with diverse immune 
functions, lead to TDP-43 neuropathology and FTD (Ahmed et al., 2007). Whilst the exact 
pathological cascade is uncertain it seems likely that haploinsufficiency of progranulin results 
in dysregulated microglial activation and TDP-43 accumulation (Kleinberger, Capell, Haass, 
& Broeckhoven, 2013).  More recently mutations in TBK-1, a protein involved in the 
regulation of interferon anti-viral responses, has also been demonstrated as a genetic cause of 
FTD (Gijselinck et al., 2015; Oakes, Davies, & Collins, 2017).  Genome-wide association 
studies have also provided more indirect evidence for immune dysfunction in FTD with 
several immune loci identified in large studies as risk factors for FTD (Broce et al., 2018).  
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Many of these are the same sites identified for other neurodegenerative diseases (Ramanan & 
Saykin, 2013).   
Mouse models of FTD also support an early role for neuroinflammation.  Mouse models of 
FTD tauopathy feature inflammatory changes which precede the accumulation of aggregated 
tau (Yoshiyama et al., 2007), and a pro-inflammatory profile of molecules which increase tau 
hyperphosphorylation and aggregation (Bhaskar et al., 2010).  Fractalkine, an endogenous 
chemokine which modulates microglial activity, reduces this microglial activation and 
subsequent tau aggregation (Nash et al., 2013).  Mouse models of CHMP2B FTD also show 
microglial activation and a marked pro-inflammatory state preceding neuronal loss and 
behavioural symptoms, with a similar chemical inflammatory profile seen in human brain 
post mortem in CHMP2B disease (Clayton et al., 2017, 2015).  Mouse models of C9orf72 
disease, the most common genetic cause of FTD, show that C9orf72 appears to be required 
for proper microglial function (O’Rouke et al., 2016).   
Studies in humans add further weight to the role of neuroinflammation.  Epidemiology reveals 
an increased incidence of autoimmune disease in individuals with FTD due to TDP-43 
aggregates and also in C9orf72 expansion carriers (Miller et al., 2013, 2016).  Studies of 
cerebrospinal fluid in FTD have demonstrated increased levels of tissue necrosis factor and 
transforming growth factor β (Sjogren, Folkesson, Blennow, & Tarkowski, 2004), the latter 
has also been found to be increased in the plasma of individuals with semantic variant PPA 
and FTD due to GRN mutation (Kleinberger et al., 2013).  Whilst PET studies using markers 
of activated microglia are few and on a small scale, previous efforts have suggested increased 
levels of activated microglia in the frontotemporal regions of participants with FTD compared 
with healthy volunteers (Cagnin, Rossor, Sampson, MacKinnon, & Banati, 2004), and have 
shown microglial activation in asymptomatic carriers of MAPT mutations (Miyoshi et al., 
2010).   
Imaging and biomarkers with relevance to FTD 
Until the advent of non-invasive brain imaging (CT, then MRI) researchers relied largely on 
post mortem studies to determine the topography of neurodegeneration.  The human brain 
mapping made possible by MRI has enabled identification of prototypical patterns of disease 
in Alzheimer’s disease and FTD.  In many ways, our current understanding of the molecular 
pathophysiology of FTD is similar to that of the topography of atrophy in FTD prior to the 
advent of MRI. Although there are strong hypotheses about protein aggregation and 
neuroinflammation, based primarily on pathological findings, our knowledge of mechanisms 
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of toxicity and relationships to clinical symptoms are drawn largely from in vitro and animal 
models (Ling, Polymenidou, & Cleveland, 2013; Tracy & Gan, 2018).   
The development of imaging techniques as mechanistic biomarkers would enable 
stratification and quantification of pathology in vivo, in the same way that atrophy and 
functional measures have been investigated, and would be a huge step forward as it would 
allow fundamental questions regarding this component of pathophysiology and its 
relationship to downstream events to be addressed.  In the following sections I will summarise 
the structural findings from studies in FTD and introduce the role for PET studies to approach 
important questions regarding molecular processes in FTD.  
Structural magnetic resonance imaging findings in FTD 
Both structural and functional imaging methods have been used to study FTD. Here I will 
focus on the structural studies which have correlated atrophy patterns with clinical syndrome, 
genetic diagnosis and pathological subtype.  Rates of atrophy have also been calculated 
(Gordon et al., 2010; Knopman et al., 2009; Rohrer et al., 2008; Rohrer, Clarkson, Kittus, 
Rossor, & Ourselin, 2012; Whitwell et al., 2015) and may be useful in assessing response to 
future therapies.  These imaging abnormalities, of brain structure or function, have also 
become part of the diagnostic criteria for behavioural variant FTD as they improve specificity 
(Rascovsky et al., 2011).   
Behavioural variant FTD 
At a group level, imaging in these patients reveals predominantly frontal atrophy affecting the 
prefrontal cortex, anterior cingulate cortices, insula, anterior temporal lobes, striatum and 
thalamus (Gordon et al., 2016; Pan et al., 2012; Schroeter, Raczka, Neumann, & Cramon, 
2007).  The earliest atrophy may be seen in paralimbic cortices before spreading to through 
the paralimbic fronto-insular-striatal network (Rabinovici et al., 2008; Seeley et al., 2008).  A 
typical atrophy pattern for an individual with bvFTD is shown in figure 1.1.  The pattern of 
atrophy correlates more closely with clinical features (Hornberger, Geng, & Hodges, 2011; 
Hornberger et al., 2014; Lagarde et al., 2013; Woolley et al., 2007) than with underlying 
neuropathology (Piguet, Hornberger, Mioshi, & Hodges, 2011), in keeping with the fact the 
clinical features are a poor predictor of neuropathology across the FTD spectrum, and 
confirming the clinicoanatomical relationship, i.e. that symptoms reflect the location of 
damage.  Whilst these findings are consistent at a group level, it is striking how much 
heterogeneity there is between individual patients, with variable symmetry and frontotemporal 
lobar predominance (Gordon et al., 2016).  It has been postulated that this heterogeneity is 
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underpinned by four main neuroanatomical subtypes of behavioural variant FTD (Whitwell et 
al., 2009) but it is also likely to reflect the heterogeneity in clinical phenotype between 
individuals with bvFTD. 
 
Figure 1.1: Sagittal and axial views demonstrating frontal atrophy in a typical bvFTD participant. 
 
Semantic variant of primary progressive aphasia/ Semantic Dementia  
As with clinical phenotype, imaging findings are the most consistent at single subject level in 
semantic dementia.  Typically there is atrophy of the temporal lobes which is bilateral but 
asymmetrical, particularly affecting the anterior, inferior temporal lobe (Gorno-Tempini et al., 
2004; Mummery et al., 2000; Rohrer, Warren, et al., 2009).  The typical pattern of atrophy for 
an individual with svPPA is shown in figure 1.2. The earliest changes include atrophy in the 
temporal pole, inferior temporal lobe, parahippocampus and fusiform gyri (Brambati et al., 
2009; Rogalski, Cobia, Harrison, Wieneke, Weintraub, et al., 2011).  Structures such as the 
amygdala (Chan et al., 2009; Schroeter et al., 2007), insula, entorhinal cortex (Brambati et al., 
2009; Rosen et al., 2002) and hippocampus (Chan et al., 2001; Chan et al., 2009; Galton et al., 
2001) may also be involved.  Left predominance is the more common finding with atrophy 
progressing to eventually become more symmetrical (Kumfor et al., 2016) and extending to 
involve frontal and cingulate as well as temporoparietal cortices (Rohrer, Warren, et al., 
2009).  Even in left dominant cases the same pattern of atrophy is seen in the right temporal 
lobe (Chan et al., 2001).  The predominance of atrophy mirrors the clinical syndrome (Chan et 
al., 2009) and clinical measures of verbal and visual recognition correlate with left temporal 
lobe and right temporal lobe atrophy respectively (Chan et al., 2001). 
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Figure 1.2: Sagittal and axial views demonstrating the severe anterior inferior temporal atrophy typical in semantic 
dementia. 
 
Non-fluent variant of primary progressive aphasia 
Clinical imaging in these patients is often normal, as illustrated in figure 1.3, but voxel based 
morphometry studies have shown cortical loss in the left hemisphere with a pattern which is 
distinct from semantic variant primary progressive aphasia (Gorno-Tempini et al., 2004; 
Rogalski, Cobia, Harrison, Wieneke, Weintraub, et al., 2011).  Changes include perisylvian 
atrophy (Nestor et al., 2003), and volume loss in dorsolateral prefrontal cortex, inferior frontal 
gyrus (Gorno-Tempini et al., 2004; Josephs et al., 2006), superior temporal gyrus, anterior 
parietal lobe and insula, as well as in prefrontal areas, and subcortical nuclei such as the 
caudate and putamen.  Changes are also seen in right hemisphere structures with advancing 
clinical severity (Gordon et al., 2016; Seelaar, Rohrer, Pijnenburg, Fox, & van Swieten, 
2011).  It is hypothesised that apraxia of speech is particularly associated with atrophy in pre-
motor and supplementary motor areas whilst non-fluent aphasia is associated with perisylvian 
atrophy (Josephs et al., 2006; Josephs et al., 2012; Josephs & Duffy, 2008). 
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Figure 1.3: Axial and sagittal images demonstrating the relatively normal single subject images in a typical participant with 
nfvPPA 
 
Structural imaging in familial FTD 
Recent large scale studies of genetic FTD have taken similar approaches in individual 
monogenic aetiologies and even within specific mutations.  Two main questions are of 
particular importance in this setting.  First, do separate genetic variants, both different genes 
and pathogenic variants within a specific gene, have specific patterns of atrophy?  Second, 
when does this atrophy appear and can it be used to as a biomarker?   
Addressing the first question, it is becoming apparent that particular genetic aetiologies have a 
pattern of atrophy at a group level typical to the mutation.  For example in MAPT mutations, 
anteromedial temporal lobe atrophy is typically symmetrical (Josephs et al., 2009; Rohrer et 
al., 2010; Whitwell et al., 2012), while GRN mutations lead to very asymmetrical 
temporoparietal atrophy (Josephs et al., 2009; Rohrer et al., 2010; Whitwell et al., 2012).  
C9orf72 hexanucleotide expansions are associated with widespread symmetrical atrophy, 
most marked in dorsolateral and medial frontal lobe and orbitofrontal cortex, but also seen in 
anterior temporal lobes, parietal lobe, occipital lobe, thalamus and cerebellum (Whitwell et 
al., 2012).  Whilst each mutation group exhibits unique regions of atrophy which define these 
typical patterns, across all groups the atrophy affects a common network of regions including 
insula, orbitofrontal cortex and anterior cingulate cortex (Cash et al., 2018).  It is also clear 
that the role of cerebellar atrophy is particularly relevant in monogenic forms of FTD where 
38 
 
differential patterns of cerebellar atrophy are also associated with different monogenic causes 
(Bocchetta et al., 2016; Rohrer et al., 2015; Whitwell et al., 2015; Whitwell et al., 2012).   
The second question has potentially significant implications for diagnosis, and both as a 
selection and outcome measure for clinical trials of treatments in genetic subtypes of FTD.  It 
is a question which is not easily answered due to the heterogeneity of mutations in the same 
gene and the relatively small effects seen in the years prior to symptom onset.  However, there 
is now evidence that structural changes are found in pre-symptomatic mutation carriers 
affecting both white matter and grey matter.  These are present in all genetic groups, 
becoming apparent up to 10-15 years before symptom onset and progressing towards 
conversion to symptomatic FTD (Cash et al., 2018; Jiskoot, Bocchetta, et al., 2018; Jiskoot, 
Panman, et al., 2018; Rohrer et al., 2015). 
Structural imaging in pathological subtypes 
There has been great interest in trying to determine the imaging patterns of specific 
pathological subtypes of FTLD given the potentially important role of protein specific 
therapies as disease modifying treatments in the near future.  Within the FTLD-tau group, 
Pick’s disease pathology has been associated with asymmetric atrophy of the frontal cortex, 
anterior temporal lobes and insula (Rankin et al., 2011; Whitwell et al., 2011).  The four-
repeat tauopathies of progressive supranuclear palsy pathology and corticobasal 
degeneration are associated with greater atrophy in the supplementary and pre-motor areas, 
with a more distributed pattern seen in corticobasal degeneration involving the parietal lobes 
(Josephs et al., 2008; Whitwell, Jack Jr, Boeve, et al., 2010).  In the FTLD-TDP group, TDP-
43 type A, which is commonly associated with GRN mutations, has been correlated with a 
similarly asymmetric pattern of frontotemporoparietal atrophy (Rohrer et al., 2010; Whitwell, 
Jack Jr, Parisi, et al., 2010).  In contrast TDP-43 type B pathology is associated with 
symmetrical frontal lobe atrophy which also affects the anteromedial temporal lobes and 
insula, whilst TDP-43 type C is associated with asymmetrical anteroinferior atrophy in the 
temporal lobes (Rohrer et al., 2011), itself strongly associated with the clinical diagnosis of 
semantic dementia.  TDP-43 type D is rare and commonly found in disease caused by VCP 
mutations, studies to date have failed to reveal a consistent pattern of atrophy (Gordon et al., 
2016).  Whilst FUS pathology is also rare, it features striking caudate atrophy and has been 
associated with volume loss in orbitofrontal and anterior cingulate cortices, anteromedial 
temporal lobe and insula (Josephs et al., 2010; Seelaar, Klijnsma, Koning, Lugt, & Swieten, 
2010).  Despite these findings, in essence the pattern of atrophy reflects the clinical syndrome 
better than the underlying pathology.   
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PET studies for molecular imaging 
Whilst determining patterns of atrophy in neurodegenerative in vivo has improved our 
understanding of these diseases, structural imaging illustrates the downstream effects of 
disease and does not provide us the necessary insights into the biology and mechanisms of 
neurodegenerative processes.  In order to improve our understanding of these aspects of 
disease during life we need imaging techniques which allow us to visualise molecular 
biological processes. One way of doing this is by using PET, an imaging modality which 
exploits bespoke molecules labelled with a radioactive isotopes, such as Carbon-11 and 
Fluorine-18, to target specific processes of interest, termed radioligands. These radioligands 
have an unstable nucleus with an excess of protons and as these protons decay they emit a 
positron and a neutrino. The emitted positrons interact with the surrounding electrons 
resulting in annihilation events which converts the mass energy of the positron and electron to 
electromagnetic energy in the form of two anti-parallel photons travelling in almost opposite 
directions. These photons which result from annihilation events and be detected using a PET 
camera with scintillation detectors in coincidence mode, such that when two opposing 
detectors detect the annihilation photons within a very small time frame (in the order of 15 
nanoseconds) they are assumed to originate from the same annihilation event, the site of 
which can be determined to be along a line of projection connecting the detectors. The spatial 
resolution of the detectors and the kinetic energy of the positrons determine that the spatial 
resolution of PET in humans is usually several millimetres. This data can be acquired across 
time frames which can each be independently reconstructed and then corrected in a kinetic 
model. This is particularly useful as radioligands are distributed through human tissues over 
time and allows accurate quantification and localisation of a signal from specific molecular 
targets. 
PET is now well established as a research tool and in some areas in clinical medicine. It has 
been used in neurodegenerative research for many years, including previously in FTD.  
However, the majority of PET studies thus far have targeted downstream effects of 
neurodegeneration such as changes in metabolism or in neurotransmitters.  Given their 
predicted specificity for molecular targets of interest, PET ligands have potential utility as 
biomarkers of upstream events, such as protein aggregation and microglial activation.  There 
is a desperate need in FTD to follow the lead of β-amyloid imaging in Alzheimer’s disease, 
particularly as the clinical and pathological heterogeneity of FTD mean that drug discovery 
and clinical trials are challenging, to an even greater extent than in Alzheimer’s disease.  
Validation of robust PET ligands for use as biomarkers would accelerate and de-risk clinical 
trials, providing tools for stratification and surrogate outcome measures.  Ideal biomarkers of 
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pathology for disease modifying drugs trials would be selective, that is sensitive to and 
specific for, the relevant components of pathophysiology.  They would ideally correlate with 
the disease phenotype and clinical severity and would be able to track the quantity and 
distribution of pathophysiology with disease progression.  As the importance of tau and 
neuroinflammation in neurodegeneration has emerged, there has been great interest in 
developing specific compounds which could enable visualisation of these processes in vivo.  
In the following section I will give an over view of the background to radioligands in this 
setting. 
In vivo study of neuroinflammation using PET 
The potential mechanistic contribution of neuroinflammation to neurodegeneration has 
prompted the development of several PET ligands to image activated microglia in vivo.  All of 
these utilise binding to the translocator protein (TSPO – also known as the peripheral 
benzodiazepine receptor), which is upregulated on the mitochondrial membrane of microglia 
in the activated state and thus is a marker of activated microglia.  The first radioligand 
developed to bind this target was [11C]PK-11195.  This ligand has been widely used in studies 
of the central nervous system, in particular in neurodegenerative diseases such as Alzheimer’s 
disease, Parkinson’s disease and dementia with Lewy bodies, where it has provided evidence 
for in vivo neuroinflammation in neurodegeneration (Cagnin, Kassiou, Meikle, & Banat, 
2006; Edison et al., 2013; Koh, 2008; Passamonti et al., n.d.; Varley, Brooks, & Edison, 
2014).  It is highly robust as it is selective for activated microglia over quiescent microglia 
and reactive astrocytes (Banati, 2002b), is less affected by common polymorphisms in its 
target protein than its second generation relatives (Stefaniak & Brien, 2015; Zhang, 2015), 
and has robust methods of non-invasive kinetic analysis (Passamonti et al., n.d.; Turkheimer 
et al., 2007).  Whilst there are some suboptimal features to [11C]PK-11195, the other more 
recent radioligands which target TSPO also suffer similar problems and lack options for non-
invasive modelling of the PET data.  Therefore, [11C]PK-11195 remains the most robust and 
widely used radioligand to image neuroinflammation in neurodegenerative disease. 
PET imaging of tau pathology 
The importance of tau in neurodegeneration has led to concerted efforts to develop 
radioligands enabling visualisation of its quantity and distribution in vivo.  Like all good 
radioligands, candidate compounds must cross the blood-brain barrier, have low toxicity and 
low non-specific binding, as well rapid uptake by, and clearance from, the brain without 
retaining radiolabelled metabolites.  There are however several additional challenges to 
imaging tau (Laforce Jr et al., 2018; Lois, Gonzalez, Johnson, & Price, 2018; Villemagne, 
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Fodero-Tavoletti, Masters, & Rowe, 2015; Villemagne & Okamura, 2016).  These include the 
need for the radioligand to cross the cell membrane to reach intracellular tau pathology and 
the fact that tau pathology is found at lower concentrations in the brain than β-amyloid.  The 
heterogeneity of tau pathology is also a significant factor along with other post translational 
modifications and the maturity of tau tangles which may both also be relevant (Lowe et al., 
2016).   
Several ligands have been developed to bind to paired helical filament tau in Alzheimer’s 
disease.  These include families of compounds such as THK and PBB (Laforce Jr et al., 2018) 
but the most widely studied tau binding radioligand to date is the benzimidazole-pyrimidine 
derivative, [18F]AV-1451.  This compound is selective for tau versus β-amyloid and versus α-
synuclein (Xia et al., 2013).  It has strongly convincing results in vivo in Alzheimer’s disease, 
where binding recapitulates Braak staging (Schwarz et al., 2016) and correlates strongly with 
phenotypic variation (Ossenkoppele et al., 2018, 2016; Scholl et al., 2017), as well as with 
clinical severity.  More recently, longitudinal studies have shown measurable increases in 
amount of binding over time as well as changing distribution, most obvious in cognitively 
impaired and β-amyloid positive individuals (Jack et al., 2018; Lowe et al., 2018).  This tracer 
also has some drawbacks including age-related increases in binding (Johnson et al., 2016; 
Lowe et al., 2018; Scholl et al., 2016) as well as potential ‘off target’ binding to 
neuromelanin, and to iron and other mineral targets (Lowe et al., 2016; Marquié et al., 2015, 
2017).  Despite these issues, it remains the most robust ‘tau ligand’ available in Alzheimer’s 
disease.  At the onset of this study relatively little was known about its ability to bind to tau 
pathology in FTD but it was the foremost candidate to be investigated for sensitivity and 
specificity in this non-Alzheimer’s setting.  
Conclusion   
In this chapter I have summarised the clinical, pathological, genetic and imaging features 
highlighting the broad and complex spectrum of FTD.  I have also introduced some of the 
challenges facing the FTD community and how the use of molecular PET may help to unravel 
some of this complexity and address major challenges in improving our understanding of 
FTD.   
This thesis focuses on two important and likely complimentary pathophysiological processes, 
tau aggregation and neuroinflammation.  To do this I use two PET tracers, [11C]PK-11195 (a 
marker of microglial activation and a proxy of neuroinflammation) and [18F]AV-1451 (a 
marker or tau pathology).   
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The objectives of this are twofold;  
(1) First to investigate whether [18F]AV-1451 PET in FTD enables the segregation of 
FTD-tau cases from non-tau cases, a capability which would have huge clinical and 
research applications.   
(2) Second objective is to provide evidence for presence of increased tau aggregation and 
microglial activation in FTD participants compared with controls.   
To address the first question, I initially test the sensitivity of [18F]AV-1451 for FTD-tau cases 
by examining binding in a case of FTD due to a MAPT mutation and resulting from 4 repeat 
tau neuropathology.  I then test [18F]AV-1451 specificity for FTD-tau cases by examining 
binding in a cohort of participants with semantic dementia (highly likely to have TDP-43 
pathology) and FTD due to C9orf72 resulting from TDP-43 type B pathology, both situations 
where one would expect to see no increase in binding of this ‘tau radioligand’.  Finally, I 
characterise the presence and distribution microglial activation and tau aggregation across the 
whole FTD spectrum and within the individual diseases, as well as assessing the relationship 
between tau aggregation and microglial activation in FTD. 
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Chapter 2: Methods 
 
Summary 
This chapter is adapted from Bevan-Jones et al, published in BMJOpen in 2015.  Here I 
outline the methods which underpin my thesis, in particular the selection and recruitment of 
participants, the neuropsychological testing and imaging aspects of the protocol and an 
introduction of the analysis techniques which are discussed in greater detail in each chapter.  
This study of frontotemporal dementia is observational in nature and is conducted within the 
overarching Neuroimaging of Inflammation in Memory and Related Other Disorders 
(NIMROD) study (Bevan-Jones et al., 2017).   
 
 
Figure 2.1: Flow chart illustrating participants’ journey through the study. 
Aims  
The aims of this study are as follows: 
1) To assess the sensitivity of the ‘tau ligand’ AV-1451 for tau pathology in FTD 
2) To assess the specificity of the ‘tau ligand’ AV-1451 for tau pathology in FTD i.e. 
could it be used to determine tau positive cases from tau negative cases 
3) To assess the presence of microglial activation across the FTD spectrum  
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Participants, Recruitment and Selection 
Patient participants were recruited from cognitive disorder clinics in neurology, old age 
psychiatry and related services at Cambridge University Hospital (CUH) and other Trusts 
within the region including Cambridgeshire, Lincolnshire, Bedfordshire, Norfolk, Suffolk, 
Hertfordshire and Essex, where subjects are willing to travel to Cambridge for imaging 
studies.  Case registers held by the Dementias and Neurodegeneration specialty of the UK 
Clinical Research Network (DeNDRoN) and the Join Dementia Research (JDR) platform 
(“www.joindementiaresearch.nihr.ac.uk,”) were other sources of participants.  Control 
subjects were recruited from healthy adults within the region who have indicated a 
willingness to participate in dementia research via JDR or DeNDRoN.  Interested, healthy 
friends and non-blood-related family members of patients were also recruited.  
Potential participants identified as above who show willingness to take part in the research are 
provided with information about the study in the form of a patient information sheet.  
Following a period of time to consider the information, a follow-up phone call is made to 
inquire as to their interest in participation and to ask for further information to ensure they are 
eligible to take part.  An appointment is then made at the study premises or at their home to 
provide an opportunity to ask further questions and obtain formal written consent from the 
participant or, in cases where the participant does not have capacity, advice from an 
appropriate consultee in accordance with the Mental Capacity Act 2005 (England and Wales).  
Consent is for participation in the study and publication of findings. 
Eligibility criteria 
Participants were included in the study if they were aged over 50 and had sufficient 
proficiency in English to allow standardised cognitive testing.  All subjects except controls 
had a reliable informant who was able to complete questionnaires for informant related scales 
and provide a background history.  For patient participants I included only subjects with mild 
to moderate dementia, as it was likely that severely impaired patient participants would be 
highly unlikely to comply with the study protocol.  Mild to moderate dementia was defined in 
this study as MMSE > 12, though those with language and/or semantic impairments (in 
particular the semantic variant of FTD), for which the MMSE is an unsuitable screening test, 
were assessed using the Clinical Dementia Rating scale (Hughes, Berg, Danziger, Coben, & 
Martin, 1982), with a score of 2 or less indicating mild to moderate dementia.  
Exclusion criteria 
Potential participants were excluded if they had a concurrent major psychiatric illness (except 
in behavioural variant of frontotemporal dementia where this label may have been a 
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differential diagnosis or where psychiatric/psychotic symptoms may form part of the 
syndrome) or if they had a contra-indication to an MRI scan (such as a permanent 
pacemaker), were unable to tolerate an MRI (due to claustrophobia), or if they had a co-
morbidity that limits their ability to take part in the study.  Potential participants were also 
excluded if they had atypical or focal parenchymal appearances on MRI which were not in 
keeping with their diagnosis.  Systemic inflammatory disease was also an exclusion criterion, 
as was concurrent medications that might have affected study assessments (e.g. oral steroids). 
Cohorts 
Recruitment numbers for each of the three frontotemporal dementia cohorts were as follows: 
behavioural variant frontotemporal dementia 10 (only 9 had [11C]PK-11195 PET), semantic 
dementia 11 (only 9 had [11C]PK-11195 PET) and progressive non fluent aphasia 10 (all 10 
had both [11C]PK-11195 PET and [18F]AV-1451 PET), all diagnosed according to the 
clinically defined international consensus diagnostic criteria laid out by Rascovsky et 
al.(Rascovsky et al., 2011) and Gorno-Tempini et al.(Gorno-Tempini et al., 2011).  Fourteen 
healthy control subjects, defined as subjects with MMSE scores greater than 26 and with an 
absence of (i) regular memory complaints, (ii) signs or symptoms suggestive of dementia or, 
(iii) unstable or significant medical illnesses were also recruited to a ‘tau control’ arm 
(undergoing [18F]AV-1451 PET) whilst fifteen healthy control participants meeting the same 
criteria were recruited to a ‘neuroinflammation control’ arm (undergoing [11C]PK-11195 
PET). 
Overview of Protocol 
Once written consent was provided, participants underwent neuropsychological assessment 
using a test battery described in detail below.  The battery was tailored to participants with 
frontotemporal dementia.  All participants also underwent an initial clinical assessment, 
including the collection of clinical and demographic information (including medication, 
smoking, alcohol, and education histories).    
Participants then made between two and three visits for imaging.  All participants had an MRI 
scan.  Healthy control participants underwent one PET scan (either with [11C]PK-11195 or 
[18F]AV-1451).  If possible all participants in each of the frontotemporal dementia cohorts 
had two PET scans ([11C]PK-11195 and [18F]AV-1451). 
Venepuncture was carried out at the time of [11C]PK-11195 imaging in all participants to 
measure peripheral inflammatory and other degenerative markers.  Participants who provided 
additional consent also had a lumbar puncture for analysis of cerebrospinal fluid (CSF), 
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measuring both established (amyloid-β-42 and total tau) and emerging candidate biomarkers 
of neurodegeneration.  
Each participant underwent repeat neuropsychological testing annually, for up to three years, 
providing a longitudinal assessment of cognitive function.  Further details of each of these 
stages are set out below. 
Initial Clinical Assessment, Neuropsychological Battery and Informant Questionnaires 
At the initial visit, neuropsychological testing was undertaken using the battery of tests. For 
the purposes of my thesis the tests used were the Addenbrooke’s Cognitive Assessment – 
revised edition, the frontal assessment battery, pyramids and palm trees and the 
Frontotemporal dementia rating scale, the key features of which are summarised in table 1. 
The full battery of tests undertaken as part of the NIMROD study is available in appendix 1.  
Clinical assessment was carried out either at the same visit or on the day of attendance for 
imaging.  Neuropsychological follow-up using the same battery of tests was undertaken 
annually for up to 3 years from the date of initial assessment. 
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Test Name Format Purpose 
Neuropsychology Assessment 
Frontal Assessment Battery (Slachevsky, 2000) Assessment tool 
completed by 
study clinician 
Assessment of 
frontal lobe 
function 
Addenbrooke’s Cognitive Examination – Revised (Eneida Mioshi, 
Dawson, Mitchell, Arnold, & Hodges, 2006) 
Researcher 
administered 
structured test 
Multi-domain 
cognitive 
screening tool 
Pyramids and Palm Trees Researcher 
administered, 
two alternative, 
forced choice, 
picture based 
test 
Assessment of 
semantic memory 
Informant Questionnaires 
Cambridge Behavioural Inventory (Wedderburn et al., 2008) An 81 item 
carer-reported 
questionnaire 
Assessment of 
several 
behavioural 
abnormalities in 
the everyday life 
including 
impulsivity and 
apathy 
Frontotemporal dementia Rating Scale A 30 item carer-
reported 
questionnaire 
Assessment of 
behaviour and 
functional abilities 
 
Table 2.1: Neuropsychological testing within the NIMROD study for the FTD cohort 
 
MRI Imaging 
MRI scanning was performed at the WBIC using 3 Tesla Siemens scanners.  For each 
participant a three-dimensional structural high-resolution T1 weighted sequence was 
performed (176 slices of 1.0 mm thickness, TE= 2.98 ms, TR = 2300 ms, flip angle =9°, 
acquisition matrix 256x240; voxel size = 1x1x1 mm3). All images were examined by a 
Consultant Radiologist at Cambridge University Hospital to exclude unexpected brain 
abnormalities in recruits.  Participants with significant abnormalities were excluded from the 
study.  MPRAGE T1-weighted images facilitated tissue class segmentation into grey matter, 
white matter and CSF respectively, and allowed non-rigid registration of standard space 
regions of interest, from a modified version of the Hammer’s atlas that included midbrain and 
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cerebellum dentate (Hammers et al., 2003), to subject MRI space.  Each T1 image was non-
rigidly registered to the ICBM2009a template brain using ANTS 
(http://www.picsl.upenn.edu/ANTS/) and the inverse transform was applied to the Hammers 
atlas (resliced from MNI152 to ICBM2009a space) to bring the regions of interest to subject 
MRI space.  The full MRI protocol for the NIMROD study is available in appendix 1. 
PET Imaging 
All subjects also underwent PET imaging.  The radiotracers were produced at the Wolfson 
Brain Imaging Centre (WBIC) Radiopharmaceutical Chemistry laboratories.  Both [11C]PK-
11195 and [18F]AV-1451 were produced using the GE PETtrace cyclotron, a 16MeV proton 
and 8MeV deuteron accelerator.  [11C]PK-11195 was prepared using the “Disposable” 
synthesis system or GE TRACER lab FX-C module.  The production of [18F]AV-1451 was 
based on the synthetic methods developed by Avid Radiopharmaceuticals and modified to use 
the GE TracerLab FX-FN synthesizer at WBIC. 
[18F]AV-1451 PET 
In summary, 370 MBq of [18F]AV-1451 (high radiochemical purity (495%), specific activity 
of 216 +/- 60 GBq/μmol at the end of synthesis) was injected intravenously over 30 seconds 
at the onset of a 90 minutes scan,  with emission data subsequently reconstructed into 58 
contiguous time frame images for kinetic analysis with the simplified reference tissue model 
(Gunn, Lammertsma, Hume, & Cunningham, 1997).  PET scanning was performed on a GE 
Discovery 690 PET/CT. A low dose CT scan on the Discovery 690.  PET pre-processing to 
produce non-displaceable binding potentials (BPND) for 90 brain regions was performed by in-
house PET modellers (Dr Young Hong and Dr Tim Fryer).  Each emission frame was 
reconstructed using the PROMIS 3D filtered back projection algorithm into a 128 x 128 
matrix 30cm transaxial field of view, with a transaxial Hann filter cut-off at the Nyquist 
frequency (Kinahan & Rogers, 1989). Corrections were applied for randoms, dead time, 
normalization, scatter, attenuation, and sensitivity. Each emission image series was aligned 
using SPM8 to correct for patient motion during data acquisition 
(www.fil.ion.ucl.ac.uk/spm/software/spm8/). The mean aligned PET image, and hence the 
corresponding aligned dynamic PET image series, was rigidly registered to the T1-weighted 
image using SPM8 to extract values from both the Hammers atlas regions of interest and 
those in a reference tissue defined in the superior grey matter of the cerebellum using a 90% 
grey matter threshold on the grey matter probability map produced by SPM8 smoothed to 
PET resolution. The superior cerebellum was used as reference region as it is considered to 
have little or no tau pathology in frontotemporal dementia (Davies et al., 2005; Josephs et al., 
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2011). All region of interest data, including the reference tissue values, were corrected for 
CSF partial volume effects through division with the mean region of interest probability 
(normalized to 1) of grey plus white matter segments, each smoothed to PET resolution.  
BPND was determined for each Hammers atlas region of interest using a basis function 
implementation of the simplified reference tissue model operating upon the Hammers atlas 
and reference tissue region of interest data with CSF correction (Gunn et al., 1997). 
[11C]PK-11195 PET 
In summary, 500 MBq [11C]PK-11195  (high radiochemical purity (>95%), specific activity 
approximately 85 GBq/μmol at end of synthesis) was injected intravenously over 30 seconds 
at the onset of a 75 minutes scan, with emission data subsequently reconstructed into 55 
contiguous time frame images for kinetic analysis with the simplified reference tissue model 
(Yaqub et al., 2012).  PET scanning used a GE Discovery 690 PET/CT, with attenuation 
correction provided by a low dose CT scan as above. The emission protocols were 75 minutes 
of dynamic imaging (55 frames) starting concurrently with a 500 MBq [11C]PK-11195 
injection. PET pre-processing to produce BPND for 90 brain regions was performed by in-
house PET modellers (Dr Young Hong and Dr Tim Fryer).  Each emission frame was 
reconstructed using the PROMIS 3-dimensional filtered back projection algorithm into a 
128x128 matrix 30cm trans-axial field of view, with a trans-axial Hann filter cut-off at the 
Nyquist frequency (Kinahan & Rogers, 1989). Corrections were applied for randoms, dead 
time, normalization, scatter, attenuation, and sensitivity. Each emission image series was 
aligned using SPM8 to reduce the effect of patient motion during data acquisition 
(www.fil.ion.ucl.ac.uk).  The mean aligned PET image (and hence the corresponding aligned 
PET image series) was rigidly registered to the T1-weighted MR image.  Supervised cluster 
analysis was used to determine the reference tissue time-activity curve. All region of interest 
data were corrected for CSF contamination through division with the mean region of interest 
probability (normalized to 1) of grey + white matter, using SPM8 probability maps smoothed 
to PET resolution.  BPND, a measure of specific binding, was determined for each region of 
interest using a basis function implementation of the simplified reference tissue model with 
CSF contamination correction. [11C]PK-11195 BPND maps were also generated using this 
basis function simplified reference tissue model approach.  
Kinetic modelling rather than the standardised uptake value ratio (SUVR) method was used 
for [18F]AV-1451 as the latter had not been validated at the start of data acquisition 
(Shcherbinin et al., 2016).  BPND provides an estimate of the density of ligand binding sites 
and in any case is a more specific measure than SUVR and in older subjects with variable 
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perfusion, as kinetic modelling overcomes the potential problem arising from a failure to 
reach steady state.   
As part of the NIMROD study blood samples were also taken from patients for later analysis 
as well as CSF samples from a sub-group. Further details of this are not included here as data 
did not form part of this thesis, but are available in appendix 1. 
Analysis 
For this study the α was set at 0.05 with a β of 0.2 giving a power of 0.8 to detect an effect 
size of 1 between 2 groups. Primary analysis of the PET and MRI data uses the 83 brain 
regions calculated in the PET pre-processing (discarding the 7 regions which consisted of 
CSF spaces, corpus callosum and pituitary).  Using these regions of interest across the whole 
brain I perform parametric univariate comparisons of each diagnostic group to controls using 
[11C]PK-11195 BPND, [18F]AV-1451 BPND or grey matter volume.  Comparisons are also 
made of specific cases against controls adjusting for small sample sizes as required (Crawford 
& Howell, 1998; Crawford, Garthwaite, & Crawford, 2007).  Correlational analyses between 
ligands utilise Pearson correlations of raw BPND and of BPND adjusted for regional control 
mean.   
Parametric and non-parametric data driven, multivariate approaches were also used to 
examine distribution of binding across the whole brain and for classification purposes.  In 
particular I recurrently use non-parametric analyses of distribution in order to compare 
distributions of binding across cohorts blinded to absolute magnitude of binding. To describe 
the non-parametric analysis of distribution further, for each participant the 83 regional binding 
values are ranked from highest to lowest and this rank order plotted to form a single vector 
representative of the pattern of binding for that participant. A correlation analysis is then 
undertaken correlating each participant’s vector with every other participant’s vector. These 
correlations are then plotted in correlation matrices to illustrate whether the patter of binding 
in one individual is similar or different from another. The matrices then form the input into 
another method called multidimensional scaling, in this case restricted to 2 dimensions, which 
plots each individual in 2 dimensions relative to the strength of correlation with every other 
individual in order to illustrate the groups of individuals who are the most similar. When 
interpreting the correlation matrices it is only necessary to consider the top row of squares (or 
left hand column of squares as this is its mirror image). In this row the top left square will 
represent the correlation of the patient against themselves and so will be perfect. Every other 
square to the right of this will represent the correlation of the patient with one of the controls 
and will be variably dissimilar. The body of the of matrix to the right of the left hand column 
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and inferior to the top row will represent the correlation of controls with other controls. When 
interpreting the multidimensional scaling plots it is important to remember that they are not 
demonstrating correlations of 2 variables but rather spatial modes of binding according to 2 
dimensions. This enables us to visualise those individuals who have similar spatial modes of 
binding and to see the emergence of groups. The significance of these groups is then 
examined in the final chapter using a cross validation linear support vector machine.   
Ethics and radiation approval 
The study protocol was approved by the local ethics committee, East of England - Cambridge 
Central Research Ethics Committee (reference: 13/EE/0104).  The study is also ARSAC 
(Administration of Radioactive Substances Advisory Committee) approved as part of this 
process. The cohort is part of the MRC funded Dementias Platform UK collaboration.  
Approvals, consent forms and information sheets for the study are available in appendix 1. 
Limitations 
Although each of the following chapters includes discussion of specific limitations related to 
the questions each addresses, there are broader limitations which relate to the general.  I 
briefly outline these below. 
1) FTD is a heterogeneous entity and the diagnosis and recruitment in this study is based 
on clinical features and not pathologically proven. 
2) The study, although large by FTD standards, has a small sample size which increases 
the chance of type II error. 
3)  Logistical problems related to availability of scanners, ligands and patients leads to 
variable time differences between scanning modalities and the use of two different 
scanners introducing a confounding source of variability and noise into the data. 
4) The PET modelling methods used in this study reflect the available evidence when 
recruitment started in 2014 and so use standardised reference tissue models, in 
particular for AV-1451 modelling, rather than standardised uptake value ratio methods 
as these had not been validated. 
5) The use of partial volume corrected data forms the basis of the following analyses 
which whilst accounting for the effect of atrophy in these illnesses could artificially 
inflate binding potentials. 
6) The potential for off-target binding of both ligands and the difficulties in interpretation 
which this uncertainty causes. 
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Chapter 3: Sensitivity of [18F]AV-1451 to FTLD-tau pathology 
 
Preface 
The content of this chapter is predominantly the same as published in ‘Bevan Jones et al. [18F] 
AV‐1451 PET in behavioural variant frontotemporal dementia due to MAPT mutation. 
Annals of clinical and translational neurology. 2016 Dec;3(12):940-7’.  The 
neuropsychological assessments were performed by myself and by Robert Arnold.  Pre-
processing of the PET data was performed by Dr Timothy Fryer and Dr Young Hong.  
Analysis and interpretation was done by myself supported by Simon Jones and Dr Thomas 
Cope.  The post mortem analysis in appendix 1 was contributed by Jillian Kril and Shelley 
Forrest.  The text was written by myself and I am grateful for the input from my co-authors. 
Summary 
This chapter examines [18F]AV-1451 binding in the context of a microtubule associated 
protein tau mutation (10+16C>T), which is known to cause a genetic 4 repeat tauopathy and 
frontotemporal dementia, in essence assessing the sensitivity of this ligand to tau pathology in 
frontotemporal dementia.  I demonstrate that binding is significantly abnormal in both 
magnitude and distribution in this non-Alzheimer’s tauopathy.  These findings suggest that 
[18F]AV-1451 might be a useful biomarker in primary tauopathies. 
Introduction 
The pathogenic role of tau is well established in many neurodegenerative diseases but until 
recently it has only been feasible to examine the morphology, intensity and distribution of tau 
pathology post mortem.   However, the recent ability to image tau aggregates in vivo gives us 
the opportunity to unpick an important aspect of the pathophysiology of neurodegeneration 
and how it relates to clinical disease.   
There is strong evidence in vivo and post mortem that [18F]AV-1451 binds paired helical 
filaments of tau in Alzheimer’s disease (AD) (Marquié et al., 2015; Xia et al., 2013).  The 
distribution and magnitude of in vivo tau binding correlates with AD staging (Schwarz et al., 
2016), and recapitulates the anatomical distribution of focal onset forms including logopenic 
aphasia and posterior cortical atrophy (Ossenkoppele et al., 2016).  Binding to tau in primary, 
non-AD tauopathies is less well established, with inconsistency between in vivo PET findings 
and post mortem analysis in progressive supranuclear palsy (Lowe et al., 2016; Marquié et al., 
2015; Sander et al., 2016).   
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In order to reap the potential benefits of in vivo tau imaging it is important to demonstrate 
sensitivity of tau ligands to different types of tau pathology.  Genetically determined 
tauopathies provide an important opportunity in this regard for validation of tau ligands 
outside of Alzheimer’s disease.  It has already been demonstrated in individuals with 
advanced dementia due to MAPT mutation that regional [18F]AV-1451 binding in vivo 
correlates strongly with the density of immunohistochemical tau pathology post-mortem, and 
correlates with glucose hypometabolism (Smith, Puschmann, et al., 2016), but differentiation 
between patients and controls has not been established, in either distribution or magnitude of 
[18F]AV-1451 PET. In this chapter, I compare the magnitude and distribution of [18F]AV-
1451 binding in healthy controls to a patient with behavioural variant frontotemporal 
dementia (bvFTD) resulting from a 10+16C>T mutation in the microtubule associated protein 
tau gene (MAPT), testing the hypothesis that binding will be elevated in frontotemporal 
regions in this genetic tauopathy. 
Methods 
Family History 
Proband 
The patient presented aged 51 with 3 years of gradual change in behaviour and difficulty 
managing daily affairs, apathy, reduced empathy, obsessional behaviours, rigid routines, 
hyperphagia and weight gain.  Examination revealed adynamic, empty speech with preserved 
grammar, reduced verbal fluency, anomia, semantic deficits and surface dyslexia.  Eye 
movements were normal.  Praxis, cortical sensation and visuospatial function were intact.  
There were no cerebellar or extrapyramidal features and no signs of anterior horn cell disease.  
She scored 36/100 on the Addenbrooke’s Cognitive Examination (revised), and 3/26 on the 
frontotemporal dementia functional rating scale (Mioshi & Hornberger, 2010), indicating 
severe deficits.  Magnetic resonance imaging revealed asymmetric, predominantly left sided, 
frontotemporal atrophy.  She and her father had a 10+16C>T mutation of MAPT, with an 
H1H1 haplotype. 
Father 
The patient’s father presented aged 59 with 10 years of insidious personality change and 
inappropriate behaviour without insight.  He was disinhibited, restless, hyperphagic for sweet 
foods, with cognitive-rigidity, stereotyped behaviours and later apathy. He had semantic 
memory impairment, poor verbal fluency, anomia and surface dyslexia.  Visuospatial function 
and orientation were intact.  There were no ocular or motor abnormalities.  His initial 
54 
 
Addenbrooke’s Cognitive Examination score was 77/100.  MRI showed frontal and anterior 
temporal lobe atrophy, more marked on the left. He died aged 63.  
Previous neuropathological examination by the Cambridge brain bank (figure 3.1) showed 
moderate cerebral atrophy, most prominent in the frontal and temporal lobes, especially on the 
left.  There was mild neuronal loss and gliosis throughout cortex, without neuritic plaques.  
Ballooned neurons were observed, immunopositive for phosphorylated 4-repeat tau (figure 
3.1A), as well as widespread thread pathology in grey and white matter (figure 3.1B), and 
coiled bodies in temporal lobes (figure 3.1C). Their morphology and distribution appeared 
typical for sporadic frontotemporal lobar degeneration with CBD pathology (Cairns et al., 
2007; Dickson et al., 2002), in keeping with MAPT mutation (Ghetti et al., 2015). 
 
Figure 3.1: Representative neuropathological features of the proband’s father’s neuropathology in the superior frontal 
cortex showing a ballooned neuron (A), white matter threads (B), and a coiled body (C) immunostained with phosphorylated 
tau. Scale bar represents 
 
Paternal grandmother 
The patient’s paternal grandmother developed a change in personality and behaviour, with 
disinhibition, hoarding and theft.  Her death aged 51 was attributed to “cerebral atrophy”, 
without neuropsychological or post mortem examination. 
Positron emission tomography using [18F]AV-1451 
PET scanning used [18F]AV-1451 and dynamic scanning over 90 minutes with a GE Advance 
scanner. A 68Ge/68Ga transmission scan enabled attenuation correction. Binding potentials, 
relative to a non-displaceable compartment (BPND), were determined from kinetic analysis 
with a simplified reference tissue model, using superior cerebellar grey-matter as the 
reference region. In older subjects with variable perfusion, kinetic modelling overcomes the 
potential problem with standardised uptake value ratios arising from a failure to reach steady 
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state. Brain parcellation  used the Hammers brain atlas (Hammers et al., 2003), expanded to 
include subcortical structures (Gousias et al., 2008). 
Data modelling and statistical method 
The probed underwent [18F]AV-1451 PET and MRI as outlined in chapter 2.  Two questions 
were posed in the data analysis.  Firstly, were there areas of the brain with higher BPND in the 
proband than 12 healthy adults (55-80, mean age 66, 50% male)?  For each region, a robust t-
score was calculated for the patient compared to the control group, adjusting for the relatively 
small size of the sample (Crawford & Howell, 1998). This converges with a similar Bayesian 
approach (Crawford et al., 2007).   
Secondly, irrespective of the absolute level of ligand binding, did the distribution of binding 
across brain regions differ between the proband and healthy adults?  An hierarchical cluster 
analysis approach was used.  The parcellated [18F]AV-1451 BPND data were converted to 
individual linear vectors by region of interest.  These vectors were non-parametrically 
correlated (Spearman’s rho), giving a correlation matrix (figure 3.5), and converted to a 
dissimilarity matrix (1-correlation, figure 3.5). Dissimilarity fed into hierarchical cluster 
analysis with thresholding for two groups using a complete (‘farthest neighbour’) method 
(Http://cda.psych.uiuc.edu/multivariate_fall_2013/matlab_help/cluster_analysis.pdf, n.d.); the 
most stringent linkage method for a single case (figure 3.4).   
Results 
Figure 3.2 contains raw maps of BPND for all individuals. 
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Figure 3.2: Upper panel: [18F]AV-1451 BPND (left) and T1-weighted MRI scan (right) for the proband. Lower panel: 
[18F]AV-1451 BPND for each individual control. [18F]AV-1451 BPND slices for all individuals are in the same position in 
native space. 
 
Figure 3.3 illustrates the regions with significantly elevated t-scores in the proband. 
Bonferroni correction for 83 regions-of-interest comparisons confirmed significant 
differences in inferior temporal lobe, and inferior and medial temporal pole bilaterally, as well 
as right superior temporal pole (table 1).  
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Figure 3.3:  Coronal and axial sections through the template brain, overlaid with ligand binding t-scores. 
 
As an indication of the sensitivity of the ligand in these regions, table 1 also includes a 
column of the maximum BPND in each region for any of the controls, as well as the mean and 
standard deviation across all controls. For the left inferior temporal lobe, the region with the 
highest t-score, the control mean BPND was 0.0086 (standard deviation 0.0346), the maximum 
BPND observed in any of the controls was 0.0572, and the MAPT patient’s BPND was 0.2928. 
The MAPT patient’s BPND in this region was therefore 8.2 standard deviations above the 
mean, and 5.8 times more unusual than any of the controls. 
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Table 3.1:  Corrected t-scores from brain regions with statistically significant ligand binding potential (BPND) at p < 0.05 
uncorrected. Regions surviving Bonferroni correction for 83 comparisons (p < 0.0006) are in bold. For each region, the 
BPND for the for the MAPT patient is given, along with the maximum BPND observed in any of the controls and the mean and 
standard deviation of BPND across all controls. 
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Hierarchical cluster analysis of the distribution (figure 3.4) distinguished two groups. The red 
group contained 11 of the 12 healthy elderly individuals, while the cyan group contained the 
patient and 1 of the healthy individuals. 
 
 
Figure 3.4: The linkage dendrogram produced by hierarchical cluster analysis. The two resultant clusters are coloured in 
red and cyan. Controls are numbered according to their order in the upper panel correlation and dissimilarity matrices. 
 
Cluster analysis, blinded by non-parametric methods to the degree of ligand binding, therefore 
provided statistically significant classification (binomial p=0.003). The control classified 
together with the patient under the farthest neighbour method was 80 years old.  She did not 
display any cognitive abnormalities (ACE-R 98/100, MMSE 30/30) but parametric t-test 
comparison of this individual to the other controls revealed higher BPND in right hippocampus 
(t10= 5.14; p<0.05 Bonferroni corrected) and parahippocampal gyrus (t10 = 4.53; p<0.05 
corrected) but unlike the proband, the control’s BPND was not elevated in inferior temporal 
lobes. Therefore, although the overall pattern of regional binding in this control was less 
dissimilar from the MAPT patient than it was from the most dissimilar of all of the other 
controls, there was a clear dissociation from the MAPT case. It is possible that [18F]AV-1451 
detected asymptomatic Alzheimer’s disease pathology in this healthy control, as expected in a 
proportion of older adults. Validation linkage analysis with the ‘nearest neighbour’ method 
confirmed the patient distribution to be unique. 
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Figure 3.5: Left hand side - Spearman correlation matrix between all individuals. The first row and column, separated by 
black lines from the other rows and columns, represents the patient. The other twelve columns represent controls. Right hand 
side - The same data expressed as dissimilarities (1-correlation). 
 
Together, these results indicate that it is not simply the case that the proband had globally 
elevated [18F]AV-1451 BPND, but that the BPND distribution was also significantly different, 
reflecting regional frontotemporal lobar degeneration. The patient had particularly abnormal 
BPND in anterior temporal lobes and ventral anterior cingulate cortex; areas that are 
particularly prone to tau accumulation in frontotemporal dementia (Kertesz, Mcmonagle, 
Blair, Davidson, & Munoz, 2005), and that were neuropathologically most abnormal in her 
father. 
Discussion 
The main finding is of elevated [18F]AV-1451 binding potential in the anterior temporal lobes 
and ventral anterior cingulate cortex in a patient with bvFTD due to a MAPT mutation, 
recapitulating the distribution  of neuropathology expected in FTD due to a MAPT to 
mutation.  The mutation in this family leads to C>T change in the MAPT pre-mRNA at 
position 16 of the splice donor site of intron 10.  This results in the increased incorporation of 
exon 10 in MAPT mRNA, creating an accumulation of the 4-repeat tau isoform which 
neuropathologically resembles the pathology of corticobasal degeneration (Pickering-Brown 
et al., 2004).  This finding therefore provides evidence for the sensitivity of [18F]AV-1451 to 
non-Alzheimer’s tauopathy. 
Given the clinicopathological heterogeneity of FTD, replication and further validation of tau 
tracers such as [18F]AV-1451 in this setting would have major implications for diagnosis and 
clinical trials in disorders associated with frontotemporal lobar degeneration.  PET studies in 
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cases with MAPT mutations provide an important facet of such validation, especially in 
combination with a strong, clear history and the availability of neuropathological 
confirmation.  It is also the case that morphology and biochemistry of tau pathology varies 
with different MAPT mutations and the expectation is that the sensitivity of [18F]AV-1451 to 
these variations in tau pathology will be significant given the difference in magnitude of 
binding in Alzheimer’s disease compared to this case. 
The primary limitation of this report is that it is of one participant with a MAPT mutation.  It 
also does not address the specificity of binding of [18F]AV-1451, which will be addressed in 
the next chapter which assesses [18F]AV-1451 binding in syndromes associated with TDP-43 
deposition.  Whilst one control was linked with the patient in the hierarchical cluster analysis, 
this may be accounted for by the fact that she was an outlier of the control group in age and is 
perhaps more likely to harbour asymptomatic Alzheimer’s pathology. 
In conclusion, the intensity and distribution of binding of the tau ligand [18F]AV-1451 in a 
patient with a MAPT 10+16C>T mutation supports the use of this ligand in clinical studies of 
dementia, including frontotemporal lobar degeneration and corticobasal syndrome. 
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Chapter 4: Specificity of [18F]AV-1451 in FTLD – binding in 
Semantic dementia 
 
Preface 
The content of this chapter is predominantly the same as published in ‘Bevan-Jones et al. [18F] 
AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the 
semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2018 Oct 
1;89(10):1032-7.’.  The neuropsychological assessment was performed by myself and by 
Robert Arnold.  Pre-processing of the PET data was performed by Dr Timothy Fryer and Dr 
Young Hong.  Analysis and interpretation was done by myself supported by Simon Jones and 
Dr Thomas Cope.  The text was written by myself and I am grateful for the input from my co-
authors. 
Summary 
Semantic dementia, including the semantic variant of primary progressive aphasia (svPPA), is 
strongly associated with TDP-43 type C pathology. It provides a useful model in which to test 
the specificity of in vivo binding of the putative tau ligand [18F]AV-1451, which is elevated in 
frontotemporal lobar degeneration tauopathies as demonstrated in the previous chapter.  In 
this chapter I examine [18F]AV-1451 binding in seven patients (five with svPPA, two with 
‘right’ semantic dementia).  Two independent pre-processing methods were used and both 
demonstrate clearly elevated binding potential (BPND) in temporal lobes, lateralising 
according to their clinical syndrome. [18F]AV-1451 binding in vivo in regions that are likely 
to contain TDP-43 and not significant tau pathology suggests a non-tau target for [18F]AV-
1451 and question the specificity of this ligand for tau pathology in frontotemporal dementia. 
Introduction 
The importance of biomarkers in neurodegenerative disorders is well established.  Positron 
emission tomography (PET) has played an important role in biomarker development, 
illustrated by the impact of the Pittsburgh Compound B on both research and clinical practice 
in Alzheimer’s disease (Klunk et al., 2004).  Whilst β-amyloid is central to the 
neuropathology of Alzheimer’s disease, in the vast majority of cases of frontotemporal lobar 
degeneration the pathology is characterised by misfolding and aggregation of either tau 
(~40%) or TDP-43 (~50%), with fewer cases of fused in sarcoma (FUS) pathology (<10%) 
(Mackenzie et al., 2009, 2011; MacKenzie et al., 2010). A major aim for clinical research and 
drug development has been the development of biomarkers that enable pathological 
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classification and longitudinal assessment in vivo, with quantitative and qualitative 
differentiation of neurodegenerative syndromes based on their underlying proteinopathy: tau 
vs TDP-43 vs β-amyloid.   
The radioligand [18F]AV-1451 was developed from compound screening in Alzheimer’s 
brains and is selective for tau versus β-amyloid and versus α-synuclein (Xia et al., 2013). In 
vitro and in vivo studies have confirmed that [18F]AV-1451 binding in Alzheimer’s disease 
correlates strongly with phenotypic variation (Ossenkoppele et al., 2016), clinical severity and 
Braak stage (Johnson et al., 2016; Scholl et al., 2016; Schwarz et al., 2016).  There are fewer 
studies in frontotemporal lobar degeneration, but [18F]AV-1451 has also been shown to be 
sensitive in vivo to frontotemporal dementia associated with mutation of the microtubule 
associated protein tau gene (MAPT) (Bevan-Jones et al., 2016; Smith, Puschmann, et al., 
2016; Spina et al., 2017), and in progressive supranuclear palsy (Passamonti et al., 2017).  
There is also evidence of modest binding to primary tauopathies in post mortem studies 
(Sander et al., 2016). However, the specificity of [18F] AV-1451 for tau pathology remains 
controversial.  
Here, I test the properties of [18F]AV-1451 in semantic dementia, including the semantic 
variant of primary progressive aphasia (svPPA) and its non-dominant homologue, right 
semantic dementia (R-SD). Both syndromes display TDP-43 pathology in 75-90% of 
cases(John R Hodges et al., 2010; Spinelli et al., 2017), with tau pathology rarely present at 
post mortem. I test two complementary hypotheses: 
1) In clinically diagnosed semantic dementia (likely TDP-43 pathology) the non-
displaceable binding potential (BPND) of [18F]AV-1451 is not increased compared with 
healthy older adults. 
2) Independent of absolute levels of [18F]AV-1451 BPND, the distribution of binding 
across brain regions is similar in patients and healthy controls. 
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Table 4.1: Demographic, clinical, neuropsychological [Addenbrooke’s Cognitive Examination – revised (ACE-R), Frontal 
Assessment Battery (FAB), and Pyramids and Palm trees (PPT)] and diagnosis for each participant with semantic dementia 
and for the group of 12 controls. 
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Methods 
MRI and PET imaging 
Each participant underwent T1-weighted MRI (3T Siemens Trio or 3T Siemens Prisma, 
MPRAGE sequence, 1mm isotropic voxels) before PET. Manufacture of [18F]AV-1451 used 
synthetic methods developed by Avid Radiopharmaceuticals, modified for GE TracerLab FX-
FN synthesizer at the Wolfson Brain Imaging Centre, Cambridge.  A GE Discovery TM 690 
PET/CT scanner was used.  370 MBq of [18F]AV-1451 was injected over 30 seconds at the 
onset of a 90 minutes scan. Emission data were reconstructed in 58 contiguous time frame 
images.  Each emission frame was reconstructed using the PROMIS 3D filtered back 
projection algorithm into a 128 x 128 matrix 30cm transaxial field of view, with a transaxial 
Hann filter cut-off at the Nyquist frequency (Kinahan & Rogers, 1989). Corrections were 
applied for randoms, dead time, normalization, scatter, attenuation, and sensitivity. Each 
emission image series was aligned to correct for patient motion during data acquisition 
(www.fil.ion.ucl.ac.uk/spm/software/spm8).  The BPND was determined by kinetic modelling 
with a simplified reference tissue model.  The reference tissue was defined in the superior 
grey matter of the cerebellum, using a 90% grey matter threshold on the grey matter 
probability map produced by SPM8, smoothed to the PET resolution.  The superior 
cerebellum was chosen as a reference region as it is unlikely to contain substantial pathology 
in semantic dementia (0 out of 15 cases of semantic dementia in the Cambridge brain bank 
had cerebellar pathology). 
Two independent pre-processing methods were evaluated. (i) The data were co-registered 
with T1-weighted images. Regions of interest were defined by cortical parcellation and 
modified subcortical segmentation using the Desikan-Killiany atlas in the PetSurfer toolbox 
within Freesurfer (Greve et al., 2016, 2014). The BPND values in each region were partial 
volume corrected using the Symmetric Geometric Transfer Matrix method (Sattarivand, 
Kusano, Poon, & Caldwell, 2012). (ii) the mean aligned PET image, and hence the 
corresponding aligned dynamic PET image series, was rigidly registered to the T1-weighted 
image using SPM8, so as to extract values from the Hammersmith Atlas n30r83 (http://brain-
development.org/brain-atlases) modified with brain stem and cerebellar parcellation.  All 
region of interest data, including the reference tissue values, were corrected for the 
cerebrospinal fluid fraction through division with the mean region of interest probability 
(normalized to 1) of grey plus white matter segments, each smoothed to PET resolution.  
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Analysis 
To test Hypothesis 1, I used general linear models with t-tests for each region of interest, 
excluding extraparenchymal regions, first comparing each patient to the control group, as a 
case series [c.f. (Bevan-Jones et al., 2016)]. I then compared the patients group-wise to the 
controls. Data were corrected for multiple comparisons to control the false discovery rate at 
q<0.05 (Benjamini & Hochberg, 1995; Genovese, Lazar, & Nichols, 2002).  
To test Hypothesis 2, regional binding potentials for each subject were converted to a linear 
vector. Spearman’s rank order method was used to perform non-parametric correlation with 
all other subjects, creating a correlation ‘similarity’ matrix of the distribution of BPND, 
disregarding its absolute intensity. The inverse of this matrix (the ‘dissimilarity’ matrix) 
formed the input to multi-dimensional scaling and hierarchical cluster analysis. The 
performance of both farthest neighbour and average linkage methods was assessed (c.f. 
Passamonti et al, 2017). 
Results 
Figure 4.1 shows axial and sagittal views of the T1 weighted images for each participant with 
semantic dementia, confirming the severe asymmetric temporal polar atrophy in svPPA and 
R-SD respectively.  Also shown are the uncorrected raw [18F]AV-1451 BPND maps for each 
individual patient and a representative control. Statistical comparisons against controls using 
method (i) are shown for each patient individually and for the group. All patients had 
significant elevation of BPND in temporal lobes compared to controls, and in all but one 
individual this survived correction for multiple comparisons across the whole brain. As a 
group, for method (i), significant elevation of BPND at FDR q<0.05 was observed in the 
following regions of the left hemisphere: superior, middle and inferior temporal lobe, insula 
cortex, fusiform gyrus, temporal banks and accumbens.  In the right hemisphere: amygdala, 
caudate and superior temporal cortex. For method (ii), the following regions showed 
significant elevation of BPND at FDR q<0.05:  In the left hemisphere: medial anterior and 
lateral anterior temporal lobe, superior, middle and inferior temporal gyri, fusiform gyrus, 
insula, thalamus and nucleus accumbens.  In the right hemisphere: lateral anterior temporal 
lobe, middle and inferior temporal gyrus, medial anterior temporal lobe. 
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Figure 4.1: Using data pre-processed by extra method (i).  Upper panel – column 1: axial and sagittal views of T1-weighted 
images for each semantic dementia participant, column 2: raw axial and sagittal BPND maps for each patient, column 3: 
unthresholded surface-rendered regional T-maps for each subject against all controls, column 4: equivalent T-maps 
thresholded at p<0.05, corrected for false discovery rate. Lower panel – T1-weighted images and BPND maps for a 
representative control and the group comparisons of all 7 patients vs 12 controls both uncorrected (column 3) and corrected 
for false discovery rate p<0.05 (column 4).   The numbering of individual patients is consistent with figure 4.2 and table 4.1. 
 
Non-parametric multidimensional scaling of BPND distribution clearly separated patients from 
controls (figure 4.2). With either pre-processing method, hierarchical cluster analysis of these 
data detected SD with 86% sensitivity and 100% specificity. Cluster analysis, blinded by non-
parametric methods to the degree of ligand binding, therefore provided statistically significant 
unsupervised classification (Yates corrected χ2 (1, N= 19) = 11.3, p = 0.0008). Identical 
results were obtained with both average and farthest neighbour linkage methods. The patient 
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misclassified as a control had mild and relatively early disease and lay between the control 
and patient distributions on multidimensional scaling (figure 4.2, case L7). 
 
Figure 4.2: Two dimensional scaling of non-parametric whole brain regional correlations using data pre-processed by the 
extra method. Red dots represent patients, and green dots controls. Patient labels correspond to semantic dementia 
participants in table 1. 
 
Discussion 
I present evidence for consistently elevated [18F]AV-1451 BPND in seven cases with either 
svPPA or its non-dominant right hemisphere homologue, R-SD.  Contrary to the null 
hypotheses, in all seven cases individually and at the group level, the regions known to be 
most affected by TDP-43 pathology (Cairns et al., 2007; Keith A. Josephs et al., 2011) 
demonstrated increased [18F]AV-1451 binding compared to controls.  This did not merely 
reflect a global increase in BPND, as six of the seven cases were correctly classified by the 
relative distribution of BPND across the brain.  The significant regional binding to likely TDP-
43 pathology in svPPA and R-SD indicates that this ligand is not selective for tau, and casts 
doubt on the utility of [18F]AV-1451 to sub-type frontotemporal dementias according to tau 
vs. TDP-43 pathology. While this suggests that the use of [18F]AV-1451 to select tau-
mediated frontotemporal dementia populations for clinical trials is unlikely to be effective, the 
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ligand may still retain a potential role in the longitudinal assessment of the degree and 
distribution of pathological burden across the frontotemporal dementia spectrum.  
Semantic dementia in the form of svPPA represents a highly stereotyped and well defined 
clinical syndrome with characteristic structural neuroimaging  (Hodges et al., 1992; Snowden 
et al., 1989; Warrington, 1975).  Its non-dominant homologue displays similar features, but 
typically with a later presentation, more behavioural disturbance and prosopagnosia (Chan et 
al., 2009).  Within the spectrum of frontotemporal dementias, both svPPA and R-SD show 
very strong clinicopathological correlations with TDP-43 pathology, especially type C (Cairns 
et al., 2007; Hodges et al., 2010; Josephs et al., 2011; Mackenzie et al., 2011; Snowden et al., 
2007). This contrasts with the behavioural variant of frontotemporal dementia which can 
result from either TDP-43 or tau pathology with approximately equal likelihood. 
Although the majority of semantic dementia cases have TDP-43 pathology, a small minority 
of cases may arise from tauopathies, most often Alzheimer’s disease pathology or Pick’s 
disease pathology (Hodges et al., 2010; Snowden et al., 2007; Spinelli et al., 2017). In 
keeping with this, 25 of 34 patients clinically diagnosed with semantic dementia (or svPPA) 
and in the Cambridge Brain Bank are positive for Ubiquitin or TDP-43 and negative for both 
tau and β-amyloid.  Similarly, the recent report of post mortem examination in clinical cases 
of svPPA at four centres in North America (Spinelli et al., 2017) confirmed that the majority 
(24/29) had TDP-43 pathology (mainly type C). The five who did not have TDP-43 pathology 
exhibited clinical features out of keeping with the classical syndrome of svPPA, such as short 
disease duration and extrapyramidal features.  These features are not present in any of the 
individuals I report.  Although I do not have autopsy confirmation of the cases reported here, 
four out of seven participants have negative biomarkers for Alzheimer’s pathology and, 
overall, it is highly unlikely that the explanation for our findings is that all individuals in this 
study had a primary or secondary tauopathy. 
Whilst the in vivo and post mortem studies of [18F]AV-1451 in Alzheimer’s disease are 
compelling, the binding characteristics of [18F]AV-1451 in non-AD tauopathies remain 
controversial. In vivo studies have been encouraging, with significant binding demonstrated in 
frontotemporal dementia due to mutations in the Microtubule associated protein tau (MAPT) 
gene (Bevan-Jones et al., 2016; Smith, Puschmann, et al., 2016; Spina et al., 2017) and in 
progressive supranuclear palsy (Passamonti et al., 2017). This contrasts with reports from post 
mortem studies, which predominantly describe low level binding to the tau aggregates of 
frontotemporal lobar degeneration (Lowe et al., 2016; Marquié et al., 2015; Sander et al., 
2016).  These post mortem studies make it increasingly clear that the primary, tertiary and 
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quaternary structures of tau, as well as the type and maturity of tau pathology (Lowe et al., 
2016), are important determinants of [18F]AV-1451 binding.  This implies that the 
predominantly straight filaments of 4 repeat tau that constitute the pathology of progressive 
supranuclear palsy and corticobasal degeneration, and the 3 repeat tau of intraneuronal Pick 
bodies, lead to less intense binding than that seen in Alzheimer’s pathology, with its balanced 
3-/4-repeat tauopathy in the form of paired helical filaments.  
The discordance between in vivo and post mortem findings led to the proposal of ‘off target’ 
binding sites.  In the last two years several possibilities have been hypothesised, particularly 
to explain the characteristic pattern of basal ganglia binding seen in almost all participants.  
These include neuromelanin (Hansen et al., 2016; Marquié et al., 2015), iron, calcium, and 
Biondi ring tangles (Lowe et al., 2016).  None of these potential targets is anatomically 
compatible with the pattern of cortical binding seen here, which is in a distribution expected 
for pathology in semantic dementia (Cairns et al., 2007; Snowden et al., 2007).  One plausible 
explanation for the elevated signal observed here could be spill out from increased binding in 
white matter, for example to the expression of monoamine oxidase B by reactive astrocytes.  
The intrinsic resolution of PET, combined with the degree of atrophy in the semantic 
dementia cohort, makes it very difficult to distinguish binding in white or grey matter. 
However, there is a paucity of evidence for [18F]AV-1451 binding to monoamine oxidase B, 
unlike other tau radioligands such as the THK compounds.  The possibility of binding to 
monoamine oxidase B was explored early in the development of [18F]AV-1451 (Chien, Bahri, 
Szardenings, Walsh, & Mu, 2013; Xia et al., 2013) and its favourable profile in this regard 
was important in its progress to clinical studies.   
Another possibility is that [18F]AV-1451 binds to very low levels of abnormal tau that have 
been reported to co-exist with TDP-43 in some cases [25], to proteins associated with cellular 
stress in TDP-43 pathologies, or to some other cellular marker of  neurodegeneration.  
Alternatively, it could be that the in vivo binding demonstrated here mirrors the post mortem 
binding of [18F]AV-1451 to TDP-43 type C [14,34], despite the low level or absent binding to 
most TDP-43 pathology [14,34].  Overall, I retain an open mind as to the identity of the non-
tau proteins and cell types to which [18F]AV-1451 is binding in Semantic Dementia. 
One must also consider some caveats in the analytical methods of the imaging pipelines.  In 
particular, the extreme regional atrophy of SD complicates normalisation and PET analysis, 
including modelling decisions such as partial volume correction, which is necessary in order 
to prevent significant binding being obscured by the degree of atrophy.  Mis-registration 
errors arising from extreme atrophy may also influence PET estimates. However, these 
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considerations are unlikely to account for these findings for two main reasons.  Firstly, the 
bright signal of elevated [18F]AV-1451 binding is visible in the temporal lobes of uncorrected 
BPND maps in all single subjects in native space (figure 4.1).  Secondly, highly similar 
patterns of significant binding are seen with two independent methods of data pre-processing, 
using different tissue segmentation and correction methods and parcellation with different 
brain atlases.  The use of an appropriate reference tissue region may also be complicated in 
neurodegenerative diseases.  In particular, there is emerging evidence that specific patterns of 
atrophy occur in the cerebellum across a range of disorders (Gellersen et al., 2017).  In 
frontotemporal dementia, cerebellar atrophy and pathology are well described in cases of the 
behavioural variant, and particularly in cases resulting from expansions in C9orf72 (Whitwell 
et al., 2012).  However, in semantic dementia cerebellar atrophy has not been described, and 
the typical distribution of TDP-43 type C pathology does not involve the cerebellum (Davies 
et al., 2005).  We have examined fifteen cases of semantic dementia in the Cambridge brain 
bank, and in no case was cerebellar pathology found.  Additional reassurance that our results 
are not driven by a possible group difference in cerebellar pathology comes from our 
hierarchical cluster analysis. This non-parametric analysis of the distribution of pathology 
across the whole brain is blind to absolute BPND values; the effect of a group difference in a 
reference region would be to change the overall level of binding across the brain, without 
modifying the relative distribution of pathology. The fact that I was able to recover the group 
structure with 86% sensitivity and 100% specificity argues against cerebellar pathology being 
a significant driver of our findings. 
Validation of the specificity of [18F]AV-1451 binding in both Alzheimer’s disease and 
frontotemporal lobar degeneration is highly important.  Binding in the presence of 
neurodegeneration without tauopathy poses serious questions for both clinical and research 
applications of this ligand, although it may nonetheless be useful to evaluate the progression 
of neurodegenerative diseases and normal ageing.  The magnitude of elevations in binding 
potential were similar to those previously observed in MAPT mutation (Bevan-Jones et al., 
2016) and Progressive Supranuclear Palsy, but lower than those observed in Alzheimer’s 
disease (Passamonti et al., 2017).  While this study did not directly compare FTD-TDP (in 
semantic dementia) to FTD-tau cases, the lack of selectivity of [18F]AV-1451 for tauopathies 
challenges the utility of this ligand for pathological differentiation in vivo.  Determining the 
binding site or sites will be important as, even if this is not specific to tau aggregation, it may 
provide valuable insights into the cellular mechanisms of neurodegeneration, perhaps in 
regions that are yet to display volume loss or hypometabolism.  In order to determine the best 
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use of this ligand, full characterisation of the behaviour of [18F]AV-1451 in frontotemporal 
lobar degeneration with longitudinal imaging and post mortem validation is essential. 
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Chapter 5: Specificity of [18F]AV-1451 in FTLD – binding in 
C9orf72 FTD 
 
Preface 
The content of this chapter is predominantly the same as published in ‘Bevan‐Jones et al. [18F] 
AV‐1451 binding is increased in frontotemporal dementia due to C9orf72 expansion. Annals 
of Clinical and Translational Neurology. 2018 Oct;5(10):1292-6.’.  The neuropsychological 
assessment was performed by myself and by Robert Arnold.  Pre-processing of the PET data 
was performed by Dr Timothy Fryer and Dr Young Hong.  Analysis and interpretation was 
done by myself supported by Simon Jones and Dr Thomas Cope.  The text was written by 
myself and I am grateful for the input from my co-authors. 
Summary 
In this chapter I assessed [18F]AV-1451 binding in behavioural variant frontotemporal 
dementia due to a hexanucleotide repeat expansion in C9orf72, characterised by TDP-43 
pathology. This builds on findings in the previous chapter of increased binding in patients 
with semantic dementia (where patients are presumed to have TDP-43 pathology) and tests 
whether this is the case in a genetic form of frontotemporal dementia where TDP-43 is known 
definitively to be the pathology. Answering this question,  I show that 
the C9orf72 mutation increases binding in frontotemporal cortex, with a distinctive 
distribution of binding compared with healthy controls. 
Introduction 
[18F]AV-1451 was developed as a specific marker of paired helical filament tau (PHF-tau) 
pathology in Alzheimer’s disease (AD), and is selective for PHF-tau over β-amyloid and α-
synuclein in vitro (Xia et al., 2013). In vivo studies have confirmed elevated and distributed 
binding in keeping with typical and atypical presentations of Alzheimer’s disease 
(Ossenkoppele et al., 2016; Scholl et al., 2017), consistent with Braak staging (Schwarz et al., 
2016).  Binding characteristics in neurodegenerative diseases other than Alzheimer’s disease 
are controversial.  
In vivo and post mortem studies indicate increased [18F]AV-1451 binding in patients with 
frontotemporal dementia due to mutations in the microtubule associated protein tau (MAPT), 
albeit with differences between mutations associated with paired helical filament tauopathy 
and straight filament tauopathy (Bevan-Jones et al., 2016; Smith, Ohlsson, et al., 2016).  
Regionally elevated binding also occurs in another tauopathy, progressive supranuclear palsy 
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(Cope et al., 2018; Passamonti et al., 2017). However, [18F]AV-1451 binding is also seen in 
patients with semantic dementia, a disease strongly associated with TAR DNA binding 
Protein-43 (TDP-43), especially type C (Bevan-Jones et al., 2017; Makaretz et al., 2017).  The 
non-tau target of [18F]AV-1451 binding in semantic dementia is unknown and, whilst post 
mortem studies suggest a lack of binding to TDP-43 pathology (Lowe et al., 2016; Marquié et 
al., 2015; Sander et al., 2016), the elevated binding seen in vivo is in keeping with the 
characteristic anatomical distribution of neuropathology in semantic dementia.  
A limitation of previous studies of [18F]AV-1451 binding in semantic dementia cases is their 
reliance on clinico-pathological correlations to interpret the neuroimaging data. In this report, 
I describe [18F]AV-1451 binding in a patient with a clear familial case of frontotemporal 
dementia (FTD) due to a hexanucleotide repeat expansion in the C9orf72 gene. This is the 
commonest genetic cause of FTD (Bang et al., 2015) and it is strongly associated with TDP-
43 pathology (Mackenzie et al., 2011) without the presence of any tau.  I examine not only the 
magnitude of the [18F]AV-1451 binding, but also the pattern of regional distribution across 
cortical and sub-cortical structures.   
Case and controls 
A 53 year old man presented with 3 year history of progressive behavioural change 
characterised by disinhibition, grandiosity, and stereotyped behaviours.  He subsequently 
developed semantic impairments and anomia, with loss of single word comprehension and 
surface dyslexia.  At the time of imaging, he scored 53/100 on the Addenbrooke’s Cognitive 
Examination – revised edition (ACE-R, reference range >88) and 25/30 on the Mini Mental 
State Examination (MMSE).  There were significant carer endorsements for changes in 
memory, challenging behaviours, altered eating habits and abnormal beliefs on the revised 
Cambridge Behavioural Inventory.  Structural magnetic resonance imaging of his brain 
confirmed frontotemporal atrophy.  His maternal uncle had died of motor neurone disease.  
Genetic testing confirmed a hexanucleotide repeat expansion in C9orf72.  He met diagnostic 
criteria for definite behavioural variant frontotemporal dementia (Gorno-Tempini et al., 2011; 
Rascovsky et al., 2011).  He underwent research structural MRI and [18F]AV-1451 positron 
emission tomography (PET) as part of the Neuroimaging of Inflammation in Memory and 
Related Other Disorders (NIMROD) study (W Richard Bevan-Jones et al., 2017)(Passamonti 
et al., 2017).  Thirteen healthy volunteers acted as controls (age range 55-80, 6 Male, ACE-R 
range 89-99, MMSE range 28-30) and underwent the same neuroimaging and behavioural 
protocol. 
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Data modelling and statistical method 
When comparing the case with the C9orf72 genetic expansion and controls, two questions 
were posed.  First, were there regions of the brain with increased non-displaceable binding 
potential (BPND)?  Secondly, irrespective of the absolute level of ligand binding, did the 
distribution of binding across brain regions differ? This second question focusses on the 
multivariate distribution or pattern of binding, in relation to the distribution of 
neuropathological substrates of frontotemporal dementias. The pattern may be abnormal, even 
where no single region on its own has particularly high binding of [18F]AV-1451.  
To address the first question, the brain was parcellated into 83 regions using the 
Hammersmith atlas n30r83 modified to include some additional subcortical structures 
(Passamonti et al., 2017). The [18F]AV-1451 BPND in each region was calculated using the 
methods described in Passamonti et al (Passamonti et al., 2017) to obtain regional BPND 
which were adjusted for cerebrospinal fluid (CSF) partial volume effects. Individual t-tests 
were then performed in each region to compare the observed [18F]AV-1451 BPND in the 
C9orf72 case and controls, correcting for multiple comparisons across the full data range 
(FDR correction, p<0.05, plus illustration at the more liberal threshold of p<0.05 
uncorrected). 
To address the second question, a hierarchical cluster analysis was used.  The CSF corrected 
and parcellated [18F]AV-1451 BPND data were then converted to individual linear vectors 
containing all regions of interest.  The pairwise Spearman’s rank order correlations were 
calculated between all subjects, and the inverse taken to produce a dissimilarity matrix. This 
represents the difference in [18F]AV-1451 BPND distribution between every pair of subjects, 
blinded to the absolute level of that binding. These dissimilarity measures were used to 
calculate a linkage dendrogram using an average distance method.  
I also compared regional grey matter volume between the case and control group.  Regional 
grey matter volumes were calculated during PET processing and parcellated using the same 
atlas.  For each region, linear models were used with region volume, age and total intracranial 
volume as covariates (O’Brien et al., 2012). T-tests were performed between the residual of 
the patient's volume and predicted volume, based on the controls' regression, and the control 
residuals.  The p-values for each test were increased to compensate for the degrees of freedom 
used in the control regression. False discovery rate (FDR) correction was then applied to these 
adjusted p-values in the same manner as the [18F]AV-1451 BPND.  
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Results 
[18F]AV-1451 in C9orf72 FTD versus controls 
T1 weighted MPRAGE images are shown in figure 5.1A and raw BPND images uncorrected 
for partial volume effects in figure 5.1B.  The left frontotemporal regions demonstrated 
increased BPND in the C9orf72 case compared to controls.  After correcting for multiple 
comparisons (p<0.05 FDR), significant abnormalities were observed in left fusiform gyrus, 
left medial anterior temporal lobe, left middle and inferior temporal gyri, and left lateral 
inferior temporal lobe (figure 5.1E). In addition to this, more liberal thresholding without 
correction for multiple comparisons demonstrated bilateral changes, with elevated BPND also 
found in the right medial anterior temporal lobe, left anterior superior temporal gyrus, 
superior and middle frontal gyri, pallidum, and substantia nigra (figure 5.1D).   
 
 
Figure 5.1: Panels A shows selected sagittal, coronal and axial slices from the structural MRI (T1 weighted MPRAGE) of the 
C9orf72 case. Panel B shows the [18F]AV-1451 binding potential (BPND) without correction for partial volume effects in 
the same planes. Panel C shows the unthresholded t-scores for grey matter atrophy on a volumetric rendering on the 
smoothed MNI152 template MRI. Panel D shows unthresholded t-scores for (BPND) in the same way. Panel E shows the 
same data but thresholded at p<0.05 corrected for false discovery rate. 
 
The distribution of BPND was also clearly dissimilar in the C9orf72 case compared to all 
controls (upper panel of figure 5.2). The hierarchical clustering analysis indeed classified the 
patient as an outlier compared to controls (lower panel of figure 5.2). 
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Figure 5.2: Upper panel: Spearman dissimilarity matrix (1-correlation) between all individuals (C9orf72 FTD case and 12 
controls). The first row and column, separated by black lines from the other rows and columns, represents the patient. The 
other thirteen columns represent controls. Lower panel: the average linkage dendrogram produced by hierarchical cluster 
analysis. The two resultant clusters are coloured in red and black. 
 
The regional volume analysis revealed widespread grey matter loss, most marked in the 
temporal lobes, which remained after FDR correction (figure 5.1C).  T-scores along with FDR 
corrected p-values for both [18F]AV-1451 and grey matter volume are shown in table 5.1 
below. 
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Region name AV T 
score 
AV FDR corrected 
p value 
Atrophy T 
score 
Volume FDR corrected 
p value 
Left middle and inferior 
temporal gyrus 
5.98 0.01 11.40 0.000 
Left anterior temporal lobe 
medial part 
5.19 0.01 4.59 0.002 
Left fusiform gyrus 4.20 0.03 6.24 0.001 
Left anterior temporal lobe 
lateral part  
3.95 0.04 6.75 0.000 
Left superior temporal gyrus 
anterior part 
3.60 0.06 8.61 0.000 
Left pallidum  2.83 0.17 0.02 0.987 
Left substantia nigra  2.78 0.17 2.07 0.078 
Right anterior temporal lobe 
medial part  
2.58 0.22 5.25 0.001 
Left superior frontal gyrus  2.44 0.25 2.75 0.029 
Left middle frontal gyrus 2.40 0.25 5.62 0.001 
Left precentral gyrus  1.99 0.42 2.26 0.059 
Right anterior temporal lobe 
lateral part 
1.83 0.46 6.18 0.001 
Right middle and inferior 
temporal gyrus 
1.70 0.51 11.27 0.000 
Right fusiform gyrus 1.68 0.51 4.61 0.002 
Right presubgenual frontal 
cortex  
1.62 0.51 4.10 0.004 
Left cerebellum dentate 1.54 0.52 3.08 0.018 
Left putamen  1.35 0.64 2.24 0.059 
Left gyrus cinguli posterior 
part  
1.26 0.67 3.37 0.011 
Right superior frontal gyrus  1.23 0.67 2.55 0.038 
Left inferior frontal gyrus 1.11 0.74 8.30 0.000 
Right superior temporal 
gyrus anterior part 
1.08 0.74 8.62 0.000 
Right substantia nigra  1.05 0.74 1.86 0.109 
Left insula 1.05 0.74 4.51 0.003 
Left amygdala 1.04 0.74 4.96 0.001 
Left subgenual frontal cortex 0.93 0.77 2.66 0.033 
Right nucleus accumbens  0.91 0.77 0.16 0.887 
Left posterior orbital gyrus 0.90 0.77 5.61 0.001 
Right middle frontal gyrus  0.87 0.77 9.21 0.000 
Right putamen  0.85 0.77 1.11 0.325 
Left inferiolateral remainder 
of parietal lobe 
0.82 0.77 6.23 0.001 
Left thalamus  0.80 0.77 4.07 0.004 
Left superior temporal gyrus 
posterior part  
0.77 0.79 5.06 0.001 
Left posterior temporal lobe 0.74 0.80 8.69 0.000 
Left postcentral gyrus 0.70 0.81 3.06 0.018 
Right medial orbital gyrus  0.66 0.83 3.55 0.009 
Right subgenual frontal 0.64 0.83 2.26 0.059 
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cortex 
Left medial orbital gyrus 0.59 0.87 3.49 0.010 
Left nucleus accumbens 0.52 0.89 0.36 0.745 
Right pallidum 0.36 0.95 1.27 0.259 
Left caudate nucleus 0.33 0.95 2.56 0.038 
Right straight gyrus  0.33 0.95 2.83 0.026 
Right thalamus  0.32 0.95 3.60 0.008 
Right caudate nucleus 0.32 0.95 0.65 0.567 
Right anterior orbital gyrus 0.27 0.95 5.29 0.001 
Right amygdala  0.24 0.95 5.51 0.001 
Left straight gyrus  0.20 0.96 4.53 0.003 
Left lateral orbital gyrus  0.16 0.97 5.20 0.001 
Bilateral brainstem pons 0.11 0.99 5.19 0.001 
Right cerebellum grey matter 0.08 0.99 4.83 0.002 
Right gyrus cinguli posterior 
part  
0.07 0.99 3.42 0.011 
Left cingulate gyrus anterior 
part  
0.06 0.99 6.12 0.001 
Right lateral orbital gyrus  0.05 0.99 3.92 0.005 
Left superior parietal gyrus  -0.02 0.99 2.64 0.034 
Left cerebellum grey matter -0.02 0.99 5.29 0.001 
Right subcallosal area  -0.03 0.99 0.71 0.540 
Left presubgenual frontal 
cortex  
-0.17 0.97 2.43 0.045 
Right precentral gyrus  -0.25 0.95 1.28 0.259 
Bilateral brainstem midbrain -0.25 0.95 3.76 0.007 
Left anterior orbital gyrus -0.28 0.95 5.09 0.001 
Right parahippocampal and 
ambient gyri  
-0.37 0.95 2.83 0.026 
Right superior parietal gyrus  -0.38 0.95 4.06 0.004 
Right insula -0.39 0.95 5.63 0.001 
Right inferior frontal gyrus  -0.48 0.92 4.00 0.005 
Right posterior orbital gyrus  -0.52 0.89 4.06 0.004 
Right cingulate gyrus anterior 
part  
-0.52 0.89 5.38 0.001 
Right posterior temporal 
lobe 
-0.81 0.77 5.82 0.001 
Left lateral remainder of 
occipital lobe  
-0.87 0.77 3.84 0.006 
Left subcallosal area  -0.89 0.77 5.42 0.001 
Right postcentral gyrus -0.91 0.77 5.94 0.001 
Right inferiolateral 
remainder of parietal lobe  
-1.15 0.73 5.61 0.001 
Bilateral brainstem medulla -1.23 0.67 4.17 0.004 
Left parahippocampal and 
ambient gyri  
-1.26 0.67 3.05 0.018 
Right superior temporal 
gyrus posterior part  
-1.44 0.58 7.81 0.000 
Left lingual gyrus  -1.57 0.52 2.53 0.039 
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Right lateral remainder of 
occipital lobe  
-1.57 0.52 2.79 0.027 
Right cerebellum dentate  -1.63 0.51 1.97 0.092 
Right hippocampus -1.82 0.46 1.38 0.229 
Right cuneus  -1.95 0.42 0.69 0.546 
Right lingual gyrus  -1.96 0.42 5.07 0.001 
Left cuneus -2.16 0.36 0.63 0.571 
Left hippocampus  -3.16 0.11 5.66 0.001 
 
Table 5.1: T-scores and FDR corrected p-values for [18F]AV-1451 binding potential and for atrophy in each region, ordered 
by magnitude of [18F]AV-1451 binding potential T-score. 
 
Discussion 
C9orf72 expansions are strongly associated with TDP-43 type B and dipeptide repeat 
pathology.  I therefore infer that at 53 years old, with the C9orf72 expansion, and a classical 
FTD presentation, the present case has TDP-43 pathology without tauopathy. Despite this, the 
participant exhibited elevated [18F]AV-1451 binding in frontotemporal regions of a magnitude 
greater than the 95th centile of binding in controls but within the interquartile range for 
binding in Alzheimer’s disease (Passamonti et al., 2017) and semantic dementia (Bevan-Jones 
et al., 2017) (figure 5.3).  Combined with similar findings in 14 cases with semantic dementia 
(Bevan-Jones et al., 2017; Makaretz et al., 2017), this suggests that the [18F]AV-1451 PET 
ligand is not specific for tau over TDP-43 pathology in Frontotemporal lobar degeneration.  
Therefore, while [18F]AV-1451 might retain a role in tracking disease by visualising the 
distribution and/or severity of neuropathology in a person with frontotemporal dementia, it is 
unlikely to have utility for cohort selection for disease modifying trials that target tau or TDP-
43 specific disease mechanisms.   
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Figure 5.3: Boxplots of the non-displaceable [18F]AV-1451 binding potential in those regions of interest that are 
significantly elevated in the C9orf72 case compared to controls after FDR correction. As well as data for the C9orf72 case 
and the control population, comparative data are shown using the same analysis methods for our previously published 
cohorts with Alzheimer’s disease and Semantic Dementia.  
 
As expected in this participant with moderate dementia from a C9orf72 expansion, there was 
widespread grey matter loss with a predilection for frontotemporal regions, and particularly 
temporal regions in keeping with his clinical syndrome.  The regions of elevated BPND with 
largest t-scores were situated within the atrophic regions but elevated BPND did not occur 
across all atrophic regions.  The colocation of elevated BPND and atrophy is perhaps 
unsurprising if [18F]AV-1451 is binding to a non-tau molecule associated with C9orf72-
related neurodegeneration.   
There are limitations in this study.  First I have analysed data from a single case against a 
control group.  Larger studies in C9orf72 FTD might expand upon these results, as C9orf72 
frontotemporal dementia is clinically and neuroanatomically heterogeneous (Devenney et al., 
2014).  While the C9orf72 case is young, mutation positive, and meets diagnostic criteria for 
definite behavioural variant frontotemporal dementia, I lack biomarker or pathology proof of 
the absence of coincidental Alzheimer tau pathology that may occur in a small percentage of 
adults in their fifties. However, age-related pre-symptomatic Alzheimer pathology is rendered 
an unlikely explanation for the data, both by the low population prevalence at 53, and the 
regions found to have elevated binding in the case which are clearly distinct from those 
usually observed in Alzheimer’s disease. Finally, I note that the calculation of [18F]AV-1451 
BPND data uses the superior cerebellar grey matter as a reference region, as in my other recent 
papers (Bevan-Jones et al., 2016; Bevan-Jones et al., 2017; Passamonti et al., 2017).  
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Although across most of the genetic and sporadic forms of FTD this region remains 
unaffected,  in previous cases with C9orf72 expansion, cerebellar atrophy and dipeptide 
aggregation have been described (Mackenzie et al., 2013).  In mitigation of this potential 
shortcoming, whilst as expected there was cerebellar grey matter atrophy in the present 
C9orf72, there was no observable elevated cerebellar [18F]AV-1451 signal in the uncorrected 
PET BPND map.  Moreover, if elevated binding in this reference cerebellar region were 
present, it would have only reduced the estimated BPND elsewhere, making the risk of false 
negative results more likely. In any case, it is important to note that the level of cerebellar 
binding does not affect the non-parametric analysis of distributional binding differences. 
Elevated binding in genetic TDP-43 associated FTD provides further evidence for 
anatomically specific binding of [18F]AV-1451 to non-tau targets. However, the sensitivity to 
longitudinal changes in TDP-43 associated FTD, and the molecular identity of the [18F]AV-
1451 target, remain to be determined.  
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Chapter 6: Neuroinflammation and protein aggregation in the 
early stages of FTD pathogenesis 
 
Preface 
The content of this chapter is predominantly the same as published in ‘Bevan‐Jones et al. ‘In 
vivo evidence for pre‐symptomatic neuroinflammation in a MAPT mutation carrier. Annals of 
Clinical and Translational Neurology. 2018’.  The neuropsychological assessment was 
performed by myself and by Robert Arnold.  Pre-processing of the PET data was performed 
by Dr Timothy Fryer and Dr Young Hong.  Analysis and interpretation was done by myself 
supported by Simon Jones and Dr Thomas Cope.  The text was written by myself and I am 
grateful for the input from my co-authors. 
Summary 
Neuroinflammation occurs in frontotemporal dementia, however its timing relative to protein 
aggregation and neuronal loss is unknown.  In this chapter I quantify these processes in a pre-
symptomatic carrier of the 10+16 MAPT mutation I show microglial activation in 
frontotemporal regions, despite a lack of protein aggregation or atrophy in these areas.  The 
distribution of microglial activation better discriminated the carrier from controls than did 
protein aggregation at this pre-symptomatic disease stage.  These findings suggest an early 
role for microglial activation in frontotemporal dementia.   
Introduction 
Genetic aetiologies account for up to a third of cases of frontotemporal dementia (FTD) (Bang 
et al., 2015), and may provide important insights into the pathophysiology of sporadic FTD 
(Forrest et al., 2018; Josephs, 2018).  Whilst disease arising from genetic abnormalities in 
microtubule associated protein tau (MAPT) accounts for 5-10% of cases, around 40% of 
patients with FTD display tau pathology (Bang et al., 2015).  Pre-symptomatic studies of 
familial FTD have shown cognitive, structural, and network functional connectivity changes 
preceding symptomatic onset of FTD by several years (Cash et al., 2018; Rohrer et al., 2015).  
The study of pre-symptomatic mutation carriers with other modalities such as positron 
emission tomography (PET) may yield insights into early pathophysiological processes 
(Forrest et al., 2018; Josephs, 2018).   
Here, I focus on two key, potentially modifiable processes, neuroinflammation and tau protein 
aggregation.  Neuroinflammation has been implicated in FTD by cerebrospinal fluid (Sjogren 
et al., 2004), genetic (Baker et al., 2006; Broce et al., 2018; Rayaprolu et al., 2013) and PET 
84 
 
studies (Cagnin et al., 2004).  Microglial activation may alter brain homeostasis in protective 
or deleterious manners through inflammatory pathways, cytotoxicity, and changes in neuronal 
plasticity (Perry, Nicoll, & Holmes, 2010).  Despite evidence of neuroinflammation in FTD, 
little is known about their in vivo relationship to protein aggregation and neuronal loss.   
Neuroinflammation and tau pathology can be quantified using PET.  [11C]PK-11195 is a 
biomarker of activated microglia and therefore a surrogate measure for neuroinflammation 
(Banati, 2002b). [18F]AV-1451 binds preferentially to paired helical filament tau 
neuropathology (Marquié et al., 2015; Xia et al., 2013) but is also sensitive to the straight 
filament tauopathy present in the 10+16 MAPT mutations in familial FTD (Bevan-Jones et 
al., 2016). I use both ligands and structural magnetic resonance imaging (MRI) in a pre-
symptomatic carrier of the 10+16 MAPT mutation, associated with a straight filament 4 
repeat tauopathy, to test the hypothesis that neuroinflammation occurs before detectable tau 
aggregation and brain atrophy, even when the primary driver of the disease must be associated 
with tau following the MAPT mutation.  
Methods 
A 53 year old female pre-symptomatic carrier of a 10+16 MAPT mutation underwent 
neuropsychological testing, structural MRI, [11C]PK-11195 PET, and [18F]AV-1451 PET 
within a two-month period.  Blood was taken for analysis of C-reactive protein (CRP), a non-
specific peripheral marker of inflammation, at the time of [11C]PK-11195 PET.  A first-degree 
relative with the same MAPT mutation had previously been diagnosed with behavioural 
variant FTD.   
For each PET ligand two questions were posed.  Firstly, were there areas of the brain with 
higher BPND in the MAPT carrier compared to the control group? For each region, a t-score 
was calculated compared to the control group. Secondly, irrespective of the absolute level of 
ligand binding, did the distribution of binding across brain regions differ between the MAPT 
carrier and the control group? For each ligand the parcellated data were converted to 
individual linear vectors of regions of interest.  These vectors were non-parametrically 
correlated (Spearman’s rho), resulting in a correlation matrix, which was converted to a 
dissimilarity matrix, and fed into hierarchical cluster analysis based on average linkage 
distance. The information provided by these ligands was compared by assessing the non-
parametric correlation of their distributions in the MAPT carrier and controls separately. 
Finally, I compared regional grey matter volumes in the 83 regions which had been calculated 
from the T1-weighted MPRAGE images as part of the PET pre-processing method and 
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parcellated using the same atlas.  A general linear model was applied to each region 
independently to look for differences between the MAPT carrier and [18F]AV-1451 control 
group including age and total intracranial volume as predictors of no interest.   
Data from all three modalities were also compared to an individual with established MAPT 
behavioural variant FTD, whose full background and [18F]AV-1451 results have previously 
been published (Bevan-Jones et al., 2016). 
Results 
Demographics and neuropsychological scores for the MAPT carrier and controls are 
summarised in table 6.1.   
 
 
MAPT carrier AV-1451 
controls 
PK-11195 
controls 
Age 53 67 (55-80) 70 (59-84) 
Gender (F:M) Female 7:6 8:7 
Education (years) 11 16 (11-19) 14 (10-19) 
Addenbrooke's cognitive examination - revised 
(out of 100) 
86 95 (89-99) 93 (79-100) 
Frontal Assessment Battery (out of 18) 16 n/a n/a 
FTD rating scale (%) 80 n/a n/a 
 
Table 6.1: Demographic information and neuropsychological test scores for the MAPT mutation carrier and the two control 
groups. 
 
 
 
 
 
 
 
 
 
 
86 
 
Raw BPND maps for both [11C]PK-11195 and [18F]AV-1451 alongside T1-weighted 
MPRAGE images for the MAPT carrier are displayed in figure 6.1.   
 
 
Figure 6.1: Sagittal, axial and coronal slices of the raw BPND maps for [11C]PK-11195, [18F]AV-1495 and T1-weighted 
MPRAGE in the MAPT carrier.  The BPND scale bar runs along the bottom of the figure. 
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Un-thresholded t-scores for [11C]PK-11195 and [18F]AV-1451 are shown in figure 6.2 for 
display purposes.   
 
Figure 6.2:  Un-thresholded maps of t-scores for the MAPT carrier against controls for PK-11195 and AV-1495.  Regions 
coloured red (to the right of the black line on the colour scale) survived FDR correction within each modality. 
 
The brain regions with elevated [11C]PK-11195 BPND that survived correction for false 
discovery rate (FDR) in the MAPT carrier relative to controls were the left lateral anterior 
temporal lobe (t(12)=3.88, q=0.046), left fusiform gyrus (t(12)= 4.70, q=0.014), and right 
fusiform gyrus (t(12)=10.33, q<0.001).  The distribution of [11C]PK-11195 BPND was clearly 
dissimilar in the MAPT carrier compared to controls (figure 6.3). Hierarchical clustering 
analysis based on average linkage classified the patient radio-ligand distribution as the most 
abnormal. Blood sampling at the time of [11C]PK-11195 PET found a CRP <4mg/L (the 
lower limit of test sensitivity).   
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Figure 6.3: Dissimilarity matrices for across-individual whole-brain distributions of PK-11195 (left) and AV-1451 (right); 
for each matrix the case is represented in the first row and column, with each control providing a subsequent row and 
column. 
 
No regions showed elevated [18F]AV-1451 BPND after FDR correction.  The distribution of 
[18F]AV-1451 BPND was only moderately dissimilar for the MAPT carrier compared to 
controls (figure 6.3).  Hierarchical clustering analysis based on average linkage classified the 
patient distribution as the third most abnormal.  Atrophy in the right amygdala was the only 
structural change that survived FDR correction (t(10)=5.26, q=0.031).  Figure 6.4 shows 
BPND for [18F]AV-1451 and [11C]PK-11195 in the control group, MAPT carrier and a 
previously published case with established MAPT behavioural variant FTD (Bevan-Jones et 
al., 2016). 
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Figure 6.4: PK-11195 (left) and AV-1495 (right) binding potential for the MAPT carrier in regions with elevated PK-11195, 
in comparison to AV-1495 binding potential in the control groups and in a more advanced MAPT FTD case previously 
described in chapter 3. 
Discussion 
The primary finding is that the pre-symptomatic phase of MAPT mutation carriage is 
associated with temporal lobe neuroinflammation in the absence of significant binding of the 
“tau” PET ligand [18F]AV-1451 (figure 6.2), even though this ligand has been shown to bind 
in symptomatic cases with the same mutation (Bevan-Jones et al., 2016).  The multivariate, 
non-parametric dissimilarity matrices confirmed this by showing that the pre-symptomatic 
carrier was clearly discriminated from controls by her [11C]PK-11195 binding distribution, 
but not her [18F]AV-1451 binding distribution (figure 6.3).   
Of note, there was only marginal grey matter atrophy (in a single, small region, the amygdala) 
in the pre-symptomatic MAPT mutation carrier.  Together, these results suggests limited 
accumulation of the tau aggregates to which AV1451 binds, and minimal neuronal loss, 
despite the presence of neuroinflammation.   
The relatively small degree and distribution of [18F]AV-1451 binding, indicative of tau 
burden, also confirms that the proband was in the early phase of a potentially long natural 
history of neurodegeneration associated with a MAPT mutation (Rohrer et al., 2015).  Overall 
these findings suggest that microglial activation precedes clinical symptom onset and 
significant structural changes in this hereditary tauopathy, constituting an early feature rather 
than a late consequence of neurodegeneration.  The hypothesis that microglial activation 
precedes clinical symptom onset has been previously suggested (Miyoshi et al., 2010) and is 
supported by the comparison with an individual with symptomatic FTD due to the same 
10+16 MAPT mutation (figure 6.4).  The pre-symptomatic carrier demonstrated a similar 
level of elevation in [11C]PK-11195 binding compared to this symptomatic individual, but did 
not demonstrate the same elevation of [18F]AV-1451 binding. 
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There are two obvious potential interpretations of this phenomenon.  Firstly, it is possible that 
microglial activation promotes abnormal tau aggregation.  Alternatively, microglial activation 
might be induced prior to the presence of tau aggregates, by oligomeric tau to which [18F]AV-
1451 has lower affinity.  Therefore, while the data suggest an early role for inflammation in 
MAPT-related FTD, they do not settle the debate about whether microglial activation 
promotes tau aggregation, whether it is a reactive or even protective process.  This question 
could be directly assessed in future work by mediation analysis in longitudinally examined 
cohorts of genetic carriers, such as that afforded by the Genetic Frontotemporal dementia 
Initiative (GENFI) (Rohrer et al., 2015). 
This study has the limitations of a single case report, even when compared to a larger control 
group. However, it illustrates the potential utility of multimodal imaging in pre-symptomatic 
stages of FTD-related diseases to investigate the early pathophysiology of neuropathological 
subtypes.  Whilst the MAPT carrier is pre-symptomatic, she is approaching the age at which 
she would be expected to manifest symptoms, and older than the age at which her sibling 
clinically manifested the disease. She already demonstrates the abnormalities on structural 
imaging and neuropsychological testing (table 1) that have been described 5-10 years before 
symptom onset in genetic FTLD (Rohrer et al., 2015). However, her disease process is at a 
relatively early stage and without the clinical features necessary to meet diagnostic criteria for 
FTD, allowing us to be clear that abnormal microglial activation is not a feature of only late 
disease.  One must also consider the potential for differences in the signal-to-noise of the two 
PET methods and MRI volumetry.  Differences in data variance in the two methods would 
lead to differences in statistical maps, even for equivalent magnitudes of disease effects on 
inflammation, tau and atrophy.  Against this however are the findings from the 
representational similarity analysis, using measures based on BPND distribution not absolute 
binding values.  There are also limitations related to [18F]AV-1451.  Unlike in Alzheimer’s 
disease, binding in non-Alzheimer’s neurodegeneration is less understood.  Concerns 
regarding specificity relate to the demonstration of ‘off-target’ binding in the basal ganglia of 
healthy individuals (Marquie et al., 2015) and increased binding in FTD cases likely to have 
TDP-43 pathology (Bevan-Jones et al., 2018; Bevan-Jones et al., 2017; Makaretz et al., 2017).  
Binding to monoamine oxidase has also been described and is of potential relevance as 
isoforms may be present in neurons or in reactive astrocytes (Barrio, 2018; Vermeiren et al., 
2015).  However, [18F]AV-1451 is sensitive to the level and distribution of neuropathology in 
FTD due to the same MAPT mutation as in this case, demonstrated in chapter 3 (Bevan-Jones 
et al., 2016; Smith, Puschmann, et al., 2016).  Finally, given the disparity in age between the 
case and the healthy control group, the potential confound of age warrants discussion.  Both 
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[11C]PK-11195 and [18F]AV-1451 binding are potentially influenced by age with previous 
studies showing increased binding with increasing age in healthy individuals (Scholl et al., 
2016; Schuitemaker et al., 2012).  The presence of increased binding with age would make it 
more difficult to find differences between a younger case and an older healthy control group 
rather than vice versa, and therefore would not be an explanation of the group differences in 
[11C]PK-11195 binding found here.  This could provide a plausible explanation for the null 
result found in the [18F]AV-1451 data.  However, in the control groups in the dataset no 
significant effect of age on the binding potential of either ligand at a regional or global level 
could be found, suggesting that such effects, if present, are likely to be small.  
Overall, the ability of PET tracers to detect pathophysiological changes upstream of neuronal 
loss demonstrates promise for future research in larger cohorts.  Using these techniques in 
pre-symptomatic mutation carriers may yield insights into the pathophysiology of distinct 
neuropathological subtypes which, as well as leading to advances in the treatment of genetic 
forms of FTD, may elucidate the pathogenesis of sporadic FTD and other neurodegenerative 
tauopathies.  Similar studies using larger patient cohorts and longitudinal assessment of the 
role of neuroinflammation in early-stage neurodegeneration will improve understanding of 
mechanisms of disease with a view to early targeted intervention. 
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Chapter 7: Neuroinflammation and protein aggregation across 
the FTD spectrum 
 
Preface 
The content of this chapter substantially similar to a manuscript which is currently submitted 
and under review (Bevan-Jones et al. ‘Neuroinflammation and protein aggregation co-localize 
across the frontotemporal dementia spectrum. bioRxiv. 2019 Jan 1:525642.’).  The 
neuropsychological assessment was performed by myself and by Robert Arnold.  Pre-
processing of the PET data was performed by Dr Timothy Fryer and Dr Young Hong.  
Analysis and interpretation was done by myself supported by Simon Jones and Dr Thomas 
Cope.  The text was written by myself and I am grateful for the input from my co-authors. 
Summary 
The clinical syndromes of frontotemporal dementia are clinically and neuropathologically 
heterogeneous, but processes such as neuroinflammation may be common across the disease 
spectrum.  In this chapter I examine how neuroinflammation relates to the aggregation of tau 
and TDP-43 in frontotemporal dementia, and to the heterogeneity of clinical disease.  I 
suggest that [18F]AV-1451 may be a surrogate marker of non-β-amyloid protein aggregation. I 
assessed 31 patients with frontotemporal dementia (10 with behavioural variant 
frontotemporal dementia, 11 with the semantic variant of primary progressive aphasia and 10 
with the non-fluent variant of primary progressive aphasia), 28 of whom underwent both 
[18F]AV-1451 and [11C]PK-11195 PET, and matched controls (14 for [18F]AV-1451 and 15 
for [11C]PK-11195).  Using univariate region-of-interest analyses, and multivariate analysis of 
the distribution of binding that explicitly control for individual differences in ligand affinity 
for TDP-43 and different tau isoforms, I found differences between patients and controls in 
frontotemporal regions for both neuroinflammation and protein aggregation, and a strong 
positive correlation between these two processes in all disease groups.  Despite this regional 
co-localisation, the multivariate distribution of [11C]PK-11195 binding related better to 
clinical heterogeneity than did the distribution of [18F]AV-1451: distinct spatial modes of 
neuroinflammation were associated with different frontotemporal dementia syndromes and 
supported accurate group classification of participants.  These in vivo findings indicate a close 
association between neuroinflammation and protein aggregation in frontotemporal dementia. 
The inflammatory component may be important in shaping the clinical and neuropathological 
patterns of the diverse clinical syndromes of frontotemporal dementia.  
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Introduction 
Frontotemporal dementia (FTD) encompasses a clinically and pathologically heterogeneous 
group of neurodegenerative conditions, including the behavioural variant (bvFTD) 
(Rascovsky et al., 2011), non-fluent variant primary progressive aphasia (nfvPPA) and 
semantic variant primary progressive aphasia (svPPA) (Gorno-Tempini et al., 2011).  In 
recent years, attention has focused on understanding the pathogenic role of protein misfolding 
and aggregation, which is a cardinal feature of the post mortem diagnostic criteria for 
frontotemporal lobar degeneration (MacKenzie et al., 2010). However, there are several 
different pathological proteins and aggregation morphologies in FTD, with generally weak 
correlations between clinical syndrome and the type of pathological protein (Seelaar, Rohrer, 
Pijnenburg, Fox, & van Swieten, 2011) (with the exception of svPPA, which is strongly 
associated with TDP-43 type C neuropathology (Spinelli et al., 2017)). However, other 
neuropathological processes may be present in common across these diverse clinical 
syndromes and present potential therapeutic targets. In particular, there is converging 
evidence for the role for neuroinflammation in neurodegenerative dementias, including FTD, 
from genetic associations (Broce et al., 2018; Guerreiro et al., 2013; Rayaprolu et al., 2013), 
cerebrospinal fluid (Sjogren, Folkesson, Blennow, & Tarkowski, 2004; Woollacott et al., 
2018), epidemiology (Miller et al., 2013, 2016), post mortem tissue (Lant et al., 2014; 
Venneti, Wang, Nguyen, & Wiley, 2008) and animal models (Bhaskar et al., 2010; Yin et al., 
2010; Yoshiyama et al., 2007).  Both the intensity of neuroinflammation, and its distribution 
across the brain, may be relevant determinants of the clinical syndrome.   
Positron emission tomography (PET) allows the topographic quantification of specific 
molecules using radioligands.  In this study, I measured neuroinflammation and protein 
aggregation in vivo in patients with bvFTD, svPPA and nfvPPA, to answer key questions 
regarding the relationship of these pathophysiological processes.  [11C]PK-11195, which 
binds to the translocator protein (TSPO) that is expressed on the outer mitochondrial 
membrane of activated microglia, is a robust and sensitive marker of microglial activation 
with an established role as a proxy for neuroinflammation in neurodegenerative diseases 
(Stefaniak & O’Brien, 2015).  [18F]AV-1451 was originally developed to bind to paired 
helical filament tau in Alzheimer’s disease (Chien, Bahri, Szardenings, Walsh, & Mu, 2013; 
Xia et al., 2013; Zhang et al., 2012), and has been extensively used in Alzheimer’s and non-
Alzheimer’s diseases.  Elevated in vivo binding is seen in tauopathies characterised by straight 
filaments (Bevan-Jones et al., 2016; Jones et al., 2018;  Passamonti et al., 2017; Smith et al., 
2017), albeit with generally lower binding affinity than in Alzheimer’s disease, and also in 
TDP-43 related disease (Bevan-Jones et al., 2018; Bevan-Jones et al., 2017; Makaretz et al., 
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2017). It also has low affinity for β-amyloid and α-synuclein (Xia et al., 2013). Therefore, 
although the molecular interpretation of increased binding is incompletely understood 
(Marquié et al., 2015; Sander et al., 2016), this elevated in vivo binding suggests [18F]AV-
1451 may represent a proxy index of aggregated non-β-amyloid pathological proteins across 
the FTD spectrum. Given the evidence for differences in affinity of [18F]AV-1451 for 
different tau and TDP-43 conformational targets, our analysis strategy concentrates on the 
relative topographical distribution of binding across regions within each individual, rather 
than the simple magnitude of binding. In this way I explicitly control for difference in binding 
affinity between syndromes and protein strains within each syndrome.    
I test the hypotheses that, in FTD, neuroinflammation and protein aggregation are both 
increased in frontotemporal regions compared to controls, and that neuroinflammation and 
protein aggregation co-localise in each FTD syndrome, consistent with the syndrome-specific 
neuropathological distributions (e.g., co-localization of neuroinflammation and protein 
aggregation in the temporal pole of patients with svPPA).  I use data driven approaches to 
elucidate the spatial modes of neuroinflammation associated with FTD, and machine learning 
based on multi-dimensional scaling of distributional dissimilarities, to investigate whether the 
cortical distribution of neuroinflammation and protein aggregation can accurately discriminate 
diagnostic groups thereby illustrating their mechanistic importance. 
Methods 
As part of the NIMROD study (Bevan-Jones et al., 2017), 31 patients (10 with bvFTD, 11 
with svPPA and 10 with nfvPPA) underwent PET scanning with [18F]-AV1451.  28 of the 31 
(9 with bvFTD, 9 with svPPA and 10 with nfvPPA) also underwent a PET scan with [11C]PK-
11195.  The order of scans was randomised. Fourteen healthy control participants underwent 
[18F]AV-1451 PET and, to minimise radiation exposure in healthy individuals, a different 
group of 15 healthy participants underwent [11C]PK-11195 PET scanning.  Genetic and β-
amyloid status (by PET or cerebrospinal fluid biomarkers) for patients were tested if clinically 
indicated.   
PET with [18F]AV-1451 and [11C]PK-11195 was performed on a GE Discovery 690 PET/CT 
(GE Healthcare) with a low dose CT for attenuation correction or on a GE Advance PET 
scanner (GE Healthcare) with a 15-min 68Ge/68Ga transmission scan for attenuation 
correction.  The PET scan itself used dynamic imaging for 90 ([18F]AV-1451) and 75 
([11C]PK-11195) minutes respectively. All radioligands were prepared at the Wolfson Brain 
Imaging Centre (WBIC), University of Cambridge, with high radiochemical purity (>95%). 
Each subject underwent contemporaneous 3T magnetic resonance imaging (MRI) using a 
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Siemens Magnetom Skyra, Verio or Tim Trio (www.medical.siemens.com). A high-
resolution T1 weighted sequence was acquired (176 slices of 1.0 mm thickness, TE= 2.98 ms, 
TR = 2300 ms, flip angle =9°, acquisition matrix 256x240; voxel size = 1x1x1 mm3) and 
used for tissue segmentation (grey and white matter along with CSF), and for non-rigid 
registration of standard space regions of interest.   For both ligands, non-displaceable binding 
potential (BPND) was calculated in 83 regions of interest, defined by a Hammers atlas 
modified to include the midbrain and the dentate nucleus of the cerebellum, by kinetic 
modelling using a simplified reference tissue model, with cerebellar grey matter as reference 
region for [18F]AV-1451 (Passamonti et al., 2017) and supervised cluster analysis used to 
define the [11C]PK-11195 reference region (Yaqub et al., 2012). Prior to kinetic modelling all 
region of interest data were corrected for cerebrospinal fluid contamination of the region (i.e. 
partial volume corrected) through division by the mean region grey plus white matter fraction, 
determined using tissue probability maps smoothed to PET spatial resolution. 
Four data analysis approaches were used, each designed to answer a different focused 
question and to explicitly control for expected between-subject and between-region 
differences in ligand affinity.   
As a first-stage data exploration of between-group differences, a repeated-measures ANOVA 
was performed across the 83 regions, including age as a covariate and Greenhouse-Geisser 
penalisation of degrees of freedom to correct for non-sphericity.  Post hoc t-tests were then 
performed between each group, corrected for false discovery rate (FDR) over regions.   
Second, to examine the relationship between neuroinflammation and protein aggregation in 
each disease group, a correlation between the regional BPND of each ligand was performed. 
PET scanning with any ligand characteristically results in a general pattern of lower BPND in 
brain regions such as temporal lobe and higher BPND in deep brain nuclei. I was concerned 
that such non-specific effects might drive apparent correlations, and weak correlations were 
observed between our cohorts of controls for each ligand (figure 7.1). To control for this, I 
examined the between-ligand correlation within each disease group both with and without 
subtraction of the control mean BPND for each of the 83 regions of interest.  
Third, to elucidate the topographical patterns of inflammation and protein aggregation in 
FTD, I entered the BPND of each ligand in each of the 83 regions of interest into a principal 
component analysis.  Components were retained by Cattell’s criterion (i.e. to the elbow of the 
Scree plot) and then tested for group differences across diagnosis in a repeated measures 
ANOVA.  Post hoc t-tests examined group differences in the expression of each 
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topographical pattern. These first three analyses were performed in SPSS Statistics version 25 
(IBM). 
Finally, I undertook an analysis of the relative distribution of ligand binding potential for each 
ligand for every individual.  This used previously published non-parametric methods (Bevan-
Jones et al., 2016), that were explicitly designed to control for between-subject differences in 
the scaling of each ligand, such as might result from differences in the affinity of [18F]AV-
1451 for different conformations of tau or TDP-43, as well as spatial dependence between 
adjacent regions in PET data due to signal spread.  These methods can be conceptualised as 
analogous to multi-voxel pattern analysis techniques for fMRI (Kriegeskorte, Mur, & 
Bandettini, 2008), but rather than attempting to classify observed stimuli within an individual 
on the basis of their representational similarity, here I am attempting to classify individuals on 
the basis of the similarity of relative ligand BPND distributions within their brain, blinded to 
overall differences in binding affinity. To do this, for each ligand and every individual 
separately, the parcellated data were converted to 83-element linear vectors.  For each ligand 
separately, the resultant vectors were non-parametrically correlated (Spearman’s rho) pairwise 
between individuals, resulting in two matrices that represented the similarity of each 
individual's scan to each other individual for that ligand. The inverse of these matrices (i.e. the 
between-individual dissimilarities) were used to calculate a two-dimensional scaling for each 
disease sub-group pair, using the squared metric stress distance criterion of the ‘mdscale’ 
function in Matlab R2017b (Mathworks). The resulting locations in two-dimensional space 
formed the inputs to a ten-fold cross-validated linear support vector machine (CV-SVM) for 
between-group classification based on each ligand separately. Statistical significance of the 
classification was assessed by comparison of the loss function of the CV-SVM against a null 
distribution of loss functions created by 1000 repetitions of the same procedure for identical 
data but shuffled group assignment labels. For those individuals who underwent scanning 
with both ligands, the CV-SVM process was repeated on multi-modal, four-dimensional 
scaling. 
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Results 
Summary demographics are outlined in table 7.1, and individual neuropsychological test 
scores, motor features, genetic and CSF status for each participant are provided in table 7.2.  
Within the bvFTD group, two patients were positive for pathogenic mutations in the 
microtubule associated protein tau (MAPT) and three for expansions in C9 open reading 
frame 72 (C9orf72).  One of the nfvPPA group had a mutation in progranulin (GRN).  CSF or 
PET β-amyloid status was assessed in 6 participants (4 with svPPA, and 2 with nfvPPA), all 
of whom were negative.  
 
 
 
Table 7.1: Summary demographics and neuropsychometry: a=F test significant p<0.05 across all groups, b=p<0.05 
significant pairwise comparison nfvPPA vs combined control group, c=p<0.05 significant pairwise comparison svPPA vs 
combined control group, d=p<0.05 significant pairwise comparison bvFTD vs combined control group.  Pairwise 
comparisons are by t-test for each demographic except sex comparison by Chi-squared. 
 
 
 
 
 
 
 
 
 
Group Number M:F Mean 
age 
Education 
years 
ACE-R 
/100 
MMSE 
/30 
FAB 
/18 
FTDRS 
Logit 
FTDRS Percent 
/100 
nfvPPA 10 3:7 71 12 79 27 11 1.92 71.7 
svPPA 11 9:2 68 14 63 25 12 0.74 52.8 
bvFTD 10 5:5 60 13 57 22 8 -2.46 17.4 
Tau 
controls 
14 7:7 67 16 95 29 -- -- -- 
PK 
controls 
15 7:8 69 14 92 29 -- -- -- 
  b a, d a, b, d a, b, c, d a, d 
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Case Diagnosis Gene/β-
amyloid status 
Sex Entry 
age 
Education 
years 
ACE-R 
/100 
MMSE 
/30 
FAB 
/18 
FTDRS Logit 
score 
Motor 
features 
1 nfvPPA Aβ-ve (CSF) M 55 14 93 29 15 3.35 - 
2 nfvPPA - F 67 16 88 28 13 2.19 - 
3 nfvPPA Aβ-ve (CSF) F 62 11 90 27 15 1.92 + 
4 nfvPPA - F 84 11 85 30 11 5.39 + 
5 nfvPPA - F 81 10 78 28 15 0.16 - 
6 nfvPPA - F 74 10 40 16 7 -0.8 - 
7 nfvPPA GRN M 66 10 76 22 9 -0.2 - 
8 nfvPPA - F 77 11 86 30 13 0.34 + 
9 nfvPPA - M 74 11 87 30 10 1.47 + 
10 nfvPPA - F 70 11 71 25 6 5.39 - 
11 svPPA - M 77 16 45 22 11 -1.27 - 
12 svPPA - M 69 16 77 28 11 -1.54 - 
13 svPPA Aβ-ve (CSF) M 61 15 79 30 16 -0.4 - 
14 svPPA Aβ-ve (PiB) F 65 18 72 27 16 - - 
15 svPPA Aβ-ve (CSF) M 67 17 71 27 17 2.49 - 
16 svPPA Aβ-ve (CSF) M 65 13 68 27 13 5.39 - 
17 svPPA - M 72 13 63 25 12 1.26 - 
18 svPPA - F 63 10 59 26 14 0.7 - 
19 svPPA - M 69 18 85 30 14 2.19 - 
20 svPPA - M 63 10 61 27 8 -0.8 - 
21 svPPA - M 72 9 9 3 0 -0.59 - 
22 bvFTD - F 63 12 79 29 11 -3.09 - 
23 bvFTD - M 61 11 47 15 5 -2.18 - 
24 bvFTD MAPT F 50 16 43 21 9 -3.8 - 
25 bvFTD - M 75 16 68 21 6 -0.4 + 
26 bvFTD MAPT F 70 16 38 14 7 -3.09 - 
27 bvFTD - F 67 11 71 28 8 -0.8 - 
28 bvFTD - M 51 14 81 29 11 -2.58 - 
29 bvFTD C9orf72 M 56 10 53 25 6 -1.03 + 
30 bvFTD C9orf72 F 51 10 41 16 7 -3.8 - 
31 bvFTD C9orf72 M 58 9 46 17 5 -3.8 - 
 
Table 7.2: Demographics, neuropsychological testing, genetic/β-amyloid status and motor phenotype for each disease 
participant.  Aβ-ve: negative tests for β-amyloid by cerebrospinal fluid biomarkers (CSF) or Pittsburgh compound B PET 
scan. MAPT: microtubule associated protein tau. 
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The regional correlation between binding potentials of the two ligands in control participants 
is shown in figure 7.1. 
 
Figure 7.1: Plot of control participants of regional mean PK11195 binding against mean regional AV1451 binding 
 
Group comparisons of frontotemporal dementia with controls 
The repeated-measures ANOVA of regional [11C]PK-11195 binding across the FTD groups 
and controls demonstrated a significant interaction between region and diagnosis (F(39.5, 
500.6)=9.2, p<0.0001).  T-maps from the post-hoc pairwise comparisons between the control 
group and each disease group are shown in figure 7.2.  After correction for FDR, regions with 
significantly elevated binding were: in the bvFTD group; bilateral superior frontal gyri and 
putamen, right nucleus accumbens, left posterior orbital gyrus, inferior frontal gyrus and 
middle frontal gyrus.  In the svPPA group; left insula, middle and inferior temporal gyri, right 
superior parietal gyrus, middle and inferior temporal gyrus, bilateral postcentral gyri, superior 
temporal gyrus, parahippocampal and ambient gyri, amygdala, inferior lateral anterior 
temporal lobe, medulla, nuclei accumbens, medial anterior temporal lobe, fusiform gyri.  In 
the nfvPPA group no differences survived FDR correction but the peak t-score was in left 
inferior frontal gyrus (t(23)=2.17, uncorrected p=0.04), which would be expected a priori to 
be the disease epicentre (Rogalski, Cobia, Harrison, Wieneke, Thompson, et al., 2011).  
The repeated measures ANOVA of regional [18F]AV-1451 binding across the FTD groups 
and controls showed a significant interaction between region and diagnosis (F(33.4, 
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445.1)=10, p<0.0001).  T-maps from the post-hoc pairwise comparisons between the control 
group and each disease group are shown in figure 7.2.  After correction for FDR, significantly 
elevated binding was seen in svPPA, in the following regions; left amygdala, fusiform, medial 
anterior temporal lobe, middle and inferior temporal gyri and superior temporal gyrus, 
bilateral inferolateral anterior temporal lobes.   
 
 
Figure 7.2: Unthresholded regional T-scores for each disease group compared to the control group for [11C]PK-11195 
BPND in the left column and [18F]AV-1451 BPND in the right column. 
 
101 
 
Correlation of [11C]PK-11195 with [18F]AV-1451 in frontotemporal dementia 
Regional control adjusted group mean [11C]-PK11195 BPND was strongly correlated with 
regional group mean [18F]-AV1451 BPND in each group both before and after the subtraction 
of the control group values in every region: svPPA (r(81) = 0.727, p<0.0001 before, r(81) = 
0.883, p<0.0001 after), bvFTD (r(81) = 0.582, p<0.0001 before, r(81) = 0.499, p<0.0001 
after), and nfvPPA (r(81) = 0.427, p<0.0001 before, r(81) = 0.589, p<0.0001 after) (figure 
7.3). 
 
Figure 7.3: Scatter plot of the regional mean BPND for [11C]PK-11195 against regional mean BPND of [18F]AV-1451 by 
disease group. 
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Principal component analysis of [11C]PK-11195 and [18F]AV-1451 
Four principal components were detected in the [11C]-PK11195 BPND data before the elbow 
of the scree plot, which together explained 64% of the variance in the data (figure 7.4).  
Component 1 reflected whole brain binding. Component 2 was strongly weighted to the 
bilateral anterior temporal lobes.  Component 3 primarily comprised frontal binding with a 
right sided predominance. Component 4 was not strongly loaded onto any single region but 
was weighted towards motor cortex.  In a repeated measures ANOVA including these 3 
principal components, there was a main effect of diagnosis (F(3, 39)=20.8, p<0.0001) and a 
significant interaction between principal component weighting and diagnosis (F(5.307, 
68.99)=9.885, p<0.0001).  Post hoc t-tests between individual disease groups and controls 
showed svPPA was associated with an increase in component 2 (t(10.2)=8.3, p<0.0001), 
bvFTD associated with both increased component 2 (t(9.297)=3.37, P=0.008) and component 
3 (t(8.85)=3.95, p=0.003) and nfvPPA associated with increased component 3 (t(23)=2.68, 
p=0.013) (figure 7.4). Components 1 and 4 did not significantly differ between controls and 
any disease group. 
Five principal components were detected in the [18F]AV-1451 BPND data before the elbow of 
the scree plot, which together accounted for 76% of the variance in the data.  Component 1 
again reflected global binding but less marked in the temporal poles, which were loaded onto 
component 2 (left) and component 4 (right).  Component 3 was weighted asymmetrically 
towards frontal lobe binding. Component 5 was not strongly loaded onto any single region but 
was weighted towards bilateral superior temporal poles.  In a repeated measures ANOVA 
including these 5 principal components, there was a main effect of diagnosis (F(3, 41)=5.43, 
p=0.003) and a significant interaction between principal component weighting and diagnosis 
(F(11, 150.6)=3.68, p<0.0001).  The bvFTD group had increased weightings in component 3 
(t(22)=2.345, p=0.28) and component 4 (t(11.575)=3.284, p=0.007), and svPPA had increased 
weightings in component 2 (t(15.005)=6.819, p<0.0001) and component 4 (t(12.9)=2.475, 
p=0.028) (figure 7.4).  There were no significant post hoc differences between nfvPPA and 
controls. Components 1 and 5 did not significantly differ between controls and any disease 
group. 
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Figure 7.4: First four principal components for [11C]PK-11195 in the left column and [18F]AV-1451 in the right column. 
[18F]AV-1451 component 5 was also retained by Cattell’s criterion but was not strongly weighted to any region and did not 
discriminate groups so is omitted here for parsimony.  The bottom row plots the estimated marginal means from the repeated 
measures ANOVA for each ligand, illustrating the association between principal component and diagnosis for each ligand. 
 
Non-parametric analysis of [11C]PK-11195 and [18F]AV-1451 distributions 
The principal component analyses suggest that a large amount of the variance between-
subjects relates to whole brain PET signal. While this might reflect global differences in 
protein aggregation and neuroinflammation, it could also be explained by variations in 
radioligand affinity for different protein pathologies or other non-specific influences 
discussed below. I therefore performed an analysis of the relative distribution of PET signal 
for each individual scan, blinded to differences in overall signal magnitude by non-parametric 
rank-order statistical methods. 
Multi-dimensional scaling plots of the non-parametric similarity between ligand distributions, 
for each sub-group pair and for all groups combined, are shown in figure 7.5. The CV-SVM 
classification accuracy and permutation-based statistical significance are indicated next to 
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each plot. Classification was significantly better than chance in all cases, except for the 
finding that the non-parametric distribution of [18F]AV-1451 was unable to distinguish 
between bvFTD and nfvPPA.  
For those FTD participants that underwent scanning with both ligands, the classification 
procedure was repeated after combining the multi-dimensional scaling data such that the CV-
SVM operated on four dimensions rather than two. This resulted in an improvement in the 
differentiation of bvFTD and svPPA compared to either ligand alone (88.9% classification 
accuracy, p<0.001). Multimodal nfvPPA vs svPPA classification accuracy matched the 
performance of [11C]-PK11195 at 100%, p<0.001, but bvFTD vs nfvPPA classification 
performance was intermediate compared to each ligand alone, at 73.7%, p=0.033. 
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Figure 7.5: Pairwise classification accuracy for each ligand: [11C]PK-11195 on the left, [18F]AV-1451 in the middle, and 
using combined data on the right.  The graphs represent a two-dimensional projection of the between-individual PET signal 
distribution dissimilarity according to the squared metric stress criterion. A ten-fold cross-validated support vector machine 
was applied to each plot, and the classification accuracy compared to a null distribution of 1000 randomisations for non-
parametric significant testing.  For each comparison percentage classification and p-value is stated. 
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Discussion 
This in vivo study provides insights into complementary pathophysiological processes of 
frontotemporal dementia. Taken as a whole, the findings support an important role for 
neuroinflammation across the FTD spectrum, corroborating suggestions from epidemiological 
(Lant et al., 2014; Venneti et al., 2008), genetic (Broce et al., 2018; Guerreiro et al., 2013; 
Rayaprolu et al., 2013), imaging (Cagnin, Rossor, Sampson, MacKinnon, & Banati, 2004; 
Miyoshi et al., 2010) and animal studies (Bhaskar et al., 2010; Yin et al., 2010; Yoshiyama et 
al., 2007). Using regional analysis of variance, I have shown that neuroinflammation (indexed 
by [11C]PK-11195) and protein aggregates (tau or TDP43, as indexed by [18F]AV-1451) are 
elevated across the FTD spectrum (figure 7.2). Furthermore, neuroinflammation is highly co-
localised with protein aggregation within the individual syndromes, including most strongly 
in svPPA, where the predominant aggregated protein inclusions are TDP-43 rather than tau 
(figure 7.2).  Principal component analysis also revealed distinct spatial modes of 
neuroinflammation, with frontotemporal, temporal pole and global distributions (figure 7.4).  
The weighting of these regional distributions differs between groups, supporting the regional 
differences in the pair-wise comparisons.  The spatial modes of protein aggregation (figure 
7.4) similarly reflect the well characterised distributions of pathology and are likewise 
weighted towards specific groups. However, the distribution of protein aggregation appears to 
be less focal than neuroinflammation in nfvPPA.  To test the distinctiveness of inflammation 
and aggregation patterns, and to explicitly control for non-specific, between-individual 
differences in ligand binding affinity, I used non-parametric multi-dimensional scaling and 
cross-validated linear support vector machines to classify patients. I demonstrated that the 
distribution of neuroinflammation can accurately distinguish each of the FTD syndromes 
from controls and from each other (figure 7.5). Classification was often possible based on the 
distribution of protein aggregation, but with less accuracy.  The greater discriminatory ability 
of neuroinflammation emphasises its potential mechanistic relevance to the pathophysiology 
of FTD.  Despite being strongly correlated at a regional level, the two PET tracers carry some 
unique information across these conditions, as illustrated by the improvement in 
distinguishing bvFTD from svPPA when multi-modal data were available to the classifier.  
The correlation between regional distributions of neuroinflammation and protein aggregation 
supports a close relationship between these processes in FTD, mirroring recent evidence from 
Alzheimer’s disease that neuroinflammation is correlated with tau aggregation (Dani et al., 
2018), and extending this to TDP-43 associated diseases.  One interpretation of co-localised 
neuroinflammation and protein aggregation is that microglial activation is an early or 
initiating pathophysiological process, which promotes or accelerates abnormal protein 
107 
 
misfolding and aggregation.  Whilst it was previously thought that inflammation in the brain 
only occurred in the context of direct infection or after breakdown of the blood brain barrier, 
it is now recognised that microglia play a key role in orchestrating the innate immune 
response of the brain. They can be activated by misfolded proteins, and mediate responses 
through inflammatory pathways, cytotoxicity and changes in plasticity (Nakajima & Kohsaka, 
2001; Nayak, Roth, & McGavern, 2014).  In neurodegenerative diseases, this state of 
activation may become chronic, dysfunctional, and toxic, contributing to pathogenicity 
(Pasqualetti, Brooks, & Edison, 2015; Serrano-Pozo, Betensky, Frosch, & Hyman, 2016).   
There is evidence for inflammatory processes in FTD (Heneka, Kummer, & Latz, 2014), from 
genetic (Broce et al., 2018; Guerreiro et al., 2013; Rayaprolu et al., 2013), cerebrospinal fluid 
(Sjogren et al., 2004; Woollacott et al., 2018), epidemiology (Miller et al., 2013, 2016), post 
mortem (Lant et al., 2014; Venneti et al., 2008) and animal studies (Bhaskar et al., 2010; Yin 
et al., 2010; Yoshiyama et al., 2007).  It is well established that an innate immune response, 
characterised by activated microglia, is a feature of the neuropathology of FTD (Lant et al., 
2014).  Furthermore, mutations leading to haplo-insufficiency of progranulin, a growth factor 
that has peripheral immune and central microglial regulatory functions (Petkau et al., 2010; 
Pickford et al., 2011; Yin et al., 2010), leads to FTD syndromes characterised by TDP-43 
pathology.  Expansions in C9orf72 have effects on microglial function as well as neurons 
(O’Rouke et al., 2016), and risk variants for FTD in TREM2 are associated with microglial 
activation (Giraldo et al., 2013).  Neuroinflammation is an early feature of pathophysiology in 
mouse models of tauopathy, where inflammatory changes precede the accumulation of 
aggregated tau (Yoshiyama et al., 2007) and pro-inflammatory molecules increase tau 
hyperphosphorylation and aggregation (Bhaskar et al., 2010).  In vivo PET studies in small 
samples have shown that neuroinflammation anticipates atrophy in clinically established FTD 
(Cagnin et al., 2004) and precedes both symptoms and the detectability of tau aggregation by 
PET in MAPT mutation carriers (Bevan-Jones et al., 2018; Miyoshi et al., 2010).  Although 
neuroinflammation appears early in the pathogenesis of FTD and other neurodegenerative 
disorders, it remains unclear whether it is an independently initiating factor or whether it is 
induced by oligomeric proteins or pre-tangles.  
Much of the evidence supporting the presence of inflammation in FTD comes from ex vivo 
studies.  The need to improve our understanding of this process during life has led to the 
development of PET radioligands for this purpose, but there is some controversy over the 
optimum ligand for imaging activated microglia.  PET ligands which target TSPO have long 
been the mainstay of imaging microglia.  However TSPO expression patterns in microglia are 
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complex and the functional effects, i.e. deleterious versus protective, of different microglial 
phenotypes are incompletely understood (Gomez-Nicola & Perry, 2015).  Furthermore, TSPO 
is also expressed by other cell types, notably astrocytes (McCarthy & Harden, 1981).  
However, in favour of the use of [11C]PK-11195 is its demonstrated selectivity for activated 
microglia over quiescent microglia and reactive astrocytes (Banati, 2002); its relative 
insensitivity to common polymorphisms in TSPO compared to second generation TSPO 
radioligands (Stefaniak & O’Brien, 2015; Zhang, 2015), and the fact it has well established 
methods of non-invasive kinetic analysis (Passamonti et al., n.d.; Turkheimer et al., 2007).  
[11C]PK-11195 has also been effectively used in studies of other neurodegenerative diseases 
and shown ability to reveal pathologically-related patterns of neuroinflammation (Edison et 
al., 2013; Passamonti et al., n.d.; Stefaniak & Brien, 2015; Varley, Brooks, & Edison, 2015). 
There remain some disadvantages, including relatively high non-specific binding and low 
brain penetration. Whilst this signal to noise has been cited as an explanation for previous 
negative studies using [11C]PK-11195, it does not undermine positive findings such as those 
shown here, especially within our multi-variate analyses that explicitly control for differences 
in ligand penetration and affinity.  A further problem lies with interpreting the meaning of 
increased [11C]PK-11195 binding.  This must include consideration of the potential 
contribution of reactive astrocytes expressing upregulated TSPO, but also our incomplete 
understanding of the functional consequences of activated microglia and reactive astrocytosis, 
and the potential effects of glial neuropathology on the immune/inflammatory component of 
pathophysiology.  Whilst it seems reasonable to determine that increased [11C]PK-11195 
binding equates to immune activation or neuroinflammation, the functional consequences or 
causality of this cannot be assumed. 
In contrast to [11C]PK-11195, the [18F]AV-1451 binding provided a less clear signal despite 
such aggregation being an essential feature of FTD and many other dementias. I propose that 
[18F]AV-1451 binding is a proxy measure of aggregated non-β-amyloid protein.  In 
Alzheimer’s disease the sensitivity of in vivo imaging with [18F]AV-1451, and its affinity for 
tau in neurofibrillary tangles, is well established and has contributed significantly to our 
understanding of its pathogenesis and progression.  However, the situation in FTD is more 
complex due to its pathological heterogeneity and our incomplete understanding of [18F]AV-
1451 binding to the various morphologies of aggregated protein observed in FTLD-tau and 
FTLD-TDP43 pathologies.  This heterogeneity is problematic and although six of our patients 
have genetic mutations, and six others were β-amyloid biomarker negative (tables 1&2), we 
cannot definitively ascertain the majority of patients’ pathological type ante mortem.  In this 
context, the molecular targets for [18F]AV-1451 binding remain controversial.  Supporting our 
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use of [18F]AV-1451 as a marker of non-β-amyloid protein aggregation, previous post mortem 
work has demonstrated some binding to FTLD pathologies, albeit at a lower magnitude than 
that seen with Alzheimer’s pathology (Lowe et al., 2016; Marquié et al., 2015; Mcmillan et 
al., 2016; Sander et al., 2016).  This appeared to be corroborated by in vivo studies of patients 
with a straight filament 4-repeat tauopathy and clinical FTD resulting from MAPT mutations, 
showing binding in areas typically affected in FTD and affected at post mortem (Bevan-Jones 
et al., 2016; Smith et al., 2016), and by the elevated binding in the affected brain regions of 
patients with svPPA (Bevan-Jones et al., 2017; Makaretz et al., 2017) and bvFTD due to 
C9orf72 expansions (Bevan-Jones et al., 2018), who have TDP-43 rather than tau pathology. 
However, even within genetically determined FTD binding affinity varies according to 
different tau isoforms and strains (Jones et al., 2018) supporting varying affinity to different 
morphologies of tau.   
Other non-tau, non-TDP-43, targets may also account for this increased binding.  It is noted 
that this elevated [18F]AV-1451 binding is seen in a distribution that closely resembles that of 
neuropathology, suggesting potential binding to other proteins expressed by degenerating 
neurons or reactive glial cells, such as isoforms of monoamine oxidase (Vermeiren et al., 
2018).  Monoamine oxidase subtypes are expressed by both neurons (monoamine oxidase A) 
and reactive astrocytes (monoamine oxidase B) (Ben Haim, Carrillo-de Sauvage, Ceyzériat, & 
Escartin, 2015; Fowler, Logan, Volkow, & Wang, 2005) which may contribute to the patterns 
of cortical binding seen.  Indeed, if [18F]AV-1451 binding were driven by ‘off target’ binding 
to reactive astrocytes, which are induced by activated microglia (Liddelow et al., 2017), this 
would only provide further evidence for the importance of neuroinflammation in FTD.  
Further to this, upregulation of TSPO in reactive astrocytes could occur alongside that of 
MAO-B accounting for the regional correlation found between ligand binding.  However, the 
pre-symptomatic dissociation of [11C]PK-11195 and [18F]AV-1451 binding (Bevan-Jones et 
al., 2018) argues strongly against such simple cross-affinity.  
In the face of uncertainty about molecular targets and variations in affinity, it is important to 
emphasise that through our classification analysis I focus on distribution rather than 
quantification of binding, using a non-parametric method that is insensitive to absolute 
binding values and purely reflects the pattern of binding. This takes into account the potential 
differences in affinity of [18F]AV-1451 for different protein targets.  Overall, whilst it is clear 
that [18F]AV-1451 binding does not bind specifically to tau aggregates, the distribution of 
binding co-localises and varies with that expected of aggregated protein in these diseases, and 
post mortem immunohistochemistry of tau.  Indeed, [18F]AV-1451 may provide a usefully 
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non-selective marker of non-β-amyloid aggregated protein, whether tau or TDP-43, allowing 
in vivo examination across the spectrum of sporadic FTD syndromes. Whilst in the complex 
setting of FTLD I interpret [18F]AV-1451 binding as a non-specific marker of non-β-amyloid 
neuropathology, the biological relevance of elevated binding in non-AD neurodegenerative 
disease remains incompletely understood.  Further work examining [18F]AV-1451 binding 
across large post mortem cohorts of FTLD pathology will be required to independently 
validate our hypothesis. 
The main limitation of this study is group size which, although larger than most previous PET 
studies in FTD, is still small for each individual diagnosis. The small sample size reduces the 
power of the study to find parametric group differences in binding, particularly given that 
both ligands have a degree of insensitivity to their target, as well as limiting the ability to 
detect associations with clinical features and severity. Characterisation of the groups is also 
limited in that the genotyping and β-amyloid assays were based on clinical indications and 
consent: I did not directly examine β-amyloid status in all individuals and whilst there is a 
mix of both genetic and sporadic cases I did not genotype every participant. The inability to 
perform pathological subtyping in vivo makes interpretation of results more difficult in view 
of the generally poor relationship between phenotype and underlying neuropathology in FTD.  
Consequently, I cannot use the clinical diagnostic groups alone to draw conclusions about the 
relationship between microglial activation and specific forms of protein aggregation. I am also 
limited in the inferences about the predilection for immune dysregulation in a particular 
neuropathological subtype, such as the relationship suggested between immune dysfunction 
and FTLD-TDP-43 (Miller et al., 2013, 2016), except for the cases with genetic mutations.  
To conclude, I provide in vivo evidence for neuroinflammation in FTD, which has a close 
relationship with [18F]AV-1451 binding, taken in this study to represent a marker of FTLD-
tau or FTLD-TDP-43 neuropathology. PET measurement of inflammation provided a more 
accurate classification of syndromes than did protein aggregation emphasising its potential 
importance in shaping the clinical and neuropathological patterns of the diverse clinical 
syndromes of frontotemporal dementia.  A causal role for neuroinflammation in 
neurodegeneration would inform future drug targets and potential clinical trials in 
frontotemporal dementia. Our findings therefore warrant further longitudinal mechanistic 
investigation into the role of neuroinflammation in early-stage neurodegeneration, its 
relationship to specific protein aggregation and to clinical progression. 
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Chapter 8: General Discussion and future applications 
 
Introduction 
In this chapter I summarise the findings of the original research presented in this thesis and 
discuss their relevance to the literature.  I emphasise the role of inflammation, and how it can 
be understood in relation to other aspects of pathology, in particular the abundance of 
intracellular protein aggregates. I comment on advantages and limitations of the PET ligands, 
and end with reflections on potential future directions of research. 
Summary of findings 
I investigated both neuroinflammation and protein aggregation in vivo in clinically diagnosed 
FTD.  Initially I established that the ‘tau ligand’ [18F]AV-1451 was sensitive to a straight 
filament 4-repeat FTLD-tauopathy resulting from a 10+16 mutation in the MAPT gene, which 
is biochemically and morphologically distinct from the paired helical filament balance 3-
repeat/4-repeat tauopathy of Alzheimer’s disease.  However, I then established that [18F]AV-
1451 is not specific for tau pathology in FTD, by demonstrating increased anatomically 
appropriate binding in svPPA and in a case of FTD caused by an expansion in the C9orf72 
non-coding region, both of which are characterised by TDP-43 pathology.  On this basis I 
postulated that, whilst not selective for FTLD-tau pathology in the setting of FTD, [18F]AV-
1451 may be a marker of aggregated non-β-amyloid protein, be it tau or TDP-43.   
Using region-of-interest and data driven analyses to assess both neuroinflammation and 
protein aggregation across the clinical and genetic spectrum of FTD, I have shown that both 
processes are increased in frontal and temporal regions compared with healthy volunteers, in a 
topographical pattern which reflects the known distributions of neuropathology in FTD.  The 
two processes are also co-localised, in that where there is more neuroinflammation there is 
more protein aggregation.  Despite this co-localisation, individual classification of 
participants was more accurate using the whole brain distribution of neuroinflammation rather 
than that of protein aggregation.   
In a pre-symptomatic carrier of a 10+16 MAPT mutation, I have shown increased 
neuroinflammation in the temporal lobe regions classically affected in this illness, in the 
absence of significant tau aggregation, despite the known sensitivity of [18F]AV-1451 for the 
tauopathy caused by this mutation.  Taking all these findings together, this thesis provides 
evidence for the in vivo presence of both neuroinflammation and protein aggregation in FTD.  
In particular, the role of neuroinflammation is emphasised as it appears to occur early, 
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potentially preceding significant tau aggregation in genetic tauopathy, but also as it has 
patterns which both better reflect known patterns of neuropathology in FTD and which are 
more strongly associated with diagnostic group than those of protein aggregation.  These 
findings are important because they provide in vivo support for evidence from in vitro, post 
mortem and animal studies, and also because they demonstrate that it is feasible and 
informative to investigate pathophysiological processes such as these in vivo.   
Pathophysiology of FTD 
Although FTD is clinically and pathologically heterogeneous, a clearer picture is emerging of 
the underlying biology of disease and in particular the role of specific processes such as 
aggregation of toxic protein species and neuroinflammation.  In this section I discuss the ex 
vivo evidence supporting these two processes in FTD with reference to the FTD literature and 
also to lessons learned from the most common neurodegenerative disease, Alzheimer’s 
disease. 
Protein aggregation 
Most neurodegenerative diseases are associated with accumulation of modified and misfolded 
proteins, for example aggregates of tau, β-amyloid, TDP-43 and α-synuclein are all 
neuropathological hallmarks of specific diseases.  There is also comprehensive evidence 
implicating these modified and misfolded protein species as toxic drivers of 
neurodegenerative disease.  This has gained support from genetic studies which showed that 
mutations in genes which code for proteins characteristic of particular neurodegenerative 
diseases, such as the amyloid precursor protein (APP) in Alzheimer’s disease and MAPT in 
FTD, are sufficient to cause disease.  The nature of the toxicity of protein species and the 
mechanisms of spread have been extensively investigated in animal and in vitro models.  
Much of this work has focused on tau species and mutation models, particularly in 
Alzheimer’s disease but also in FTLD.  These have established ‘gain of function’ and ‘loss of 
function’ as potential toxic mechanisms.  It has also been noted that as well as causing 
neurodegeneration directly (Ballatore, Lee, & Trojanowski, 2007), tau pathology may have a 
toxic effect through its interaction with apolipoprotein ε4 and neuroinflammation (Currais, 
Fischer, Maher, & Schubert, 2017; Yates, 2017), and may have  functional effects via 
synaptic dysfunction and loss with a resultant impact on plasticity (Wang & Mandelkow, 
2015).   Animal and in vitro models investigating cellular vulnerability to and spread of tau 
pathology have also emphasised the hypothesis of ‘prion-like’ cell to cell transmission of 
toxic protein species as the dominant paradigm (Clavaguera, Hench, Goedert, & Tolnay, 
2015; Eisele et al., 2015; Tracy & Gan, 2018; L. C. Walker & Jucker, 2015).  More recently, 
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work in TDP-43 models has drawn parallels with this and has emphasised the importance of 
RNA and protein homeostasis in the neurodegenerative process of FTD (Ling et al., 2013).  
Post mortem studies have provided a structure in which to interpret the role of protein 
aggregation and its spread, for example in Alzheimer’s disease where the cross sectional 
studies of Braak and Braak demonstrated that the distribution of tau pathology at post mortem 
in Alzheimer’s diseases could be classified into stages (Braak & Braak, 1991).  The narrative 
of progressive Braak stages of pathology provides a compelling story of progressive 
proteinopathy, and one which may be linked to progressive neuronal damage by experimental 
evidence and extrapolated to clinical disease.  However, there has been a fundamental lack of 
in vivo evidence corroborating this by demonstrating that distribution and burden of protein 
pathology correlate with clinical symptoms and severity.  Despite the advances in our 
understanding of the framework for and effects of protein aggregation, the relationship of 
protein aggregation and spread to disease remains incompletely understood and may differ 
between diseases.   
Neuroinflammation 
There is increasing and converging evidence for the importance of neuroinflammation across 
the spectrum of neurodegenerative disease (Perry et al., 2010) and the progression in our 
understanding of the role of neuroinflammation in neurodegeneration has followed a similar 
course to that of protein aggregation.  Building on observational and epidemiological 
evidence from humans which have shown reduced incidence of neurodegenerative diseases 
such as Alzheimer’s disease in people who have been on long term anti-inflammatory 
medications for other indications (Mcgeer & Mcgeer, 2007; McGeer & McGeer, 2013; Samii, 
Etminan, Wiens, & Jafari, 2009), the function of microglia, as the coordinators of the immune 
system in the central nervous system, has been studied in vitro and in animal models as well 
as genome-wide association studies.  The hypotheses for immune dysfunction in FTD come 
from a variety of sources.  These include pre-clinical evidence from cell and animal models, 
as well as epidemiological, genetic and pathological studies in FTD.  As in other 
neurodegenerative diseases post mortem studies have demonstrated gliosis to be a core feature 
of the neuropathology of FTD (Lant et al., 2014).  Animal models, using the main genes 
associated with FTD, have also repeatedly shown the presence of microglial dysfunction and 
neuroinflammation alongside protein aggregation.  They have also illustrated the ability of 
immune modulation to affect this relationship and therefore modify the evolution of protein 
pathology.  Genetic models have demonstrated that as well as having neuronal effects on 
protein homeostasis and aggregation, the monogenic causes of FTD also cause changes in 
microglial function.  In patients, genome-wide association studies in FTD have implicated 
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several risk loci with immune and microglial functions whilst epidemiological studies have 
found an increased prevalence of autoimmune diseases (Broce et al., 2018; Miller et al., 2013, 
2016).   
Pathophysiological targets for disease modifying drugs in neurodegeneration 
The focus on different aspects of pathology, such as protein aggregation and 
neurodegeneration, in neurodegenerative disease has been necessary to improve our 
understanding of the biology of disease.  Improved understanding of these processes and their 
relationship to disease is essential as it will underpin rationales to propose and support drug 
development targets and also the design of clinical trials.  The details of different potential 
approaches to these targets in disease modification is beyond the scope of this thesis however.  
For both protein aggregation and neuroinflammation there is a converging body of molecular, 
cellular, genetic and clinical evidence supporting their importance and pathogenicity.  In 
particular animal models have improved our understanding of the relationship between 
processes such as protein aggregation, neuroinflammation, neuronal dysfunction and death, as 
well as providing evidence that modifying these processes can be beneficial (Dagher et al., 
2015; Eisele et al., 2015; Gomez-Nicola et al., 2013; Kumar et al., 2016; Martínez-Muriana et 
al., 2016; Nash et al., 2013; Olmos-Alonso et al., 2018; Spangenberg et al., 2018). However 
exact mechanisms and relationships to disease phenotype and progression remain to be 
established. To corroborate and build upon this wealth of post mortem, in vitro, animal and 
epidemiological evidence we need to test these hypotheses in participants with disease during 
life.  In order to do this we need tools which can ideally quantify and map pathophysiology in 
vivo.  In short, in vivo evidence is the next piece of the jigsaw required to verify our 
understanding of pathophysiology and to underscore targets for future clinical trials.  In the 
next section I will discuss this further with particular reference to PET. 
Using PET to measure pathophysiology in vivo 
In recent years the advent of PET ligands targeting specific protein species and allowing their 
visualisation, has enabled the above hypotheses about the biology of neurodegeneration to be 
probed in vivo.  The first protein to be imaged in vivo was β-amyloid but studies correlating 
the amount and distribution of β-amyloid with symptoms and disease severity in Alzheimer’s 
disease showed only weak correlations (Jagust, 2016).  Coinciding with this, alternatives to, 
or modifications of, the ‘amyloid hypothesis’ began to emerge, for example with tau as the 
toxic protein species in Alzheimer’s neurodegeneration, and this drove the development of 
ligands selective for tau pathology.  However, it is important to note that the development of 
PET ligands to investigate pathophysiology has been primarily driven by the Alzheimer’s 
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disease research field, leading to a literature of in vivo studies focused on Alzheimer’s disease 
using tools developed for Alzheimer’s disease.  As a result in the following section I will 
briefly outline the current evidence in Alzheimer’s disease for both ‘tau PET’ and 
‘inflammation PET’ and its relevance and limitations for FTD.   
The advent of ‘tau ligands’, particularly [18F]AV-1451, has allowed in vivo studies in 
Alzheimer’s disease to support the idea of tau toxicity, with evidence that quantity and 
distribution of paired helical filament tau are related to symptoms and severity, and that they 
increase longitudinally in line with disease progression, essentially recapitulating the Braak 
stages (Jack et al., 2018; Lowe et al., 2018; Ossenkoppele et al., 2016; Schwarz et al., 2016).  
Studies have also begun to address the question of how tau pathology spreads, indicating this 
may potentially be trans-synaptic in Alzheimer’s disease (Cope et al., 2018).  These findings 
have helped to pave the way for ‘anti-tau’ therapies to come to trial in Alzheimer’s disease, 
and provided rational for anti-tau therapies in primary tauopathies such as progressive 
supranuclear palsy.  These advancements have even led some to suggest that [18F]AV-1451 
should be used for diagnosis and ‘staging’ of Alzheimer’s disease as well as providing an 
outcome measure in clinical trials in Alzheimer’s (Hansson & Mormino, 2018; Mattsson et 
al., 2018; Ossenkoppele et al., 2018).   
The ligands used in these initial trials were all developed to bind to Alzheimer’s disease 
tauopathy.  Whilst they are commonly thought of as ‘tau specific’ their specificity is actually 
to the conformation of the β pleated sheet conformation adopted by tau in its fibrillary form.  
This structure is not unique however and is shared by fibrils of other proteins such as TDP-43, 
α-synuclein and β-amyloid.  This leads to the potential for non-specific, off-target binding and 
other well documented limitations which are discussed elsewhere in this thesis.  Recognition 
of this has fuelled the development of ‘second generation’ ligands with the aim of optimising 
ligand properties to maximise affinity and selectivity of binding whilst minimising ‘off target’ 
binding (Perani et al., 2019).  Some of these ligands use structures derived from first 
generation ligands, for example [18F]RO-948 and [18F]PI-2620) whilst others, such as 
[18F]MK-6240 and [18F]JNJ311, are relatively novel.  Work with these ligands is still at an 
early stage and in small numbers of participants but thus far seems to illustrate some of the 
same problems, for example [18F]RO-948 derived from [18F]AV-1451, appears to suffer from 
a degree of off target binding to neuromelanin, but also show some improvements and 
preserved strengths, for example reduced off target binding in relevant structures such as 
striatum and choroid plexus seen with [18F]PM-PBB3, [18F]PI2620, and [18F]MK6240, as well 
as a distribution of binding in Alzheimer’s disease which recapitulates Braak stages ([18F]RO-
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948 and [18F]MK-6240) (Leuzy et al., 2019; Perani et al., 2019).  Further research in greater 
numbers across the tauopathy spectrum will be necessary to characterise their strengths and 
limitations before they can be used effectively to enhance our understanding of these diseases.  
The recent description of the cryo-electron microscopic structure of tau filaments in 
Alzheimer’s disease (Fitzpatrick et al., 2017) also opens up other avenues of identifying 
potential PET ligand binding sites which may be better exploited by other classes of 
molecules such as peptides and antibodies rather than the polyheterocyclic compounds used to 
date.   
Similarly to ‘tau PET’, there is a comprehensive literature from in vivo PET studies of 
microglial activation in Alzheimer’s disease.  This shows evidence for early and persistent in 
vivo neuroinflammation, with a distribution of microglial activation which overlaps with that 
of atrophy and with that expected for neuropathology (Kreisl et al., 2017).  Increased 
neuroinflammation is correlated with worsening cognitive and functional scores and disease 
severity (Kreisl et al., 2013) and has also been correlated with tau aggregation (Dani et al., 
2018).  Interestingly it seems that the strength of the relationship between microglial 
activation and tau pathology in Alzheimer’s disease is increased with disease severity (Dani et 
al., 2018).  The relationship between inflammation, progression and severity in Alzheimer’s 
disease is complex however.  A biphasic role has been postulated, where high degrees of 
neuroinflammation in early or prodromal disease appear to be protective (Hamelin, Lagarde, 
Dorothe, et al., 2018), whilst in contrast greater increases in neuroinflammation longitudinally 
are associated with worsening clinical and functional assessments (Hamelin, Lagarde, Potier, 
et al., 2018).   
The importance of the Alzheimer’s disease PET literature is emphasised by the scarcity of 
molecular PET studies in FTD where prior to the start of this thesis there were only two small 
studies investigating inflammation in FTD and MAPT carriers respectively (Cagnin et al., 
2004; Miyoshi et al., 2010).  Whilst not specifically applicable to FTD, the Alzheimer’s 
disease literature not only generates hypotheses to be tested in FTD, but also a road map for 
the process of doing so.  In the next section I will discuss how my findings begin this journey 
and what needs to be learned from this study to optimise our future approaches to PET 
research in FTD.   
Relevance to other disorders  
This thesis begins the journey of investigating in vivo pathophysiological processes in FTD.  
It is important as it provides corroborative evidence to support pre-clinical, clinical and 
animal model generated hypotheses for the presence of neuroinflammation, and its 
117 
 
relationship with protein aggregation, in the pathophysiology of FTD.  They also mirror 
similar findings and relationships in Alzheimer’s disease (Dani et al., 2018), and extend the 
relationship between neuroinflammation and protein aggregation to include TDP-43 
associated diseases such as svPPA.  The studies of [18F]AV-1451 binding in FTD have been 
at the forefront of the investigation of [18F]AV-1451 binding across the neurodegenerative 
spectrum over the last 3 years, and have contributed to the understanding of in vivo binding 
and its interpretation in non-Alzheimer’s disease settings.  They have helped to establish that 
whilst present, the sensitivity of [18F]AV-1451 to FTD-tau is less than that seen in 
Alzheimer’s disease, and have subsequently been replicated and extended in various studies 
(Ali et al., 2018; Cho et al., 2018; Jones et al., 2018; Josephs et al., 2018; Smith et al., 2017).  
Similarly, this study was the first to publish a lack of specificity for FTD-tau cases, by 
demonstrating binding in FTD-TDP43 cases, a finding since validated by others (Josephs et 
al., 2018; Makaretz et al., 2017).   
Through these findings this thesis has begun to address some of the fundamental research 
requirements in the FTD field, with relevance to both mechanistic and diagnostic questions.  
It has also proved that it is feasible to undertake PET studies recruiting significant numbers of 
participants with FTD, emulating the direction of travel of in vivo studies in Alzheimer’s 
disease.  It has shown that the findings can be highly informative, not only providing in vivo 
corroboration of the presence of key pathophysiological processes, but also generating 
hypotheses which should be further examined in FTD.  Importantly, it has also illustrated the 
limitations of using tools developed in one disease to study other, pathologically distinct, 
disease.  A potential ‘tau ligand’ in FTD could have fulfilled a much needed role by 
classifying pathological diagnosis as tau or non-tau in vivo, and also could have provided 
insights in the toxicity of tau in FTD, similar to those enabled in Alzheimer’s disease.  
Although potentially somewhat mitigated by the possibility of [18F]AV-1451 binding 
representing aggregation of tau or TDP-43 protein, i.e. as a marker of non-β-amyloid 
neuropathology in FTD, the failure of [18F]AV-1451 to provide this in vivo classification is 
unfortunate, but ultimately perhaps unsurprising, given the well-known and significant 
differences between subtypes of tau pathology at a biochemical, ultrastructural and 
morphological level.  Ultimately, it is of the upmost importance that we develop improved, 
FTD-specific tools to examine the biology of disease in vivo.  On the basis of the findings and 
lessons learned from this thesis, future in vivo PET studies in FTD should go forward to 
address some of the questions of timing, distribution, and toxicity which still need to be 
answered and which, after discussing the limitations of the project in more detail, I discuss 
below. 
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Limitations of this study 
There are several limitations to this study which I will discuss individually below.   
Recruitment and group composition 
The individual diagnostic groups in this study are small. Whilst this is the result of these 
diseases being relatively rare it leads to limitations of power in the study and an increased 
chance of type 2 error. The groups are also inherently biased due to the strict inclusion criteria 
and the necessity to exclude individuals with floridly disinhibited symptoms or advanced 
disease who would be unable to complete the study protocol.  A further source of bias is that 
the participants were recruited almost entirely from a single tertiary referral neurology clinic.  
The resultant diagnostic groups reflect the range of FTD seen in this setting but may not be 
truly representative of the FTD population in the community.  The complexity of FTD also 
impacts on the purity of each diagnostic group. Although the groups are analysed on the basis 
of clinical syndrome they will also be pathologically heterogeneous.  This is certainly the case 
in the bvFTD group where there are individuals with MAPT, GRN and C9orf72 mutations.  
Ante mortem pathological confirmation is not possible and so analysis on the basis of 
pathological diagnosis is not possible.  We do not yet have post mortem validation of FTLD 
pathology as only one recruited participant has died and been examined in the brain bank.  We 
also do not have β-amyloid status on FTD participants to exclude Alzheimer’s pathology as a 
cause or concomitant feature of their disease. 
Effects of atrophy on image processing 
Marked atrophy is often a feature of FTD.  This is an important consideration when 
processing the imaging data.  In particular, significant atrophy, such as that seen in svPPA and 
in genetic forms of bvFTD, complicates spatial normalisation of MRI and co-registration to 
PET.  Segmentation of MRI into grey and white compartments may also be compromised.  
Importantly, there is also an effect of atrophy on PET signal, resulting from contamination of 
patient voxels by an increased CSF fraction.  To account for this partial volume correction is 
often undertaken in which the probabilistic contribution of CSF to a region of interest is 
calculated and used to adjust the binding potential.  This is necessary to prevent binding being 
obscured by the degree of atrophy and essentially has the effect of pushing the observed 
binding into a smaller brain volume thereby inflating the PET value.  This inflation is 
proportionate to the degree of atrophy and so is more marked in regions with severe atrophy.  
Given this high binding value coming from a small volume it seems reasonable to interpret 
the signal as highly likely to be coming from brain tissue with a high burden of pathology, 
particularly as atrophy is thought to be downstream of other pathophysiological processes 
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such as microglial activation and protein aggregation.  Consequently, partial volume 
correction is accepted as standard practice in PET studies and has been used in all studies in 
this thesis. 
Limitations of PET ligands 
There are limitations regarding both PET ligands.  [18F]AV-1451 is less sensitive to 
neuropathology outside of Alzheimer’s disease and whilst increased in vivo binding is seen 
the substrates of this are yet to be confirmed.  Furthermore, post mortem studies thus far have 
shown minimal binding to FTLD-tau and FTLD-TDP43 species and so the biological 
relevance of this binding remains uncertain.  Whilst the assumption that the anatomically 
appropriate binding in both tau and TDP-43 cases reflects in vivo binding to both tau and 
TDP-43 aggregates seems reasonable, it is a hypothesis which requires further investigation in 
order to be validated.  What is more, other cells involved in neurodegeneration may 
upregulate certain proteins which may provide a binding site which though ‘off-target’ may 
be relevant to the pathophysiology of disease.  For example, there is possible binding to 
monoamine oxidase expressed by reactive astrocytes in the vicinity of degenerating neurons 
(Barrio, 2018).  A significant degree of truly ‘off-target’ binding, likely to pigments and 
minerals and unaffected by neurodegenerative processes, is also a feature of studies using 
[18F]AV-1451.  This is a particular problem in the basal ganglia and medial temporal lobe, 
regions which are relevant to FTD, leading to complications in interpreting the source of 
increased binding in these regions which likely suffer from disease effects but which also 
suffer from non-specific binding to pathological targets.  
[11C]PK-11195 also has limitations (Chauveau, Boutin, & Camp, 2008).  It is less sensitive 
than newer TSPO radiotracers and although the effect of TSPO polymorphisms is less 
significant it is still likely to be present.  This lack of sensitivity and potential inter-subject 
variability is a problem, potentially leading to poor signal to noise ratio and an inability to 
find effects which are present.  Whichever TSPO ligand is studied, interpretation of results is 
also complicated by potential binding to upregulated TSPO on other cells involved in 
neurodegeneration such as reactive astrocytes.  Our understanding of microglial TSPO 
expression patterns and functional outcomes from different microglial phenotypes is also 
incomplete and so whilst the presence of activated microglia may be assumed from increased 
binding the more subtle question of its effects cannot be addressed.   
Aside from acknowledging these difficulties with both radiotracers, I have also tried to 
account for the common theme of variable sensitivity and signal to noise in the analysis by 
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using a multivariate approach, insensitive to absolute binding values and therefore to 
differences in sensitivities of tracers for different targets. 
Statistical approaches 
Finally I will address the approaches used in this thesis, some of which are non-standard. The 
purpose of the thesis has been to begin to answer some basic questions about pathophysiology 
in vivo in Frontotemporal dementia, and concomitantly about the tools used to study them. In 
every analysis I have used well established parametric methods to examine differences 
between groups and individuals or relationships between ligand binding. However, as 
discussed in the preceding chapters there are many variables which contribute to these 
findings, including patient factors, ligand factors and disease factors. These diseases are not 
subtle clinically or in the macroscopic structural changes they cause in the brain, however 
variables other than disease may affect magnitude of binding in a given participant and these 
may hide disease effects when assessed as a parametric comparison. Consequently, I adopted 
a different but complementary approach already in widespread use in neuroimaging, most 
commonly in Representational Similarity Analysis, an extremely powerful tool used in 
functional MRI where it is used to compare patterns of voxel activation in single subjects. In a 
similar way I use the individual’s whole brain pattern of binding, blinded to the regional 
magnitude, to compare patients to healthy volunteers or those with distinct forms of 
Frontotemporal dementia. When using these methods to assess the difference or otherwise of 
the patient from controls, for example using hierarchical cluster analysis, there are a number 
of methods which may be used. The simplest is ‘nearest neighbour’, where one classifies 
individuals by serially finding the most similar distributions and ordering individuals by 
uniqueness. Under this method, the patient has the most unique distribution. However, as this 
thesis in part is about the potential utility of a novel biomarker, I generally give prominence to 
the most stringent method which, when comparing a single case to a control group, is ‘farthest 
neighbour’. In this method, individuals are placed into groups based on how dissimilar they 
are from the most dissimilar member of that group. In the case of a single case, for perfect 
separation this would require all of the controls to be extremely homogenous in their 
distributions. Given that the correlation analyses are non-parametric and that control PET 
ligand binding is low and relatively uniform, this is unlikely. Therefore, the classification of 
the case as separate from the controls using this most conservative method provides strong 
evidence for the ability of the ligand to illustrate a distribution of binding which is different 
from the ‘normal’ pattern seen in controls and which may be interpreted as disease specific 
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given the anatomical location of the regional differences seen in the parametric group 
comparisons. 
Future research and potential applications  
This thesis provides evidence, both generally for the idea of using PET ligands to examine 
specific components of neurodegenerative pathophysiology in vivo, and more specifically for 
the role of both protein aggregation and neuroinflammation during FTD.  However, there are 
many important questions regarding these processes which cannot be answered by this study 
and which warrant further investigation, as well as other pathophysiological processes which 
may interact with neuroinflammation or protein aggregation.  Many of these basic questions 
about pathophysiology need to be answered to improve our in vivo understanding of the 
biology of disease in FTD and to determine whether specific components of pathophysiology 
may be targets for therapeutic intervention.  Here I will suggest 4 important questions 
regarding neuroinflammation to be addressed in the future and how they might be 
approached.  
1) Is the timing of neuroinflammation or protein aggregation early or late and does it 
continue throughout the disease process?   
We began to try to address this question by examining both processes in a pre-symptomatic 
gene carrier.  Larger studies of a similar nature will be required but also with longitudinal 
clinical and imaging follow-up to assess onset, tempo and pattern of these processes and their 
relationship to clinical phenotype and severity. 
2) Is the effect of neuroinflammation protective, deleterious or does it change from one to 
the other at different time points in the illness?   
This is linked to the above question and is difficult to answer as neuroinflammation might be 
a characteristic of the individual as much as the disease (Hamelin, Lagarde, Potier, et al., 
2018).  Large cohorts would need to be recruited early in disease, including pre-symptomatic 
gene carriers, and stratified according baseline inflammatory status.  Progression both 
clinically and in inflammation could then be assessed.  An independent disease group with 
moderate disease could be stratified by baseline inflammation and again by impact on clinical 
severity and longitudinal progression of inflammation then assessed enabling comparison 
between the presence and progression of inflammation at early and established stages of 
disease.  
3) Is neuroinflammation a feature of particular subtypes of pathology or is it a common 
mechanism across the spectrum of FTLD?  
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Cohorts of genetic FTD, where pathology is tightly correlated with genetic aetiology, and 
which may act as models of their sporadic equivalents (Forrest et al., 2018; Josephs, 2018). 
The use of PET in larger cohorts of genetic FTD will be of great interest, but the evidence 
from the sporadic and genetic cases presented here, it seems likely that all types of FTD are 
associated with elevated neuroinflammation. What is less clear is the temporal and causal 
relationship between inflammation and protein aggregation or cell death.  
4) How does neuroinflammation or protein aggregation relate to other relevant brain 
metrics, e.g. those related to information transfer such as network function and synaptic 
density?   
Answering this question will require multimodal studies which enable the relationship of 
pathophysiology to network function and clinical status.  This issue has started to be 
addressed in studies such as GENFI which have looked at the role of networks in pre-
symptomatic gene carriers.  Ideally this could be extended by evaluating neuroinflammation, 
protein aggregation and other components such as synaptic density in a similar cohort and 
also in those with established non-genetic FTD to examine associations of key 
pathophysiological processes with network function and clinical phenotype pre and post 
disease onset. 
Conclusion 
The successful proof of concept studies of genetic FTD, and the larger cohort study of 
symptomatic FTD, outlined in this thesis suggest that PET is useful to quantify and localise 
and stage pathologies. However, these studies also raise new questions about causality and 
heterogeneity that call for larger and longitudinal cohorts with multimodal imaging and in due 
course therapeutic interventions.   
PET imaging is required with ligands specific to protein pathologies (some of which have yet 
to be developed e.g. for TDP-43 and α-synuclein), as well as improved markers of 
neuroinflammation with insensitivity to polymorphisms in TSPO, better signal to noise ratios 
and high specific binding to activated microglia, or potentially to other components of the 
neuroinflammatory cascade.   Radioligands for other pathophysiological components such as 
synaptic density (which for example can be measured using the newly developed UCB-J 
ligand) would also be informative about the cascade of targetable events leading from root 
genetic and environmental causes to complex phenotypes.  These ligands will also require 
robust non-invasive models for calculating binding which do not require arterial blood 
sampling or lengthy scans so that large numbers of participants, including frail and elderly 
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people with advanced disease, as well as the more behaviourally disturbed, may be able to 
take part in these studies.  As well as including participants with svPPA, nfvPPA and bvFTD, 
these studies should also enrol pre-symptomatic gene carriers with each of the 3 major genes 
associated with FTD.   
The potential power of large-scale studies of pre-symptomatic gene carriers has already been 
illustrated by GENFI and the addition of PET may provide pathophysiological insights which 
transcend genetic FTD given that recent models of neurodegeneration in FTD suggest that 
genetic tauopathies may represent a model of sporadic FTLD-tau disease and similarly for 
TDP-43 cases (Forrest et al., 2018; Josephs, 2018).  Longitudinal studies extending from pre-
symptomatic states right through the clinical spectrum of disease will be necessary to 
determine the timing of inflammation, its relationship to other pathological process such as 
protein aggregation, neuronal loss, synaptic density and network function, and how these 
features and their relationships pertain to clinical phenotype, disease severity and progression.  
My goal is that improved radioligands could be used in clinical trials of drugs targeting 
specific mechanisms, either as stratifying inclusion criteria, surrogate end-points or both.  It is 
my hope that the work in this thesis will enable the field to begin to move beyond 
phenomenology and towards the biological definition of these diseases so that we can 
ultimately design and implement successful clinical trials and bring to an end the enormous 
health, economic and above all social burden of frontotemporal dementia.  
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Appendix 1 
Neuropsychology battery 
Test Name Format Purpose Cohort 
Clinical Assessment 
UPDRS Part III (motor subscale) (Goetz et al., 2008) Performed by 
study 
clinician 
Measure of 
Parkinsonism 
(motor aspects) 
All 
Physical Examination of Eye Movements Part of 
physical 
examination 
performed by 
study 
clinician 
Assessment of 
range and speed 
of eye 
movements 
All 
Frontal Assessment Battery (Slachevsky, 2000) Assessment 
tool 
completed by 
study 
clinician 
Assessment of 
frontal lobe 
function 
FTD, 
PSP 
Praxis Battery Part of 
physical 
examination 
performed by 
study 
clinician 
Assessment of 
manual 
ideomotor and 
copying ability 
All 
Neuropsychological Assessment 
Addenbrooke’s Cognitive Examination – Revised 
(Eneida Mioshi et al., 2006) 
Researcher 
administered 
structured 
test 
Multi-domain 
cognitive 
screening tool 
All 
INECO Frontal Screening (Torralva, Roca, 
Gleichgerrcht, López, & Manes, 2009) 
Researcher 
administered 
structured 
test 
Assessment of 
frontal lobe 
function 
All 
Trails A & B Researcher 
administered 
structured 
test 
Assessment of 
executive 
function 
All 
Pyramids and Palm Trees Researcher 
administered, 
two 
alternative, 
forced 
choice, 
picture based 
test 
Assessment of 
semantic 
memory 
All 
Cambridge Neuropsychological Test Automated Battery (CANTAB) 
Simple Reaction Time 
(“http://www.cambridgecognition.com/tests/simple-
reaction-time-srt,” n.d.) 
Researcher 
administered 
computer 
task 
Information 
processing 
speed 
All 
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Paired Associate Learning (Swainson et al., 2001) Researcher 
administered 
computer 
task 
Assessment of 
visual episodic 
memory and 
learning 
All 
Stockings of Cambridge (Robbins et al., 1998) Researcher 
administered, 
computer 
based spatial 
planning task 
Test of frontal 
lobe function 
All 
Mental Health Questionnaires 
Hospital Anxiety & Depression Scale A 14 item 
self-reported 
questionnaire 
Assessment of 
symptoms of 
anxiety and 
depression 
All 
Geriatric Depression Scale A 30 item 
self-reported 
questionnaire 
Assessment of 
depressive 
symptoms 
All 
Informant Questionnaires 
Cambridge Behavioural Inventory (Wedderburn et al., 
2008) 
An 81 item 
carer-
reported 
questionnaire 
Assessment of 
several 
behavioural 
abnormalities in 
the everyday life 
including 
impulsivity and 
apathy 
All 
except 
controls 
Frontotemporal dementia Rating Scale A 30 item 
carer-
reported 
questionnaire 
Assessment of 
behaviour and 
functional 
abilities 
FTD 
only 
Clinical Dementia Rating Scale (Hughes et al., 1982) A carer-
reported 
numerical 
scale 
Quantifying 
severity of 
dementia 
All 
except 
controls 
Bristol Activities of Daily Living Score A 20 item 
carer-
reported 
questionnaire 
Measure of 
ability of person 
with dementia 
to carry out 
ADLs 
All 
except 
controls 
Neuropsychiatric Inventory (Cumimings et al., 1994) Researcher 
administered, 
carer-
reported 13 
item 
screening 
tool 
Assessment of 
psychopathology 
in people with 
brain disorders 
All 
except 
controls 
Clinical Assessment of Fluctuating Confusion and 
Quality of Consciousness (M. P. Walker et al., 2000) 
Researcher 
administered, 
carer-
reported 9 
item 
screening 
tool  
Assessment of 
conscious level 
and degree of 
symptomatic 
arousal 
fluctuation 
All 
except 
controls 
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MRI Imaging 
MRI scanning was performed at the WBIC using 3 Tesla Siemens scanners.  The following 
sequences were performed during the scanning protocol: 
1. Three-dimensional structural high-resolution T1 weighted sequence examining for 
structural brain abnormalities (176 slices of 1.0 mm thickness, TE= 2.98 ms, TR = 
2300 ms, flip angle =9°, acquisition matrix 256x240; voxel size = 1x1x1 mm3).  
2. Perfusion (pulsed arterial spin labelling) for blood flow (9 slices of 8.0 mm thickness, 
TE = 13 ms, TR = 2500 ms, acquisition matrix 64x64; voxel size = 4x4x8 mm3, 
inversion time 1 = 700 ms, inversion time 2 = 1800 ms). 
3. Diffusor Tensor Imaging (DTI) to obtain fractional anisotropy measures of white 
matter integrity and gross axonal organisation (63 slices of 2.0 mm thickness, 63 
diffusion directions, TE = 106 ms, TR = 11700 ms, b-value 1 = 0 s/mm2, b-value 2 = 
1000 s/mm2, acquisition matrix 96x96; voxel size =2x2x2 mm3). 
4. Susceptibility weighted imaging (SWI) to identify microhaemorrhages, venous blood 
and iron deposition (40 slices of 2.0 mm thickness, TE = 20 ms, TR = 35 ms, flip 
angle = 17°, acquisition matrix 256x240; voxel size =1x1x2 mm3). 
5. High resolution hippocampal subfield sequences carried out in coronal T2 for smaller 
structural changes in the hippocampus (20 slices of 2.0 mm thickness, TR = 6420 ms, 
flip angle = 160°, acquisition matrix 512x408; voxel size =0.4x0.4x2 mm3). 
6. Resting state functional MRI with pulse and breathing monitored to examine “task-
free” functional brain connectivity (34 slices of 3.8 mm thickness, TE = 13 ms, TR = 
2430 ms, flip angle = 90°, acquisition matrix 64x64; voxel size =3.8x3.8x3.8 mm3, 
duration 11 minutes and 5 seconds). 
7. T2 Fluid Attenuated Inversion Recovery (FLAIR) for characterising periventricular 
lesions adjacent to the sulci and white matter lesions and hyperintensities (75 slices of 
2 mm thickness, TE = 132 ms, TR = 12540 ms, flip angle = 120°, acquisition matrix 
256x256; voxel size =0.9x0.9x2 mm3).  
 
Blood Samples 
80ml of blood was drawn at the time of the [11C]PK-11195 PET scan.  Basic inflammatory 
markers (e.g. C-reactive protein) were tested at the time of the sample with the remaining 
blood being centrifuged to produce serum and plasma samples to be stored at -80°C for future 
testing of inflammatory and neurodegenerative markers.  A sub group of participants also had 
159 
 
blood immuno-phenotyping based on the availability of the technique to the study.  These 
participants had blood samples analysed on the same day using flow cytometry for immune-
phenotyping.   
CSF Samples 
For those who consented to have CSF collected, samples were obtained on a separate study 
visit.  The samples (up to 10ml) were obtained by a lumbar puncture and a sample sent to the 
laboratory at UCL for quantification of total tau and amyloid-β-42.  The remainder of the 
sample was centrifuged and stored at -80°C for future testing of inflammatory and 
neurodegenerative markers. 
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Consent Form for Control Subjects 
Neuroimaging of Inflammation in MemoRy and Other 
Disorders (NIMROD) 
I,  ............................................................................................................................................ (name) 
of  .......................................................................................................................................................  
 ........................................................................................................................................... (address) 
consent to taking part in the NIMROD study. 
 Please tick 
I have read the information sheet giving details of this study, have been given a copy to 
keep and have had the opportunity to ask questions.  
I understand that my participation is voluntary and I can withdraw consent at any time 
without giving any reason and without my medical care or legal rights being affected.  
I understand that data collected during the study may be looked at in the monitoring of 
the research by clinical governance staff.  I give permission for such access to my 
records. 
 
I understand that my tissue samples will be tested for genetic factors and I agree to this. 
 
I give permission for information concerning me to be held by the University of 
Cambridge.  I understand that records will be confidential and will be stored securely 
on systems within the NHS and University. 
 
I give my permission that in the unlikely event that an abnormality is discovered my 
GP and I will be informed.  
I consent for my data and tissue samples to be used in similar studies.  
Signed .......................................................................................  Date ...............................................  
Consented by .................................................................. (sign) Date ...............................................  
Print name ..........................................................................................  
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When completed, original to be kept in research file, 1 copy for Participant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
162 
 
 
 
Consent Form for Informants 
Neuroimaging of Inflammation in MemoRy and Other 
Disorders (NIMROD) 
I,  ............................................................................................................................................ (name) 
of  .......................................................................................................................................................  
 ........................................................................................................................................... (address) 
consent to taking part in the NIMROD study by answering questions and completing 
questionnaires and other scales relating to the capabilities and behaviour of 
[Name] ......................................................................................................................... “the 
Participant” 
 
 Please tick 
I have read the information sheet giving details of this study, have been given a copy to 
keep and have had the opportunity to ask questions.  
I understand that my participation is voluntary and I can withdraw consent at any time 
without giving any reason and without the Participant’s medical care or legal rights 
being affected. 
 
I understand that data collected during the study may be looked at in the monitoring of 
the research by clinical governance staff.  I give permission for such access to the 
information I provide. 
 
I give permission for the information I provide to be held by the University of 
Cambridge.  I understand that records will be confidential and will be stored securely 
on systems within the NHS and University. 
 
I consent for the information I provide to be used in similar studies and in connection 
with the medical treatment and care of the Participant.  
Signed .......................................................................................  Date ...............................................  
Consented by .................................................................. (sign) Date ...............................................  
Print name ..........................................................................................  
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When completed, original to be kept in research file, 1 copy for Informant, 1 copy for 
Participant 
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Consent Form for Patients 
Neuroimaging of Inflammation in MemoRy and Other 
Disorders (NIMROD) 
I,  ............................................................................................................................................ (name) 
of  .......................................................................................................................................................  
 ........................................................................................................................................... (address) 
consent to taking part in the NIMROD study. 
 Please tick 
I have read the information sheet giving details of this study, have been given a copy to 
keep and have had the opportunity to ask questions.  
I understand that my participation is voluntary and I can withdraw consent at any time 
without giving any reason and without my medical care or legal rights being affected.  
I understand that sections of any of my medical notes may be looked at and 
information taken from them used in this research, or in the monitoring of the research 
by clinical governance staff.  I give permission for the researchers and clinical 
governance staff to have such access to my records. 
 
I understand that my tissue samples will be tested for genetic factors and I agree to this. 
 
I give permission for information concerning me to be held by the University of 
Cambridge.  I understand that records will be confidential and will be stored securely 
on systems within the NHS and University. 
 
I understand that my GP will be informed of my participation in this study, and give 
permission for this.  
I give my permission that in the unlikely event that an abnormality is discovered my 
GP and I will be informed.  
In the possible event of my losing mental capacity to give informed consent during this 
study, I wish it to be noted that I am minded to continue in the study.  
I consent for my data and tissue samples to be used in similar studies.  
Signed .......................................................................................  Date ...............................................  
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Consented by .................................................................. (sign) Date ...............................................  
Print name ..........................................................................................  
 
When completed, original to be kept in research file, 1 copy for Participant 
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Declaration Form for Consultees 
Neuroimaging of Inflammation in MemoRy and Other 
Disorders (NIMROD) 
I,  ................................................................................................................................ (name) 
of  .......................................................................................................................................................  
 ........................................................................................................................................... (address) 
am acting on behalf of my relative/dependant/friend in my capacity as their personal consultee 
as defined by the Mental Capacity Act (2005) with the understanding that my 
relative/dependant/friend does not have capacity to decide to participate in this research study 
for him/herself.  
I have been consulted about ............................................................................................. (name) 
taking part in the NIMROD study. 
Please tick 
I have read the information sheet giving details of this study and I have had the 
opportunity to ask questions and understand what is involved.  
In my opinion he/she would not object to taking part in the NIMROD study.  
I understand that participation is voluntary and that I can request he/she is withdrawn 
from the study at any time without giving any reason and without their medical care 
or legal rights being affected. 
 
I understand that relevant sections of my relative/dependant/friend’s medical notes 
may be looked at by the research team and information taken from them for use in 
this research, or in the monitoring  of the research by clinical governance staff. 
 
I understand that my relative/dependant/friend’s tissue samples will be tested for 
genetic factors  and in my opinion he/she would agree to this.  
I understand that information concerning my relative/dependant/friend will be held 
by the University of Cambridge. I understand that records will be confidential and 
will be stored securely on systems within the NHS and University. 
 
I understand that my relative/dependant/friend’s GP will be informed of their 
participation in this study.  
I understand that in the unlikely event that an abnormality is discovered my 
relative/dependant/friend and his/her GP will be informed.  
I agree that my relative/dependant/friend’s data and tissue samples can be used in 
future similar studies. 
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Signed .................................................................... (Consultee) Date ...............................................  
Relationship to Patient .......................................................................  
Consulted by .................................................. (Team member) Date ...............................................  
Print name ........................................................................................  
When completed, original to be kept in care record, 1 copy for consultee and 1 copy for 
research file 
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Information Sheet for Consultees 
Neuroimaging of Inflammation in MemoRy and Other 
Disorders (NIMROD) 
[Name]………………….. is being invited to take part in a research study.  We feel he/she is 
unable to decide for himself/herself whether to do so.  We would like your opinion whether or 
not they would like to be involved.  This leaflet explains why the research is being done and 
what taking part will involve.  Please read the following information carefully and discuss it 
with others if you wish.  Please consider what you know of their wishes and feelings, and 
consider their best interests.  It will help if you can let us know of any advance decisions they 
have made about participating in research as these would take precedence.  You can talk to 
the researchers before you decide. 
If you decide that they would have no objection to taking part, after reading this information 
leaflet, please sign the consultee declaration form.  We will keep you both fully informed 
during the study so you can let us know if you have any concerns or you think your 
relative/dependant/friend should be withdrawn from further participation. 
If you decide they would not wish to take part it will not affect the standard of health care 
they receive in any way. 
If you are unsure about taking the role of consultee you may seek independent advice; we 
understand if you don’t want to take on this responsibility. The following information is the 
same as we provide for people who are able to consent for themselves.   
What is the purpose of the study? 
There are several different causes of memory problems in later life, including a condition 
called Mild Cognitive Impairment as well as different types of dementia like Alzheimer’s 
disease, Frontotemporal dementia, Lewy body dementia, Progressive supranuclear palsy and 
Vascular dementia.  Older people with depression can also have memory problems. 
While considerable progress has been made over the last decade in understanding some of the 
brain protein and other changes associated with memory problems and dementia, a lot is still 
not known.  For example, why some people with memory problems get worse at a faster rate 
than others is not clear.  It has been established that mild inflammatory changes (brain 
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inflammation) are associated with some of these disorders, but the questions whether it is 
present in all of them, and if so precisely where and how it changes with time have received 
little research attention.  This is important as we do not know how much inflammation is the 
result of disease and how much it may be involved as a cause.  If it is a cause, then this is 
extremely important because it may be possible to develop new treatments to help prevent 
memory problems getting worse.  It may also be possible to use measures of inflammation to 
predict groups of individuals who may be more at risk of declining more quickly than others. 
Brain imaging is an important method to investigate brain structure and function. Magnetic 
Resonance Imaging (MRI) can be used to look at brain structure and function in great detail.  
In addition, Positron Emission Tomography (PET) imaging can be used to help visualise 
some kinds of damaged protein often found in people with memory and other problems 
(amyloid using PIB PET and tau using AV-1451 PET), and also can help detect the presence 
of inflammation in the brain (PK11195 PET).  Further, the presence of illnesses, including 
inflammation, leaves tell-tale changes in the blood and cerebro-spinal fluid, the clear fluid that 
bathes the brain and spinal cord.  In addition there are known to be genetic markers found in 
the blood that are associated with increased or decreased risk of dementia. 
This study looks for the presence of damaged protein, genetic markers, inflammation and 
changes in brain structure and function in people with a range of disorders that affect their 
thinking, attention and memory as well as suitable control subjects without such impairments.  
We will compare them to see how they differ on the tests and scans to understand the causes 
and effects of dementia and related illnesses. 
Why has your relative/dependant/friend been invited? 
Your relative/dependant/friend has been selected either because he/she has been diagnosed 
with a neurodegenerative disease or with depression or because he/she has symptoms that are 
suggestive of such a disorder. 
Does my relative/dependant/friend have to take part? 
It is up to your relative/dependant/friend to decide whether to join the study.  We will rely on 
your guidance to understand his or her wishes in this regard. 
If you decide he/she would not wish to take part it would not affect the standard of health care 
he/she receives in any way. 
If you feel that he/she would agree to take part we will ask you to sign a consent form. 
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He/she is free to withdraw at any time without giving a reason.  This would not affect the 
standard of health care he/she receives in any way. 
What will your relative/dependant/friend be asked to do? 
The study includes the following types of test, although not everyone will necessarily be 
asked to do all parts of the study: 
1. A clinical assessment including  tests of memory, words, vision etc 
2. A blood test.  
3. An MRI brain scan 
4. Either one or two PET scans  
 
Participants will have tests of memory, language, vision and attention, which take about one 
and a half hours to complete.  This would be repeated every year for the duration of the study 
(up to 3 years) and can be carried out either at your relative/dependant/friend’s home or here 
at Addenbrooke’s Hospital, whichever they and you prefer.  We may use an audio device to 
record some of their answers.  Recordings will only be used as a supplement to written notes 
to ensure accuracy and will be deleted after use. 
  We will ask you or someone else who knows them well to have a short interview to answer 
questions and complete a couple of questionnaires about how he or she is coping with 
everyday life. 
We would carry out a brief physical examination which could either be as part of a normal 
clinical attendance or combined with one of the other research visits.  This would be repeated 
annually.  We would also take a blood sample (about 80 ml, or 2 eggcups full).  These take 
about 10 minutes.  
We propose to undertake up to two PET scans at Addenbrooke’s Hospital in the Wolfson 
Brain Imaging Centre (WBIC).  On each occasion your relative/dependant/friend will be in 
WBIC for approximately 2 hours, with the scan itself taking 45 minutes in the case of PIB 
PET and 90 minutes for the others (PK11195 and AV-1451 PET).  For each PET scan they 
will have an injection of about a teaspoon of short lasting radioactive liquid.  The radiation 
dose for each PIB and PK11195 PET scan (2.7 – 3.0 milliSieverts) is similar to the radiation 
dose we each experience from radiation in the environment during one year living in the East 
Anglia region, while the radiation dose from AV-1451 PET is 9.3 milliSieverts, which is 
similar to 3½ yeas’ environmental exposure here.  The injected radioactivity fades away 
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naturally over a few hours and your relative/dependant/friend can leave the WBIC as soon as 
the scan is finished. 
In all cases our staff would communicate with them throughout the scan to check that they 
stay comfortable.  You or your relative/dependant/friend could end the scan at any point. 
The MRI brain scan also takes place at the WBIC.  This is to look at the size, shape and 
‘wiring’ of the brain.  It may be possible to arrange for this to take place on the same day as 
one of the PET scans.  Though MRI scanning is generally very safe, there are certain 
circumstances when it must be avoided.  We will go through a checklist to ask about metal 
objects attached to or inside his or her body (e.g. stents, shrapnel, plated fractures,) or 
electronic devices (e.g. heart pace-maker).  Many such items (most modern cardiac stents, for 
instance) are designed to be MRI safe.  Being scanned requires the participant to lie still and 
relaxed on a bed in the scanner’s ‘tunnel’.  This ‘tunnel’ is quite narrow so please let us know 
if your relative/dependant/friend is likely to suffer feelings of claustrophobia there.  It can be 
noisy but earplugs are supplied and the participant can also have their own choice of music 
played over headphones if they wish.  As with the PET scans, the technician performing the 
MRI scan would communicate with them throughout the scan to check that they stay 
comfortable.  It can be stopped at any point, but takes up to one hour to complete. 
What are the possible benefits of taking part? 
This is not a trial of any drug or other treatment and there is no direct benefit to you or your 
relative/dependant/friend from taking part in this study.  However if he/she does take part 
he/she will be making a significant contribution to medical knowledge and the challenge of 
dementia especially. 
Expenses 
If your relative/dependant/friend takes part in this study, we would cover all necessary travel 
expenses and if it would help we would arrange transport by taxi for your 
relative/dependant/friend (and you if you like) to come to the hospital and go home. 
Will my relative/dependant/friend’s taking part in the study be kept confidential? 
If your relative/dependant/friend does take part in the study, all information provided to us 
and the results of studies would be treated confidentially.  It will be stored securely in locked 
cabinets or on password protected computer systems under the supervision of the Chief 
Investigators. We will retain the data for over 10 years.  We will ask for your permission on 
behalf of your relative/dependant/friend to share their data and scans in an anonymised way 
with collaborators, now and in the future, including researchers in the NHS, Medical Research 
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Council, University and National Institute for Health Research.  The NHS is trying to improve 
the quality of clinical and research standards.  This is being achieved through ‘clinical 
governance’.  As part of this process, this study may be reviewed by a clinical governance 
team.  Such a team would need to look at our records to make sure that the research was 
carried out in accordance with proper procedures.   
What if there is a problem? 
Although the PET scans are for research purposes only, the MRI scan will be routinely 
reported by a specialist radiologist.  Occasionally, brain scanning and other tests reveal a 
medical problem that was not expected.  If this happens, we will inform you and your 
relative/dependant/friend, and (if you agree on their behalf) we would write to their General 
Practitioner (GP) and arrange for any necessary NHS follow up.   
  We have also arranged insurance, in the unlikely event of any problems, without 
affecting your relative/dependant/friend’s statutory rights.  If you have any concerns or 
comments related to your relative/dependant/friend’s participation in this study, you could 
contact the Chief investigator (details below) or the Patient Advisory and liaison Service 
(PALS) at Box 53, Cambridge University Hospitals, Cambridge Biomedical Campus, Hills 
Road, Cambridge, CB2 0QQ, telephone 01223 216 756, e-mail pals@addenbrookes.nhs.uk . 
Who is organising and funding the research? 
The study is funded primarily by the NIHR (National Institute for Health Research) 
Biomedical Research Unit.  The research team are based at the Departments of Psychiatry and 
Clinical Neurosciences at the University of Cambridge and Cambridge University Hospitals 
NHS Foundation Trust (Addenbrooke’s Hospital) 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect the participants’ interests.  This study has been reviewed and 
given a favourable opinion by the East of England - Cambridge Central Research Ethics 
Committee. 
Further information 
If you would like further information please contact Professor John O’Brien, or any member 
of the research team (details below). 
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What will happen next? 
The next step will be a telephone call from one of the researchers.  If you are interested in 
helping with the study, they will arrange to visit you at home.  This will give you a chance to 
ask any questions about the study and your relative/dependant/friend taking part before you 
make a decision.  If you do advise on behalf of your relative/dependant/friend that they should 
take part, the researcher will discuss a consultee declaration form with you and ask you to 
sign it.  It is up to you to decide whether to advise that your relative/dependant/friend should 
take part or not.  You should base this decision on your understanding of what your 
relative/dependant/friend would have decided had they had the mental capacity to do so.  You 
do not have to give a reason if you advise that your relative/dependant/friend should not be 
involved.  Whatever you decide will have no effect on the care your relative/dependant/friend 
receives now or in the future.  If you change your mind on behalf of your 
relative/dependant/friend you can advise that they withdraw from the study at any time 
without giving a reason.  You will be given a copy of this leaflet to keep. 
The research team should contact you in the next week or so.  If, at any time, you need to get 
in touch with someone, you can contact us as shown below: 
 
Professor John T O'Brien (Chief 
Investigator), 
Department of Psychiatry, 
University of Cambridge, 
Level E4, Box 189, 
Addenbrooke's Hospital, 
Hills Road, 
Cambridge, CB2 0SP 
Tel: +44 (0)1223 760682 
 
Dr James B Rowe (co-Chief Investigator), 
Department of Clinical Neuroscience, 
University of Cambridge, 
Herchel Smith Building,  
Forvie Site,  
Robinson Way, 
Addenbrooke’s Hospital , 
Cambridge, CB2 0SZ 
Telephone: +44 (0) 1223 273 630  
Secretary: +44 (0) 1223 760 696 
Robert Arnold (Research Assistant) 
Herchel Smith Building, 
Forvie Site, Robinson Way, 
Cambridge, CB2 0SZ 
Telephone: 01223 768003 
Email: rja39@medschl.cam.ac.uk 
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Nimrod  
 
Information Sheet for Control Participants 
Neuroimaging of Inflammation in MemoRy and Other 
Disorders (NIMROD) 
 
You are invited to take part in a research study.  This leaflet explains why the research is 
being done and what taking part will involve.  Please read the following information carefully 
and discuss it with others if you wish.  You can talk to the researchers before you decide.  If 
you decide to take part, after reading this information leaflet, please sign the consent form. 
What is the purpose of the study? 
There are several different causes of memory problems in later life, including a condition 
called Mild Cognitive Impairment as well as different types of dementia like Alzheimer’s 
disease, Frontotemporal dementia, Lewy body dementia, Progressive supranuclear palsy and 
Vascular dementia. Older people with depression can also have memory problems.  
While considerable progress has been made over the last decade in understanding some of the 
brain protein and other changes associated with memory problems and dementia, a lot is still 
not known.  For example, why some people with memory problems get worse at a faster rate 
than others is not clear.  It has been established that mild inflammatory changes (brain 
inflammation) are associated with some of these disorders, but the questions whether it is 
present in all of them, and if so precisely where and how it changes with time have received 
little research attention.  This is important as we do not know how much inflammation is the 
result of disease and how much it may be involved as a cause.  If it is a cause, then this is 
extremely important because it may be possible to develop new treatments to help prevent 
memory problems getting worse.  It may also be possible to use measures of inflammation to 
predict groups of individuals who may be more at risk of declining more quickly than others. 
Brain imaging is an important method to investigate brain structure and function. Magnetic 
Resonance Imaging (MRI) can be used to look at brain structure and function in great detail.  
In addition, Positron Emission Tomography (PET) imaging can be used to help visualise 
some kinds of damaged protein often found in people with memory and other problems 
(amyloid using PIB PET imaging and tau using AV-1451 PET imaging), and also can help 
175 
 
detect the presence of inflammation in the brain (PK11195 PET).  Further, the presence of 
illnesses, including inflammation, leaves tell-tale changes in the blood and cerebro-spinal 
fluid, the clear fluid that bathes the brain and spinal cord.  In addition there are known to be 
genetic markers found in the blood that are associated with increased or decreased risk of 
dementia. 
This study looks for the presence of damaged protein, genetic markers, inflammation and 
changes in brain structure and function in people with a range of disorders that affect their 
thinking, attention and memory. To do this we also need to study control subjects such as 
yourself without such impairments.  We will compare them to see how they differ on the tests 
and scans, to understand the causes and effects of dementia and related illnesses. 
Why have I been invited? 
  You have been chosen as a healthy person, so we can compare our tests between normal 
people and patients with dementia and other illnesses. 
Do I have to take part? 
It is up to you to decide whether to join the study.  If you decide you do not wish to take part 
it would not affect the standard of health care you receive in any way. 
If you agree to take part we will ask you to sign a consent form. 
You are free to withdraw at any time without giving a reason.  This would not affect the 
standard of health care you receive in any way. 
What will I be asked to do? 
The study includes the following types of test, although not everyone will necessarily be 
asked to do all parts of the study: 
1. A clinical assessment, including memory and other cognitive tests 
2. A blood test.  
3. An MRI brain scan 
4. Either one or two PET scans 
5. Some people may also be invited for a lumbar puncture, to examine spinal fluid. 
Participants will have tests of memory, language, vision and attention, which take about one 
and a half hours to complete.  This would be repeated every year for the duration of the study 
(up to 3 years) and can be carried out either at your home or here at Addenbrooke’s Hospital, 
whichever you prefer.  We may use an audio device to record some of your answers.  
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Recordings will only be used as a supplement to written notes to ensure accuracy and will be 
deleted after use. 
We would carry out a brief physical examination which could be combined with one of the 
other research visits. This would be repeated annually.  We would also take a blood sample 
(about 80 ml, or 2 eggcups full).  These take about 10 minutes. 
We propose to undertake up to two PET scans at Addenbrooke’s Hospital in the Wolfson 
Brain Imaging Centre (WBIC).  On each occasion you will be in WBIC for approximately 2 
hours, with the scan itself taking 45 minutes in the case of PIB PET and 90 minutes for the 
other (PK11195 PET).  For each PET scan you will have an injection of about a teaspoon of 
short lasting radioactive liquid.  The radiation dose for each PET scan (2.7 – 3.0 milliSieverts) 
is similar to the radiation dose we each experience from radiation in the environment during 
one year living in the East Anglia region.  The injected radioactivity fades away naturally 
over a few hours and you can leave the WBIC as soon as the scan is finished. 
In all cases our staff would communicate with you throughout the scan to check that you stay 
comfortable.  You could end the scan at any point. 
The MRI brain scan will take around an hour and also takes place at the WBIC. This is to 
look at the size, shape and ‘wiring’ of the brain.  It may be possible to arrange for this to take 
place on the same day as one of the PET scans.  Though MRI scanning is generally very safe, 
there are certain circumstances when it must be avoided.  We will go through a checklist to 
ask about metal objects attached to or inside your body (e.g. stents, shrapnel, plated fractures,) 
or electronic devices (e.g. heart pace-maker).  Many such items (most modern cardiac stents, 
for instance) are designed to be MRI safe.  Being scanned requires you to lie still and relaxed 
on a bed in the scanner’s ‘tunnel’.  This ‘tunnel’ is quite narrow so please let us know if you 
have experienced claustrophobia in small spaces.  It can be noisy but earplugs are supplied 
and you can also have your own choice of music played over headphones if you wish.  As 
with the PET scans, the technician performing the MRI scan would communicate with you 
throughout the scan to check that you stay comfortable.  It can be stopped at any point, but 
takes up to one hour to complete. 
Some participants would also be invited for a lumbar puncture, on another visit, to take a 
small volume (about 15ml, three teaspoonsful) of the spinal fluid that has bathed the brain 
before travelling down the spine.  It can tell us a lot about what is happening in the brain.  A 
separate information sheet is available on lumbar puncture, as it is not relevant to everyone, 
and is an optional part of the study. 
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What are the possible benefits of taking part? 
This is not a trial of any drug or other treatment and there is no direct benefit to you from 
taking part in this study.  However if you do take part you will be making a significant 
contribution to medical knowledge and the challenge of dementia especially. 
Expenses 
If you take part in this study, we would cover all necessary expenses. 
Will my taking part in the study be kept confidential? 
If you do take part in the study, all information provided to us and the results of studies would 
be treated confidentially.  It will be stored securely in locked cabinets or on password 
protected computer systems, under the supervision of the Chief investigators. We will retain 
the data for over 10 years.  We will ask for your permission to share your data and scans in an 
anonymised way with collaborators, now and in the future, including researchers in the NHS, 
Medical Research Council, University and National Institute for Health Research.  The NHS 
is trying to improve the quality of clinical and research standards.  This is being achieved 
through ‘clinical governance’.  As part of this process, this study may be reviewed by a 
clinical governance team.  Such a team would need to look at our records to make sure that 
the research was carried out in accordance with proper procedures.   
What if there is a problem? 
Although the PET scans are for research purposes only, the MRI scan will be routinely 
reported by a specialist radiologist. Occasionally, brain scanning and other tests reveal a 
medical problem that was not expected.  If this happens, we will inform you, and (if you 
agree) we would write to your General Practitioner (GP) and arrange for any necessary NHS 
follow up.  
  We have also arranged insurance, in the unlikely event of any problems, without 
affecting your statutory rights.  If you have any concerns or comments related to your 
participation in this study, you could contact the Chief Investigator (details below) or the 
Patient Advisory and Liaison Service (PALS) at Box 53, Cambridge University Hospitals, 
Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0QQ, telephone 01223 216 
756, e-mail pals@addenbrookes.nhs.uk . 
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Who is organising and funding the research? 
The study is funded primarily by the NIHR (National Institute for Health Research) 
Biomedical Research Unit.  The research team are based at the Departments of Psychiatry and 
Clinical Neurosciences at the University of Cambridge and Cambridge University Hospitals 
NHS Foundation Trust (Addenbrooke’s Hospital) 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect the participants’ interests.  This study has been reviewed and 
given a favourable opinion by the East of England – Cambridge Central Research Ethics 
Committee. 
Further information 
If you would like further information please contact Professor John O’Brien, or any member 
of the research team (details below). 
What will happen next? 
The next step will be a telephone call from one of the researchers.  If you are interested in 
helping with the study, they will arrange to visit you at home.  This will give you a chance to 
ask any questions about the study and your taking part before you make a decision.  If you do 
decide to take part, the researcher will discuss a consent form with you and ask you to sign it.  
It is up to you to decide whether to take part or not.  You do not have to give a reason if you 
decide not to be involved.  If you change your mind you can withdraw from the study at any 
time without giving a reason.  You will be given a copy of this leaflet to keep. 
The research team should contact you in the next week or so.  If, at any time, you need to get 
in touch with someone, you can contact us: 
 
Professor John T O'Brien (Chief Investigator) 
Department of Psychiatry, 
University of Cambridge, 
Level E4, Box 189, 
Addenbrooke's Hospital, 
Hills Road, 
Cambridge, CB2 0SP 
Tel: +44 (0)1223 760682 
 
Dr James B Rowe (co-Chief Investigator) 
Department of Clinical Neurosciences, 
University of Cambridge, 
Herchel Smith Building,  
Forvie Site, Robinson Way, 
Addenbrooke’s Hospital , 
Cambridge, CB2 0SZ 
Telephone: +44 (0) 1223 273 630  
Secretary: +44 (0) 1223 760 696 
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Robert Arnold (Research Assistant) 
Herchel Smith Building, 
Forvie Site, Robinson Way, 
Cambridge, CB2 0SZ 
Telephone: 01223 768003 
Email: rja39@medschl.cam.ac.uk 
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Information Sheet for Patients and their Informants 
Neuroimaging of Inflammation in MemoRy and Other Disorders 
(NIMROD) 
You are being invited to take part in a research study.  This leaflet explains why the research 
is being done and what taking part will involve.  Please read the following information 
carefully and discuss it with others if you wish.  You can talk to the researchers before you 
decide. 
 If you decide to take part, after reading this information leaflet, please sign the consent form. 
If you decide not to take part it will not affect the standard of health care you receive in any 
way. 
What is the purpose of the study? 
There are several different causes of memory problems in later life, including a condition 
called Mild Cognitive Impairment as well as different types of dementia like Alzheimer’s 
disease, Frontotemporal dementia, Lewy body dementia, Progressive supranuclear palsy and 
Vascular dementia. Older people with depression can also have memory problems.  
While considerable progress has been made over the last decade in understanding some of the 
brain protein and other changes associated with memory problems and dementia, a lot is still 
not known.  For example, why some people with memory problems get worse at a faster rate 
than others is not clear.  It has been established that mild inflammatory changes (brain 
inflammation) are associated with some of these disorders, but the questions whether it is 
present in all of them, and if so precisely where and how it changes with time have received 
little research attention.  This is important as we do not know how much inflammation is the 
result of disease and how much it may be involved as a cause.  If it is a cause, then this is 
extremely important because it may be possible to develop new treatments to help prevent 
memory problems getting worse.  It may also be possible to use measures of inflammation to 
predict groups of individuals who may be more at risk of declining more quickly than others. 
Brain imaging is an important method to investigate brain structure and function. Magnetic 
Resonance Imaging (MRI) can be used to look at brain structure and function in great detail.  
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In addition, Positron Emission Tomography (PET) imaging can be used to help visualise 
some kinds of damaged protein often found in people with memory and other problems 
(amyloid using PIB PET imaging and tau using AV-1451 PET imaging), and also can help 
detect the presence of inflammation in the brain (PK11195 PET).  Further, the presence of 
illnesses, including inflammation, leaves tell-tale changes in the blood and cerebro-spinal 
fluid, the clear fluid that bathes the brain and spinal cord.  In addition there are known to be 
genetic markers found in the blood that are associated with increased or decreased risk of 
dementia. 
This study looks for the presence of damaged protein, genetic markers, inflammation and 
changes in brain structure and function in people with a range of disorders that affect their 
thinking, attention and memory as well as suitable control subjects without such impairments.  
We will compare them to see how they differ on the tests and scans, to understand the causes 
and effects of dementia and related illnesses. 
Why have I been invited? 
You have been selected because you have either been diagnosed with a neurodegenerative 
disease or with depression or because you have symptoms that are suggestive of such a 
disorder.  
Do I have to take part? 
It is up to you to decide whether to join the study.  If you decide you do not wish to take part 
it would not affect the standard of health care you receive in any way. 
If you agree to take part we will ask you to sign a consent form. 
You are free to withdraw at any time without giving a reason.  This would not affect the 
standard of health care you receive in any way. 
What will I be asked to do? 
The study includes the following types of test, although not everyone will necessarily be 
asked to do all parts of the study: 
1. A clinical assessment, including memory and other cognitive tests. 
2. A blood test.  
3. An MRI brain scan 
4. Either one or two PET scans 
5. Some people may also be invited for a lumbar puncture, to examine spinal fluid. 
Participants will have tests of memory, language, vision and attention, which take about one 
and a half hours to complete.    We will ask someone who knows you well to have a short 
182 
 
interview to answer questions and complete a couple of questionnaires about how you are and 
how you are coping with everyday life.  This would be repeated every year for the duration of 
the study (up to 3 years) and can be carried out either at your home or at Addenbrooke’s 
Hospital, whichever you prefer.  We may use an audio device to record some of your answers.  
This will only be used as a supplement to written notes to ensure accuracy. 
We would carry out a brief physical examination which could either be as part of a normal 
clinical attendance or combined with one of the other research visits. This would be repeated 
annually.  We would also take a blood sample (about 80 ml, or 2 eggcups full).  These take 
about 10 minutes. 
We propose to undertake up to two PET scans at Addenbrooke’s Hospital in the Wolfson 
Brain Imaging Centre (WBIC).  On each occasion you will be in WBIC for approximately 2 
hours, with the scan itself taking 45 minutes in the case of PIB PET and 90 minutes for the 
others (PK11195 and AV-1451 PET).  For each PET scan you will have an injection of about 
a teaspoon of short lasting radioactive liquid.  The radiation dose for each PIB and PK11195 
PET scan (2.7 – 3.0 milliSieverts) is similar to the radiation dose we each experience from 
radiation in the environment during one year living in the East Anglia region, while the 
radiation dose from AV-1451 PET is 9.3 milliSieverts, which is similar to 3½ yeas’ 
environmental exposure here.  The injected radioactivity fades away naturally over a few 
hours and you can leave the WBIC as soon as the scan is finished 
In all cases our staff would communicate with you throughout the scan to check that you stay 
comfortable.  You could end the scan at any point. 
The MRI brain scan will take around an hour and also takes place at the WBIC. This is to 
look at the size, shape and ‘wiring’ of the brain.  It may be possible to arrange for this to take 
place on the same day as one of the PET scans.  Though MRI scanning is generally very safe, 
there are certain circumstances where it must be avoided.  We will go through a checklist to 
ask about metal objects attached to or inside your body (e.g. stents, shrapnel, plated fractures,) 
or electronic devices (e.g. heart pace-maker).  Many such items (most modern cardiac stents, 
for instance) are designed to be MRI safe.  Being scanned requires you to lie still and relaxed 
on a bed in the scanner’s ‘tunnel’.  This ‘tunnel’ is quite narrow so please let us know if you 
have experienced claustrophobia in small spaces.  It can be noisy but earplugs are supplied 
and you can also have your own choice of music played over headphones if you wish.  As 
with the PET scans, the technician performing the MRI scan would communicate with you 
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throughout the scan to check that you stay comfortable.  It can be stopped at any point, but 
takes up to one hour to complete.  
Some participants would also be invited for a lumbar puncture, on another visit, to take a 
small volume (about 15ml, three teaspoonsful) of the spinal fluid that has bathed the brain 
before travelling down the spine.  It can tell us a lot about what is happening in the brain.  A 
separate information sheet is available on lumbar puncture, as it is not relevant to everyone, 
and is an optional part of the study. 
What are the possible benefits of taking part? 
This is not a trial of any drug or other treatment and there is no direct benefit to you from 
taking part in this study.  However if you do take part you will be making a significant 
contribution to medical knowledge and the challenge of dementia especially.  
Expenses 
If you take part in this study, we would cover all necessary travel expenses and if it would 
help we would arrange transport by taxi for you to come to the hospital and go home. 
Will my taking part in the study be kept confidential? 
If you do take part in the study, all information provided to us and the results of studies would 
be treated confidentially.  It will be stored securely in locked cabinets or on password 
protected computer systems, under the supervision of the Chief investigators. We will retain 
the data for over 10 years.  We will ask for your permission to share your data and scans in an 
anonymised way with collaborators, now and in the future, including researchers in the NHS, 
Medical Research Council, University and National Institute for Health Research.  The NHS 
is trying to improve the quality of clinical and research standards.  This is being achieved 
through ‘clinical governance’.  As part of this process, this study may be reviewed by a 
clinical governance team.  Such a team would need to look at our records to make sure that 
the research was carried out in accordance with proper procedures.   
What if there is a problem? 
Although the PET scans are for research purposes only, the MRI scan will be routinely 
reported by a specialist radiologist. Occasionally, brain scanning and other tests reveal a 
medical problem that was not expected. If this happens, we will inform you, and (if you 
agree) we would write to your General Practitioner (GP) and arrange for any necessary NHS 
follow up.  
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  We have also arranged insurance, in the unlikely event of any problems, without 
affecting your statutory rights.  If you have any concerns or comments related to your 
participation in this study, you could contact the Chief Investigator (details below) or the 
Patient Advisory and Liaison Service (PALS) at Box 53, Cambridge University Hospitals, 
Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0QQ, telephone 01223 216 
756, e-mail pals@addenbrookes.nhs.uk.   
Who is organising and funding the research? 
The study is primarily funded by the NIHR (National Institute for Health Research) 
Biomedical Research Unit.  The research team are based at the Departments of Psychiatry and 
Clinical Neurosciences at the University of Cambridge and Cambridge University Hospitals 
NHS Foundation Trust (Addenbrooke’s Hospital). 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect the participants’ interests.  This study has been reviewed and 
given a favourable opinion by the East of England – Cambridge Central Research Ethics 
Committee. 
Further information 
If you would like further information please contact Professor John O’Brien, or any member 
of the research team (details below). 
What will happen next? 
The next step will be a telephone call from one of the researchers.  If you are interested in 
helping with the study, they will arrange to visit you at home.  This will give you a chance to 
ask any questions about the study and your taking part before you make a decision.  If you do 
decide to take part, the researcher will discuss a consent form with you and ask you to sign it.  
It is up to you to decide whether to take part or not.  You do not have to give a reason if you 
decide not to be involved.  If you change your mind you can withdraw from the study at any 
time without giving a reason.  You will be given a copy of this leaflet to keep. 
The research team should contact you in the next week or so.  If, at any time, you need to get 
in touch with someone, you can contact us: 
Professor John T O'Brien (Chief Investigator) 
Department of Psychiatry, 
University of Cambridge, 
Level E4, Box 189, 
Dr James B Rowe (co-Chief Investigator) 
Department of Clinical Neurosciences, 
University of Cambridge, 
Herchel Smith Building,  
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Addenbrooke's Hospital, 
Hills Road, 
Cambridge, CB2 0SP 
Tel: +44 (0)1223 760682 
 
Forvie Site, Robinson Way, 
Addenbrooke’s Hospital , 
Cambridge, CB2 0SZ 
Telephone: +44 (0) 1223 273 630  
Secretary: +44 (0) 1223 760 696 
Robert Arnold (Research Assistant) 
Herchel Smith Building, 
Forvie Site, Robinson Way, 
Cambridge, CB2 0SZ 
Telephone: 01223 768003 
Email: rja39@medschl.cam.ac.uk 
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Summary information sheet for patients 
Neuroimaging of Inflammation in MemoRy and Other 
Disorders (NIMROD) 
 
 You are invited to take part in a research study.  Taking part is entirely 
voluntary, in other words, you do not have to take part if you do not want to. 
This sheet tells you about the study.  We will also talk about the study with you 
and your relative or carer  
This is a short summary of the study.  Full information is given in the longer 
information sheets which we have given to your relative/friend/advocate to read.   
We will also ask their advice about whether or not you want to take part in this 
study.  If you take part, or say no, your normal GP and hospital care will be the 
same. 
As we get older, our memory can let us down.  We can forget where things are 
or what things are called.  We can lose interest in things.  This can be caused by 
dementia or depression, which are due to changes in the brain.  
The changes in the brain may include inflammation, as well as changes in the 
size of the brain or chemicals in the brain.  We want to know more about how 
these things cause memory problems, and how they change over time.  We can 
do this using brain scans.  Special brain scans can show signs of inflammation 
for example.  We will see how these scans match the memory and other thinking 
difficulties that people have. 
We are looking for volunteers for this study.  Some will be in good health, 
and others will have very mild memory problems.  We also want to include 
people with dementia such as Alzheimer’s disease, Lewy body dementia, 
frontotemporal dementia or vascular dementia.  
The volunteers would come to Addenbrooke’s Hospital.  A researcher (nurse or 
doctor) would ask some questions about memory, mood and general health, and 
there would be a brief examination to look at movements and walking.  This 
would take up to two hours.  We would like to ask your relative/carer some 
questions as well.  We would ask people to have some tests of memory, 
language, attention and vision.  This can be done at home if you prefer.  It will 
take up to 2 hours and people can take breaks if they get tired. 
187 
 
If you take part, you would have an MRI brain scan and up to two PET 
brain scans (done on different days).  Most patients will have had a scan in the 
NHS clinics, and these are similar.  Each PET scan involves an injection into 
your arm of a radioactive liquid.  The radioactivity fades away over a few hours 
and you can go home straight after the scan.  The amount of radiation dose from 
each PET scan equates to between one and three and a half years of exposure 
from natural background radiation by living in the UK.  For the PET scans you 
would lie in the scanner for between three-quarters of an hour and one and a half 
hours.  The MRI scan would last about an hour. The PET scanner is quiet, but 
the MRI scanner is a quite noisy so we give you earplugs (and you can listen to 
your own choice of music).  Some people find the MRI scanner a little 
claustrophobic as well so do let us know if this might be a problem.  We can 
hear you and see you all the time and if you want to stop you can let us know at 
any time.  The MRI scan will be looked at by a specialist.  Sometimes we find 
something unexpected on a scan.  If this occurs we would let you and your GP 
know.  We may also ask to take a blood sample from you, like an ordinary blood 
test. 
 
The research team will contact you in the next week or so.  If, at any time, 
you need to get in touch with someone, you can contact: 
 
Professor John T O'Brien (Chief Investigator) 
Department of Psychiatry, 
University of Cambridge, 
Level E4, Box 189, 
Addenbrooke's Hospital, 
Hills Road, 
Cambridge, CB2 0SP 
Tel: +44 (0)1223 760682 
Dr James B Rowe (co-Chief Investigator) 
Department of Clinical Neurosciences, 
University of Cambridge, 
Herchel Smith Building,  
Forvie Site,  
Robinson Way, 
Addenbrooke’s Hospital , 
Cambridge, 
CB2 0SZ 
Telephone: +44 (0) 1223 273 630  
Secretary: +44 (0) 1223 760 696 
Robert Arnold (Research Assistant) 
Herchel Smith Building, 
Robinson Way, 
Cambridge, CB2 0SZ 
Telephone: 01223 768003 
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Email: rja39@medschl.cam.ac.uk 
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Appendix 2 
Appendix 2 provides additional details relevant to chapter 3, in particular the findings from 
the post-mortem examination of the proband’s father. 
Macroscopic observations 
Following removal at autopsy, the brain was fixed in 15% neutral buffered formalin, and 
weighed 1420g. The cerebellum and brainstem were separated from the cerebrum. 
Examination of the external surfaces found moderate cerebral atrophy, which was most 
prominent in the frontal and temporal lobes. The left temporal lobe was more severely 
affected than the right temporal lobe. The atrophy extended to involve the precentral gyrus 
and the superior parietal gyrus. The cerebral hemispheres were sectioned in the coronal plane. 
The cerebral atrophy observed externally was confirmed and there was enlargement of the 
lateral ventricles. The basal ganglia and thalami were unremarkable although the subthalamic 
nucleus was slightly reduced in size. Horizontal sections of the brainstem revealed pallor of 
the substantia nigra and locus coeruleus. Apart from a small single infarct in the cerebellar 
cortex, the cerebellum was unremarkable. 
Tissue preparation and immunohistochemistry  
Standard tissue blocks from the superior frontal, precentral, inferior temporal and anterior 
cingulate cortices, the hippocampus at the level of the lateral geniculate nucleus, the basal 
ganglia at the level of the head of the caudate nucleus, the midbrain at the level of the red 
nucleus, the pons at the level of the locus coeruleus, subthalamic nucleus, the medulla at the 
level of the hypoglossal nucleus, and the cerebellar dentate gyrus were embedded in paraffin 
wax and cut on a rotary microtome. Ten μm sections were stained using haematoxylin and 
eosin and modified Bielschowsky silver.  Immunoperoxidase staining using phosphorylated 
tau (clone AT8; mouse; 1:1000; Cat. No. MN1012; Thermo Scientific Australia, Scoresby, 
Victoria) was performed using a Discovery DX autostainer (Ventana Medical Systems, 
Tuscon, AZ, USA). 3-repeat tau (mouse; 1:50; Cat. No. 05-803; Abcam; Melbourne, 
Victoria), 4-repeat tau (mouse; 1:50; Cat. No. 05-804; Abcam), p62 (rabbit; 1:250; Cat. No. 
610833; BD Biosciences; North Ryde, NSW) and α-synuclein (mouse; 1:500; Cat. No. 
610787; BD Biosciences; North Ryde, NSW) were performed manually. For antigen retrieval, 
3-repeat tau and p62 required heating in the pressure cooker at 110°C for half an hour in TE 
buffer (pH 9.0), 4-repeat tau required pre-treatment with formic acid for 15 minutes followed 
by heating in the pressure cooker at 110°C for half an hour in TE buffer, and α-synuclein 
required pre-treatment with citric acid buffer (pH 6.0) for 18 minutes in the microwave. 
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Following blocking of endogenous peroxidase activity in 100% methanol with 3% hydrogen 
peroxide for ten minutes, sections were blocked in 10% normal horse serum (NHS) in TBS 
buffer (pH 7.4). Primary antibodies diluted in TBS with 1% NHS were incubated at 37°C for 
one hour, followed by incubation in EnVision Dual Link Polymer (Cat. No. K4061; DAKO; 
North Sydney, New South Wales). Dark brown staining was visualised by adding hydrogen 
peroxidase to a 3’3’-diaminobenzidine solution. All sections were counter-stained with 
haematoxylin. 
Microscopic observations 
Histopathology 
Sections of the cerebral cortex showed mild neuronal loss and gliosis in the superior frontal 
and inferior temporal cortices with the normal laminar distribution of neurons preserved. 
Ballooned neurons were observed in cortical sections stained with haematoxylin and eosin. 
Both the hippocampal CA1 region and entorhinal cortex showed mild neuronal loss and 
sparse neurofibrillary tangles. Neuritic plaques were not observed. Consistent with the 
macroscopic examination, there was mild neuronal loss of pigmented neurons in the 
substantia nigra and depigmentation in both the substantia nigra and locus coeruleus. The 
basal ganglia and cerebellum had minimal neuronal loss. 
Tau immunohistochemistry 
Phosphorylated tau-immunopositive ballooned neurons (Fig 1A), astrocytic plaques, 
widespread grey and white matter thread pathology (Fig 1B) and coiled bodies (Fig 1C) were 
observed in the superior frontal and inferior temporal cortices. The morphology and 
distribution of these inclusions appeared similar to sporadic frontotemporal lobar 
degeneration cases with CBD pathological subtype (Cairns et al., 2007; D. W. Dickson et al., 
2002). Immunostaining with 4-repeat tau and p62 labelled a similar number of ballooned 
neurons, astrocytic plaques and coiled bodies. Both 4-repeat tau and p62 only labelled a small 
proportion of phosphorylated tau-immunopositive threads in both grey and white matter. 3-
repeat tau-immunoreactivity was not observed. Phosphorylated tau-immunopositive Pick 
bodies and tufted astrocytes were not observed. Immunostaining with α-synuclein was not 
observed in the cortex, hippocampus or brainstem. The severity of neuropathological features 
immunostained with phosphorylated tau was similar in both the superior frontal and inferior 
temporal cortices with a mild number of ballooned neurons and astrocytic plaques, and 
moderate to severe coiled bodies and thread pathology in grey and white matter of both 
regions. 
